Difference between revisions of "Multiple myeloma, relapsed-refractory"
Warner-admin (talk | contribs) m (Text replacement - "[http://www.ncbi" to "[https://www.ncbi") |
Warner-admin (talk | contribs) m (Text replacement - "#b3e2cd" to "#f2f3f4") |
||
(10 intermediate revisions by 2 users not shown) | |||
Line 39: | Line 39: | ||
|2020-07-10 to 2021-11-17 | |2020-07-10 to 2021-11-17 | ||
| style="background-color:#1a9851" |Phase 3 (E-switch-ooc) | | style="background-color:#1a9851" |Phase 3 (E-switch-ooc) | ||
− | |1a. [[#Dara- | + | |1a. [[#Dara-Pd_.28SC_daratumumab.29|DPd]]<br>1b. [[#PVD|PVd]] |
| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: NYR vs 11.8 mo<br>(HR 0.26, 95% CI 0.18-0.38) | | style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: NYR vs 11.8 mo<br>(HR 0.26, 95% CI 0.18-0.38) | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[Ciltacabtagene autoleucel (Carvykti)]] 0.75 x 10<sup>6</sup> CAR-positive viable T cells/kg IV once on day 0 | *[[Ciltacabtagene autoleucel (Carvykti)]] 0.75 x 10<sup>6</sup> CAR-positive viable T cells/kg IV once on day 0 | ||
Line 49: | Line 49: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''CARTITUDE-1:''' Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 Jul 24;398(10297):314-324. Epub 2021 Jun 24. Erratum in: Lancet. 2021 Oct 2;398(10307):1216. [https://doi.org/10.1016/s0140-6736(21)00933-8 link to original article] ''' | + | #'''CARTITUDE-1:''' Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 Jul 24;398(10297):314-324. Epub 2021 Jun 24. Erratum in: Lancet. 2021 Oct 2;398(10307):1216. [https://doi.org/10.1016/s0140-6736(21)00933-8 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34175021/ PubMed] [https://clinicaltrials.gov/study/NCT03548207 NCT03548207] |
##'''Update:''' Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 Feb 20;41(6):1265-1274. Epub 2022 Jun 4. [https://doi.org/10.1200/jco.22.00842 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9937098/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35658469/ PubMed] | ##'''Update:''' Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 Feb 20;41(6):1265-1274. Epub 2022 Jun 4. [https://doi.org/10.1200/jco.22.00842 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9937098/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35658469/ PubMed] | ||
− | #'''CARTITUDE-4:''' San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023 Jul 27;389(4):335-347. Epub 2023 Jun 5. [https://doi.org/10.1056/nejmoa2303379 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37272512/ PubMed] [https://clinicaltrials.gov/study/NCT04181827 NCT04181827] | + | #'''CARTITUDE-4:''' San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023 Jul 27;389(4):335-347. Epub 2023 Jun 5. [https://doi.org/10.1056/nejmoa2303379 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37272512/ PubMed] [https://clinicaltrials.gov/study/NCT04181827 NCT04181827] |
==Carfilzomib monotherapy {{#subobject:36c1ce|Regimen=1}}== | ==Carfilzomib monotherapy {{#subobject:36c1ce|Regimen=1}}== | ||
Line 68: | Line 68: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] as follows: | *[[Carfilzomib (Kyprolis)]] as follows: | ||
Line 103: | Line 103: | ||
|} | |} | ||
''Note: Patients enrolled in PX-171-004 could continue therapy beyond 12 cycles on PX-171-010; results of this extension study have not been published, to our knowledge.'' | ''Note: Patients enrolled in PX-171-004 could continue therapy beyond 12 cycles on PX-171-010; results of this extension study have not been published, to our knowledge.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] 20 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16 | *[[Carfilzomib (Kyprolis)]] 20 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16 | ||
Line 129: | Line 129: | ||
*At least 3 lines of therapy including bortezomib, lenalidomide or thalidomide, an alkylating agent, and corticosteroids | *At least 3 lines of therapy including bortezomib, lenalidomide or thalidomide, an alkylating agent, and corticosteroids | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] as follows: | *[[Carfilzomib (Kyprolis)]] as follows: | ||
Line 158: | Line 158: | ||
|} | |} | ||
''Note: This is the maximum predetermined dose, there was no MTD; ORR is reported for the phase 2 portion.'' | ''Note: This is the maximum predetermined dose, there was no MTD; ORR is reported for the phase 2 portion.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] as follows: | *[[Carfilzomib (Kyprolis)]] as follows: | ||
Line 192: | Line 192: | ||
|} | |} | ||
''Note: Neither Vij et al. 2012a nor Siegel et al. 2012 specified that carfilzomib was capped at a body surface area of 2.2 m<sup>2</sup>, but the package insert specifies that: "The dose is calculated using the patient’s actual body surface area at baseline. Patients with a body surface area greater than 2.2 m<sup>2</sup> should receive a dose based upon a body surface area of 2.2 m<sup>2</sup>. Dose adjustments do not need to be made for weight changes of less than or equal to 20%."'' | ''Note: Neither Vij et al. 2012a nor Siegel et al. 2012 specified that carfilzomib was capped at a body surface area of 2.2 m<sup>2</sup>, but the package insert specifies that: "The dose is calculated using the patient’s actual body surface area at baseline. Patients with a body surface area greater than 2.2 m<sup>2</sup> should receive a dose based upon a body surface area of 2.2 m<sup>2</sup>. Dose adjustments do not need to be made for weight changes of less than or equal to 20%."'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] as follows: | *[[Carfilzomib (Kyprolis)]] as follows: | ||
Line 230: | Line 230: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] as follows: | *[[Carfilzomib (Kyprolis)]] as follows: | ||
Line 243: | Line 243: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''PX-171-004 bortezomib-naive:''' Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14;119(24):5661-70. Epub 2012 May 3. [https://doi.org/10.1182/blood-2012-03-414359 link to original article] ''' | + | # '''PX-171-004 bortezomib-naive:''' Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14;119(24):5661-70. Epub 2012 May 3. [https://doi.org/10.1182/blood-2012-03-414359 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123327/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22555973/ PubMed] [https://clinicaltrials.gov/study/NCT00530816 NCT00530816] |
− | # '''PX-171-004 bortezomib-exposed:''' Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep;158(6):739-48. Epub 2012 Jul 30. [https://doi.org/10.1111/j.1365-2141.2012.09232.x link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818209/ link to PMC article] ''' | + | # '''PX-171-004 bortezomib-exposed:''' Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep;158(6):739-48. Epub 2012 Jul 30. [https://doi.org/10.1111/j.1365-2141.2012.09232.x link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818209/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/22845873/ PubMed] [https://clinicaltrials.gov/study/NCT00530816 NCT00530816] |
− | # '''PX-171-003-A0:''' Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):310-8. [https://doi.org/10.1016/j.clml.2012.08.003 link to original article] ''' | + | # '''PX-171-003-A0:''' Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):310-8. [https://doi.org/10.1016/j.clml.2012.08.003 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/23040437/ PubMed] |
− | # '''PX-171-003-A1:''' Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 4;120(14):2817-25. Epub 2012 Jul 25. [https://doi.org/10.1182/blood-2012-05-425934 link to original article] ''' | + | # '''PX-171-003-A1:''' Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 4;120(14):2817-25. Epub 2012 Jul 25. [https://doi.org/10.1182/blood-2012-05-425934 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123387/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22833546/ PubMed] [https://clinicaltrials.gov/study/NCT00511238 NCT00511238] |
## '''Subgroup analysis:''' Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec;27(12):2351-6. Epub 2013 May 14. [https://doi.org/10.1038/leu.2013.152 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865533/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23670297/ PubMed] | ## '''Subgroup analysis:''' Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec;27(12):2351-6. Epub 2013 May 14. [https://doi.org/10.1038/leu.2013.152 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865533/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23670297/ PubMed] | ||
− | # '''PX-171-005:''' Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013 Aug;27(8):1707-14. Epub 2013 Jan 31. [https://doi.org/10.1038/leu.2013.29 link to original article] ''' | + | # '''PX-171-005:''' Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013 Aug;27(8):1707-14. Epub 2013 Jan 31. [https://doi.org/10.1038/leu.2013.29 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740399/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23364621/ PubMed] [https://clinicaltrials.gov/study/NCT00721734 NCT00721734] |
− | # '''MSK 10-228:''' Lendvai N, Hilden P, Devlin S, Landau H, Hassoun H, Lesokhin AM, Tsakos I, Redling K, Koehne G, Chung DJ, Schaffer WL, Giralt SA. A phase 2 single-center study of carfilzomib 56 mg/m<sup>2</sup> with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 2014 Aug 7;124(6):899-906. Epub 2014 Jun 24. [https://doi.org/10.1182/blood-2014-02-556308 link to original article] ''' | + | # '''MSK 10-228:''' Lendvai N, Hilden P, Devlin S, Landau H, Hassoun H, Lesokhin AM, Tsakos I, Redling K, Koehne G, Chung DJ, Schaffer WL, Giralt SA. A phase 2 single-center study of carfilzomib 56 mg/m<sup>2</sup> with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 2014 Aug 7;124(6):899-906. Epub 2014 Jun 24. [https://doi.org/10.1182/blood-2014-02-556308 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624439/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24963043/ PubMed] [https://clinicaltrials.gov/study/NCT01351623 NCT01351623] |
− | # '''PX-171-007:''' Papadopoulos KP, Siegel DS, Vesole DH, Lee P, Rosen ST, Zojwalla N, Holahan JR, Lee S, Wang Z, Badros A. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol. 2015 Mar 1;33(7):732-9. Epub 2014 Sep 15. [https://doi.org/10.1200/JCO.2013.52.3522 link to original article] ''' | + | # '''PX-171-007:''' Papadopoulos KP, Siegel DS, Vesole DH, Lee P, Rosen ST, Zojwalla N, Holahan JR, Lee S, Wang Z, Badros A. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol. 2015 Mar 1;33(7):732-9. Epub 2014 Sep 15. [https://doi.org/10.1200/JCO.2013.52.3522 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25225420/ PubMed] [https://clinicaltrials.gov/study/NCT00531284 NCT00531284] |
− | # Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2016 Mar;172(5):745-56. Epub 2016 Jan 5. [https://doi.org/10.1111/bjh.13900 link to original article] ''' | + | # Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2016 Mar;172(5):745-56. Epub 2016 Jan 5. [https://doi.org/10.1111/bjh.13900 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785611/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26732066/ PubMed] |
− | # '''FOCUS:''' Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. Epub 2016 Jun 24. [https://doi.org/10.1038/leu.2016.176 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220126/ link to PMC article] ''' | + | # '''FOCUS:''' Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. Epub 2016 Jun 24. [https://doi.org/10.1038/leu.2016.176 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220126/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27416912/ PubMed] [https://clinicaltrials.gov/study/NCT01302392 NCT01302392] |
==Daratumumab monotherapy {{#subobject:d45aea|Regimen=1}}== | ==Daratumumab monotherapy {{#subobject:d45aea|Regimen=1}}== | ||
Line 263: | Line 263: | ||
|- | |- | ||
|[https://doi.org/10.1056/nejmoa1506348 Lokhorst et al. 2015 (GEN501 part 2)] | |[https://doi.org/10.1056/nejmoa1506348 Lokhorst et al. 2015 (GEN501 part 2)] | ||
− | |2008 | + | |2008 to not reported |
|style="background-color:#91cf61"|Phase 1/2 (RT) | |style="background-color:#91cf61"|Phase 1/2 (RT) | ||
|- | |- | ||
|[https://doi.org/10.1016/s0140-6736(15)01120-4 Lonial et al. 2016 (SIRIUS)] | |[https://doi.org/10.1016/s0140-6736(15)01120-4 Lonial et al. 2016 (SIRIUS)] | ||
− | |2013 | + | |2013 to not reported |
|style="background-color:#91cf61"|Phase 2 (RT) | |style="background-color:#91cf61"|Phase 2 (RT) | ||
|- | |- | ||
Line 277: | Line 277: | ||
*SIRIUS: at least 3 lines of therapy including proteasome inhibitors and immunomodulatory drugs or refractory to both proteasome inhibitors and immunomodulatory drugs | *SIRIUS: at least 3 lines of therapy including proteasome inhibitors and immunomodulatory drugs or refractory to both proteasome inhibitors and immunomodulatory drugs | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab (Darzalex)]] as follows: | *[[Daratumumab (Darzalex)]] as follows: | ||
Line 320: | Line 320: | ||
*At least 3 lines of therapy including proteasome inhibitors and immunomodulatory drugs or refractory to both proteasome inhibitors and immunomodulatory drugs | *At least 3 lines of therapy including proteasome inhibitors and immunomodulatory drugs or refractory to both proteasome inhibitors and immunomodulatory drugs | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab (Darzalex)]] as follows: | *[[Daratumumab (Darzalex)]] as follows: | ||
Line 331: | Line 331: | ||
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Plesner, Torben, Lokhorst, Henk, Gimsing, Peter, Nahi, Hareth, Lisby, Steen, Richardson, Paul G. Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study. ASH Annual Meeting Abstracts 2012 120: 73 [https://doi.org/10.1182/blood.V120.21.73.73 link to abstract] --> | <!-- # '''Abstract:''' Plesner, Torben, Lokhorst, Henk, Gimsing, Peter, Nahi, Hareth, Lisby, Steen, Richardson, Paul G. Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study. ASH Annual Meeting Abstracts 2012 120: 73 [https://doi.org/10.1182/blood.V120.21.73.73 link to abstract] --> | ||
− | # '''GEN501 part 2:''' Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19. Epub 2015 Aug 26. [https://doi.org/10.1056/nejmoa1506348 link to original article] ''' | + | # '''GEN501 part 2:''' Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19. Epub 2015 Aug 26. [https://doi.org/10.1056/nejmoa1506348 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://doi.org/10.1056/NEJMoa1506348/suppl_file/nejmoa1506348_appendix.pdf link to supplementary appendix] [https://doi.org/10.1056/NEJMoa1506348/suppl_file/nejmoa1506348_protocol.pdf link to study protocol] [https://pubmed.ncbi.nlm.nih.gov/26308596/ PubMed] [https://clinicaltrials.gov/study/NCT00574288 NCT00574288] |
## '''Pooled update:''' Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016 Jul 7;128(1):37-44. Epub 2016 May 23. [https://doi.org/10.1182/blood-2016-03-705210 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937359/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27216216/ PubMed] | ## '''Pooled update:''' Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016 Jul 7;128(1):37-44. Epub 2016 May 23. [https://doi.org/10.1182/blood-2016-03-705210 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937359/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27216216/ PubMed] | ||
## '''Pooled update:''' Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 Jun;7(6):e447-e455. [https://doi.org/10.1016/s2352-3026(20)30081-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32470437/ PubMed] | ## '''Pooled update:''' Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 Jun;7(6):e447-e455. [https://doi.org/10.1016/s2352-3026(20)30081-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32470437/ PubMed] | ||
<!-- # '''Abstract:''' Sagar Lonial, Brendan M. Weiss, Saad Zafar Usmani, Seema Singhal, Ajai Chari, Nizar J. Bahlis, Andrew Belch, Amrita Y. Krishnan, Robert A. Vescio, María-Victoria Mateos, Amitabha Mazumder, Robert Z. Orlowski, Heather J Sutherland, Joan Blade, Emma Catherine Scott, Huaibao Feng, Imran Khan, Clarissa M. Uhlar, Tahamtan Ahmadi, Peter Michael Voorhees. Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius). 2015 ASCO Annual Meeting abstract LBA8512. [https://doi.org/10.1200/jco.2015.33.18_suppl.lba8512 link to abstract] --> | <!-- # '''Abstract:''' Sagar Lonial, Brendan M. Weiss, Saad Zafar Usmani, Seema Singhal, Ajai Chari, Nizar J. Bahlis, Andrew Belch, Amrita Y. Krishnan, Robert A. Vescio, María-Victoria Mateos, Amitabha Mazumder, Robert Z. Orlowski, Heather J Sutherland, Joan Blade, Emma Catherine Scott, Huaibao Feng, Imran Khan, Clarissa M. Uhlar, Tahamtan Ahmadi, Peter Michael Voorhees. Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius). 2015 ASCO Annual Meeting abstract LBA8512. [https://doi.org/10.1200/jco.2015.33.18_suppl.lba8512 link to abstract] --> | ||
− | # '''SIRIUS:''' Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 9;387(10027):1551-60. Epub 2016 Jan 7. [https://doi.org/10.1016/s0140-6736(15)01120-4 link to original article] ''' | + | # '''SIRIUS:''' Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 9;387(10027):1551-60. Epub 2016 Jan 7. [https://doi.org/10.1016/s0140-6736(15)01120-4 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/26778538/ PubMed] [https://clinicaltrials.gov/study/NCT01985126 NCT01985126] |
## '''Pooled update:''' Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016 Jul 7;128(1):37-44. Epub 2016 May 23. [https://doi.org/10.1182/blood-2016-03-705210 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937359/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27216216/ PubMed] | ## '''Pooled update:''' Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016 Jul 7;128(1):37-44. Epub 2016 May 23. [https://doi.org/10.1182/blood-2016-03-705210 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937359/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27216216/ PubMed] | ||
## '''Pooled update:''' Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 Jun;7(6):e447-e455. [https://doi.org/10.1016/s2352-3026(20)30081-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32470437/ PubMed] | ## '''Pooled update:''' Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 Jun;7(6):e447-e455. [https://doi.org/10.1016/s2352-3026(20)30081-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32470437/ PubMed] | ||
− | #'''COLUMBA:''' Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020 May;7(5):e370-e380. Epub 2020 Mar 23. [https://doi.org/10.1016/s2352-3026(20)30070-3 link to original article] ''' | + | #'''COLUMBA:''' Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020 May;7(5):e370-e380. Epub 2020 Mar 23. [https://doi.org/10.1016/s2352-3026(20)30070-3 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32213342/ PubMed] [https://clinicaltrials.gov/study/NCT03277105 NCT03277105] |
##'''Update:''' Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV. Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica. 2022 Oct 1;107(10):2408-2417. Epub 2022 Mar 31. [https://doi.org/10.3324/haematol.2021.279459 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521240/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35354247/ PubMed] | ##'''Update:''' Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV. Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica. 2022 Oct 1;107(10):2408-2417. Epub 2022 Mar 31. [https://doi.org/10.3324/haematol.2021.279459 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521240/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35354247/ PubMed] | ||
Line 362: | Line 362: | ||
*At least 3 lines of therapy including proteasome inhibitors and immunomodulatory drugs or refractory to both proteasome inhibitors and immunomodulatory drugs | *At least 3 lines of therapy including proteasome inhibitors and immunomodulatory drugs or refractory to both proteasome inhibitors and immunomodulatory drugs | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab and hyaluronidase (Darzalex Faspro)]] as follows: | *[[Daratumumab and hyaluronidase (Darzalex Faspro)]] as follows: | ||
Line 371: | Line 371: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''COLUMBA:''' Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020 May;7(5):e370-e380. Epub 2020 Mar 23. [https://doi.org/10.1016/s2352-3026(20)30070-3 link to original article] ''' | + | #'''COLUMBA:''' Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020 May;7(5):e370-e380. Epub 2020 Mar 23. [https://doi.org/10.1016/s2352-3026(20)30070-3 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32213342/ PubMed] [https://clinicaltrials.gov/study/NCT03277105 NCT03277105] |
##'''Update:''' Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV. Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica. 2022 Oct 1;107(10):2408-2417. Epub 2022 Mar 31. [https://doi.org/10.3324/haematol.2021.279459 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521240/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35354247/ PubMed] | ##'''Update:''' Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV. Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica. 2022 Oct 1;107(10):2408-2417. Epub 2022 Mar 31. [https://doi.org/10.3324/haematol.2021.279459 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521240/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35354247/ PubMed] | ||
==Elranatamab monotherapy {{#subobject:felcc1|Regimen=1}}== | ==Elranatamab monotherapy {{#subobject:felcc1|Regimen=1}}== | ||
Line 390: | Line 390: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[Elranatamab (Elrexfio)]] as follows: | *[[Elranatamab (Elrexfio)]] as follows: | ||
Line 402: | Line 402: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''MagnetisMM-3:''' Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023 Sep;29(9):2259-2267. Epub 2023 Aug 15. [https://doi.org/10.1038/s41591-023-02528-9 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10504075/ link to PMC article] ''' | + | #'''MagnetisMM-3:''' Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023 Sep;29(9):2259-2267. Epub 2023 Aug 15. [https://doi.org/10.1038/s41591-023-02528-9 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10504075/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37582952/ PubMed] [https://clinicaltrials.gov/study/NCT04649359 NCT04649359] |
##'''PRO analysis:''' Mohty M, Bahlis NJ, Nooka AK, DiBonaventura M, Ren J, Conte U. Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3. Br J Haematol. 2024 May;204(5):1801-1810. Epub 2024 Feb 29. [https://doi.org/10.1111/bjh.19346 link to original article] [https://pubmed.ncbi.nlm.nih.gov/38420657/ PubMed] | ##'''PRO analysis:''' Mohty M, Bahlis NJ, Nooka AK, DiBonaventura M, Ren J, Conte U. Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3. Br J Haematol. 2024 May;204(5):1801-1810. Epub 2024 Feb 29. [https://doi.org/10.1111/bjh.19346 link to original article] [https://pubmed.ncbi.nlm.nih.gov/38420657/ PubMed] | ||
Line 438: | Line 438: | ||
*[[Cellular_therapy_conditioning_regimens#Cyclophosphamide_.26_Fludarabine_.28FC.29|FC]] lymphodepletion | *[[Cellular_therapy_conditioning_regimens#Cyclophosphamide_.26_Fludarabine_.28FC.29|FC]] lymphodepletion | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[Idecabtagene vicleucel (Abecma)]] 150 x 10<sup>6</sup> to 450 x 10<sup>6</sup> CAR-positive T cells IV once on day 0 | *[[Idecabtagene vicleucel (Abecma)]] 150 x 10<sup>6</sup> to 450 x 10<sup>6</sup> CAR-positive T cells IV once on day 0 | ||
Line 447: | Line 447: | ||
# '''CRB-401:''' Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019 May 2;380(18):1726-1737. [https://doi.org/10.1056/NEJMoa1817226 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8202968/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31042825/ PubMed] [https://clinicaltrials.gov/study/NCT02658929 NCT02658929] | # '''CRB-401:''' Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019 May 2;380(18):1726-1737. [https://doi.org/10.1056/NEJMoa1817226 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8202968/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31042825/ PubMed] [https://clinicaltrials.gov/study/NCT02658929 NCT02658929] | ||
# '''KarMMa:''' Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 Feb 25;384(8):705-716. [https://doi.org/10.1056/nejmoa2024850 link to original article] [https://pubmed.ncbi.nlm.nih.gov/33626253/ PubMed] [https://clinicaltrials.gov/study/NCT03361748 NCT03361748] | # '''KarMMa:''' Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 Feb 25;384(8):705-716. [https://doi.org/10.1056/nejmoa2024850 link to original article] [https://pubmed.ncbi.nlm.nih.gov/33626253/ PubMed] [https://clinicaltrials.gov/study/NCT03361748 NCT03361748] | ||
− | #'''KarMMa-3:''' Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. [https://doi.org/10.1056/NEJMoa2213614 link to original article] ''' | + | #'''KarMMa-3:''' Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. [https://doi.org/10.1056/NEJMoa2213614 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/36762851/ PubMed] [https://clinicaltrials.gov/study/NCT03651128 NCT03651128] |
##'''PRO analysis:''' Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. [https://doi.org/10.1016/s2352-3026(24)00005-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/38423700/ PubMed] | ##'''PRO analysis:''' Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. [https://doi.org/10.1016/s2352-3026(24)00005-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/38423700/ PubMed] | ||
Line 464: | Line 464: | ||
|} | |} | ||
''Note: this is the dosing used in the expansion cohort.'' | ''Note: this is the dosing used in the expansion cohort.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Ixazomib (Ninlaro)]] 2 mg/m<sup>2</sup> PO once per day on days 1, 4, 8, 11 | *[[Ixazomib (Ninlaro)]] 2 mg/m<sup>2</sup> PO once per day on days 1, 4, 8, 11 | ||
Line 485: | Line 485: | ||
*At least 1 prior line of therapy | *At least 1 prior line of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Ixazomib (Ninlaro)]] 5.5 mg PO once per day on days 1, 8, 15 | *[[Ixazomib (Ninlaro)]] 5.5 mg PO once per day on days 1, 8, 15 | ||
Line 495: | Line 495: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''C16003:''' Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug 14;124(7):1038-46. Epub 2014 Jun 11. [https://doi.org/10.1182/blood-2014-01-548826 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574453/ link to PMC article] ''' | + | # '''C16003:''' Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug 14;124(7):1038-46. Epub 2014 Jun 11. [https://doi.org/10.1182/blood-2014-01-548826 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574453/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24920586/ PubMed] [https://clinicaltrials.gov/study/NCT00932698 NCT00932698] |
− | # '''MC1181:''' Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015 Aug 14;5:e338. [https://doi.org/10.1038/bcj.2015.60 link to original article] ''' | + | # '''MC1181:''' Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015 Aug 14;5:e338. [https://doi.org/10.1038/bcj.2015.60 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558585/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26275080/ PubMed] [https://clinicaltrials.gov/study/NCT01415882 NCT01415882] |
==Lenalidomide monotherapy {{#subobject:ea18d8|Regimen=1}}== | ==Lenalidomide monotherapy {{#subobject:ea18d8|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#ee6b6e"> | <div class="toccolours" style="background-color:#ee6b6e"> | ||
Line 521: | Line 521: | ||
|} | |} | ||
''Note: This regimen is essentially of historical interest, as neither dosing of lenalidomide is in common use now.'' | ''Note: This regimen is essentially of historical interest, as neither dosing of lenalidomide is in common use now.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Lenalidomide (Revlimid)]] 30 mg PO once per day on days 1 to 21 | *[[Lenalidomide (Revlimid)]] 30 mg PO once per day on days 1 to 21 | ||
Line 531: | Line 531: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15;108(10):3458-64. Epub 2006 Jul 13. [https://doi.org/10.1182/blood-2006-04-015909 link to original article] ''' | + | # Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15;108(10):3458-64. Epub 2006 Jul 13. [https://doi.org/10.1182/blood-2006-04-015909 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895441/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/16840727/ PubMed] |
− | # '''CC-5013-MM-014:''' Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009 Jul 23;114(4):772-8. Epub 2009 May 26. [https://doi.org/10.1182/blood-2008-12-196238 link to original article] ''' | + | # '''CC-5013-MM-014:''' Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009 Jul 23;114(4):772-8. Epub 2009 May 26. [https://doi.org/10.1182/blood-2008-12-196238 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/19471019/ PubMed] [https://clinicaltrials.gov/study/NCT00065351 NCT00065351] |
==Pomalidomide monotherapy {{#subobject:0e409f|Regimen=1}}== | ==Pomalidomide monotherapy {{#subobject:0e409f|Regimen=1}}== | ||
Line 545: | Line 545: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962162/ Richardson et al. 2014 (CC-4047-MM-002)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962162/ Richardson et al. 2014 (CC-4047-MM-002)] | ||
− | |2009 | + | |2009 to not reported |
|style="background-color:#1a9851"|Randomized Phase 2 (C) | |style="background-color:#1a9851"|Randomized Phase 2 (C) | ||
|[[#Pomalidomide_.26_Dexamethasone_.28Pd.29|Pd]] | |[[#Pomalidomide_.26_Dexamethasone_.28Pd.29|Pd]] | ||
Line 556: | Line 556: | ||
*At least 2 lines of therapy including lenalidomide and bortezomib | *At least 2 lines of therapy including lenalidomide and bortezomib | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | *[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | ||
Line 564: | Line 564: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''CC-4047-MM-002:''' Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson K. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20;123(12):1826-32. Epub 2014 Jan 13. Erratum in: Blood. 2014 May 15;123(20):3208-9. [https://doi.org/10.1182/blood-2013-11-538835 link to original article] ''' | + | # '''CC-4047-MM-002:''' Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson K. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20;123(12):1826-32. Epub 2014 Jan 13. Erratum in: Blood. 2014 May 15;123(20):3208-9. [https://doi.org/10.1182/blood-2013-11-538835 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962162/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24421329/ PubMed] [https://clinicaltrials.gov/study/NCT00833833 NCT00833833] |
==Talquetamab monotherapy {{#subobject:f156c1|Regimen=1}}== | ==Talquetamab monotherapy {{#subobject:f156c1|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 582: | Line 582: | ||
|- | |- | ||
|} | |} | ||
− | ''Note: this was one of two recommended phase 2 dose levels.'' | + | ''Note: this was one of two recommended phase 2 dose levels. Step-up dosing was used in the first week but the details are not clearly reported in the manuscript or in the appendix; the dosing here is from the [https://www.talveyhcp.com/dosing/ Talvey website].'' |
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Immunotherapy==== | ====Immunotherapy==== | ||
− | *[[Talquetamab (Talvey)]] 0.4 mg/kg SC once on day 1 | + | *[[Talquetamab (Talvey)]] as follows: |
− | '''7-day cycles''' | + | **Step-up: 0.01 mg/kg SC once on day 1, then 0.06 mg/kg SC on day 4 |
+ | **Cycle 1 onwards: 0.4 mg/kg SC once on day 1 | ||
+ | '''6-day course, then 7-day cycles''' | ||
</div></div><br> | </div></div><br> | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 604: | Line 606: | ||
|- | |- | ||
|} | |} | ||
− | ''Note: this was one of two recommended phase 2 dose levels.'' | + | ''Note: this was one of two recommended phase 2 dose levels. Step-up dosing was used in the first week but the details are not clearly reported in the manuscript or in the appendix; the dosing here is from the [https://www.talveyhcp.com/dosing/ Talvey website].'' |
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Immunotherapy==== | ====Immunotherapy==== | ||
− | *[[Talquetamab (Talvey)]] 0.8 mg/kg SC once on day 1 | + | *[[Talquetamab (Talvey)]] as follows: |
− | '''14-day cycles''' | + | **Step-up: 0.01 mg/kg SC once on day 1, then 0.06 mg/kg SC on day 4, then 0.4 mg/kg SC on day 7 |
+ | **Cycle 1 onwards: 0.8 mg/kg SC once on day 1 | ||
+ | '''9-day course, then 14-day cycles''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''MonumenTAL-1:''' Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R, Girgis S, Yang S, Goldsmith RB, Yao X, Pillarisetti K, Hilder BW, Russell J, Goldberg JD, Krishnan A. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022 Dec 15;387(24):2232-2244. Epub 2022 Dec 10. [https://doi.org/10.1056/nejmoa2204591 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/36507686/ PubMed] [https://clinicaltrials.gov/study/NCT03399799 NCT03399799] | + | #'''MonumenTAL-1:''' Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R, Girgis S, Yang S, Goldsmith RB, Yao X, Pillarisetti K, Hilder BW, Russell J, Goldberg JD, Krishnan A. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022 Dec 15;387(24):2232-2244. Epub 2022 Dec 10. [https://doi.org/10.1056/nejmoa2204591 link to original article] '''contains partial dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/36507686/ PubMed] [https://clinicaltrials.gov/study/NCT03399799 NCT03399799] |
==Teclistamab monotherapy {{#subobject:fgjcc1|Regimen=1}}== | ==Teclistamab monotherapy {{#subobject:fgjcc1|Regimen=1}}== | ||
Line 630: | Line 634: | ||
|style="background-color:#91cf61"|Phase 1 (RT) | |style="background-color:#91cf61"|Phase 1 (RT) | ||
|- | |- | ||
− | |[https:// | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587778/ Moreau et al. 2022 (MajesTEC-1 Phase 2)] |
|2020-2021 | |2020-2021 | ||
|style="background-color:#91cf61"|Phase 2 (RT) | |style="background-color:#91cf61"|Phase 2 (RT) | ||
|- | |- | ||
|} | |} | ||
− | ''Note: Phase 1 and phase 2 have different clinical trial ID's and are thus recorded separately; Moreau et al. 2022 is an | + | ''Note: Phase 1 and phase 2 have different clinical trial ID's and are thus recorded separately; Moreau et al. 2022 is an update to the phase 1 portion and the first publication of the phase 2 results.'' |
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[Teclistamab (Tecvayli)]] as follows: | *[[Teclistamab (Tecvayli)]] as follows: | ||
Line 645: | Line 649: | ||
===References=== | ===References=== | ||
#'''MajesTEC-1 Phase 1:''' Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021 Aug 21;398(10301):665-674. Epub 2021 Aug 10. [https://doi.org/10.1016/s0140-6736(21)01338-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34388396/ PubMed] [https://clinicaltrials.gov/study/NCT03145181 NCT03145181] | #'''MajesTEC-1 Phase 1:''' Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021 Aug 21;398(10301):665-674. Epub 2021 Aug 10. [https://doi.org/10.1016/s0140-6736(21)01338-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34388396/ PubMed] [https://clinicaltrials.gov/study/NCT03145181 NCT03145181] | ||
− | ##'''Update:''' Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022 Aug 11;387(6):495-505. Epub 2022 Jun 5. [https://doi.org/10.1056/nejmoa2203478 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35661166/ PubMed] | + | ##'''Update:''' Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022 Aug 11;387(6):495-505. Epub 2022 Jun 5. [https://doi.org/10.1056/nejmoa2203478 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587778/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35661166/ PubMed] |
− | #'''MajesTEC-1 Phase 2:''' Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022 Aug 11;387(6):495-505. Epub 2022 Jun 5. [https://doi.org/10.1056/nejmoa2203478 link to original article] ''' | + | #'''MajesTEC-1 Phase 2:''' Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022 Aug 11;387(6):495-505. Epub 2022 Jun 5. [https://doi.org/10.1056/nejmoa2203478 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587778/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35661166/ PubMed] [https://clinicaltrials.gov/study/NCT04557098 NCT04557098] |
==Thalidomide monotherapy {{#subobject:ff02e1|Regimen=1}}== | ==Thalidomide monotherapy {{#subobject:ff02e1|Regimen=1}}== | ||
Line 686: | Line 690: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Thalidomide (Thalomid)]] as follows: | *[[Thalidomide (Thalomid)]] as follows: | ||
Line 695: | Line 699: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Siegel D, Crowley J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18;341(21):1565-71. Erratum in: N Engl J Med 2000 Feb 3;342(5):364. [https://doi.org/10.1056/NEJM199911183412102 link to original article] ''' | + | # Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Siegel D, Crowley J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18;341(21):1565-71. Erratum in: N Engl J Med 2000 Feb 3;342(5):364. [https://doi.org/10.1056/NEJM199911183412102 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/10564685/ PubMed] |
# Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM). Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome. Eur J Haematol. 2012 Mar;88(3):249-59. Epub 2012 Jan 4. [https://doi.org/10.1111/j.1600-0609.2011.01729.x link to original article] [https://pubmed.ncbi.nlm.nih.gov/22023551/ PubMed] | # Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM). Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome. Eur J Haematol. 2012 Mar;88(3):249-59. Epub 2012 Jan 4. [https://doi.org/10.1111/j.1600-0609.2011.01729.x link to original article] [https://pubmed.ncbi.nlm.nih.gov/22023551/ PubMed] | ||
Line 712: | Line 716: | ||
|} | |} | ||
''Note: Andrulis et al. 2013 is a single patient case report with a good response. Sharman et al. reports two patients with good response. In the Hyman et al. 2015 trial, there were 5 patients with multiple myeloma; "No patients with multiple myeloma have had a response to date."'' | ''Note: Andrulis et al. 2013 is a single patient case report with a good response. Sharman et al. reports two patients with good response. In the Hyman et al. 2015 trial, there were 5 patients with multiple myeloma; "No patients with multiple myeloma have had a response to date."'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Vemurafenib (Zelboraf)]] 960 mg PO twice per day | *[[Vemurafenib (Zelboraf)]] 960 mg PO twice per day | ||
Line 718: | Line 722: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''Case report:''' Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013 Aug;3(8):862-9. Epub 2013 Apr 23. [https://doi.org/10.1158/2159-8290.cd-13-0014 link to original article] ''' | + | # '''Case report:''' Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013 Aug;3(8):862-9. Epub 2013 Apr 23. [https://doi.org/10.1158/2159-8290.cd-13-0014 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/23612012/ PubMed] |
# '''Case series:''' Sharman JP, Chmielecki J, Morosini D, Palmer GA, Ross JS, Stephens PJ, Stafl J, Miller VA, Ali SM. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e161-3. Epub 2014 Jun 11. [https://doi.org/10.1016/j.clml.2014.06.004 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24997557/ PubMed] | # '''Case series:''' Sharman JP, Chmielecki J, Morosini D, Palmer GA, Ross JS, Stephens PJ, Stafl J, Miller VA, Ali SM. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e161-3. Epub 2014 Jun 11. [https://doi.org/10.1016/j.clml.2014.06.004 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24997557/ PubMed] | ||
− | # '''VE-BASKET:''' Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015 Aug 20;373(8):726-36. [https://doi.org/10.1056/NEJMoa1502309 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971773/ link to PMC article] ''' | + | # '''VE-BASKET:''' Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015 Aug 20;373(8):726-36. [https://doi.org/10.1056/NEJMoa1502309 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971773/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/26287849/ PubMed] [https://clinicaltrials.gov/study/NCT01524978 NCT01524978] |
==Venetoclax monotherapy {{#subobject:cjguzb|Regimen=1}}== | ==Venetoclax monotherapy {{#subobject:cjguzb|Regimen=1}}== | ||
Line 731: | Line 735: | ||
|- | |- | ||
|[https://doi.org/10.1182/blood-2017-06-788786 Kumar et al. 2017 (M13-367)] | |[https://doi.org/10.1182/blood-2017-06-788786 Kumar et al. 2017 (M13-367)] | ||
− | |2012 | + | |2012 to not reported |
| style="background-color:#91cf61" |Phase 1, >20 pts in this cohort | | style="background-color:#91cf61" |Phase 1, >20 pts in this cohort | ||
|- | |- | ||
Line 740: | Line 744: | ||
*t(11;14) | *t(11;14) | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Venetoclax (Venclexta)]] as follows: | *[[Venetoclax (Venclexta)]] as follows: | ||
Line 749: | Line 753: | ||
===References=== | ===References=== | ||
− | #'''M13-367:''' Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017 Nov 30;130(22):2401-2409. Epub 2017 Oct 10. [https://doi.org/10.1182/blood-2017-06-788786 link to original article] ''' | + | #'''M13-367:''' Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017 Nov 30;130(22):2401-2409. Epub 2017 Oct 10. [https://doi.org/10.1182/blood-2017-06-788786 link to original article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29018077/ PubMed] [https://clinicaltrials.gov/study/NCT01794520 NCT01794520] |
=Relapsed or refractory, doublets= | =Relapsed or refractory, doublets= | ||
Line 784: | Line 788: | ||
*CA204-009 & BELLINI: 1 to 3 prior lines of therapy | *CA204-009 & BELLINI: 1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] as follows: | *[[Bortezomib (Velcade)]] as follows: | ||
Line 840: | Line 844: | ||
*MMY-3021: [[Multiple_myeloma_-_historical#Bortezomib_monotherapy|Bortezomib]] x 4 | *MMY-3021: [[Multiple_myeloma_-_historical#Bortezomib_monotherapy|Bortezomib]] x 4 | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11 | ||
Line 869: | Line 873: | ||
*1 to 3 prior lines of therapy | *1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] as follows: | *[[Bortezomib (Velcade)]] as follows: | ||
Line 907: | Line 911: | ||
*CR013165: 1 prior line of therapy | *CR013165: 1 prior line of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11 | ||
Line 955: | Line 959: | ||
*MMY-3021: [[Multiple_myeloma_-_historical#Bortezomib_monotherapy|Bortezomib]] x 4 | *MMY-3021: [[Multiple_myeloma_-_historical#Bortezomib_monotherapy|Bortezomib]] x 4 | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11 | ||
Line 987: | Line 991: | ||
*[[Multiple_myeloma_-_historical#Bortezomib_monotherapy|Bortezomib]] x 2 to 4 cycles | *[[Multiple_myeloma_-_historical#Bortezomib_monotherapy|Bortezomib]] x 2 to 4 cycles | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11 | *[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11 | ||
Line 1,026: | Line 1,030: | ||
*SUMMIT & MMY-3001: [[Multiple_myeloma_-_historical#Bortezomib_monotherapy|Bortezomib]] x 2 to 4 cycles | *SUMMIT & MMY-3001: [[Multiple_myeloma_-_historical#Bortezomib_monotherapy|Bortezomib]] x 2 to 4 cycles | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11 | ||
Line 1,054: | Line 1,058: | ||
*ENDEAVOR: 1 to 3 prior lines of therapy | *ENDEAVOR: 1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11 | ||
Line 1,081: | Line 1,085: | ||
*1 to 3 prior lines of therapy, including proteasome inhibitors | *1 to 3 prior lines of therapy, including proteasome inhibitors | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] as follows: | *[[Bortezomib (Velcade)]] as follows: | ||
Line 1,107: | Line 1,111: | ||
|} | |} | ||
''Note: treatment could be stopped if CR was achieved.'' | ''Note: treatment could be stopped if CR was achieved.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | ||
Line 1,115: | Line 1,119: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''SUMMIT:''' Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-17. [https://doi.org/10.1056/NEJMoa030288 link to original article] ''' | + | # '''SUMMIT:''' Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-17. [https://doi.org/10.1056/NEJMoa030288 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/12826635/ PubMed] |
− | ## '''Subgroup analysis:''' Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul;91(7):929-34. [https://haematologica.org/article/view/4067 link to original article] ''' | + | ## '''Subgroup analysis:''' Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul;91(7):929-34. [https://haematologica.org/article/view/4067 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/16818280/ PubMed] |
## '''Pooled subgroup analysis:''' Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007 Jan;21(1):151-7. Epub 2006 Nov 9. [https://doi.org/10.1038/sj.leu.2404442 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17096017/ PubMed] | ## '''Pooled subgroup analysis:''' Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007 Jan;21(1):151-7. Epub 2006 Nov 9. [https://doi.org/10.1038/sj.leu.2404442 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17096017/ PubMed] | ||
− | # '''CREST:''' Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004 Oct;127(2):165-72. [https://doi.org/10.1111/j.1365-2141.2004.05188.x link to original article] ''' | + | # '''CREST:''' Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004 Oct;127(2):165-72. [https://doi.org/10.1111/j.1365-2141.2004.05188.x link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15461622/ PubMed] |
− | ## '''Subgroup analysis:''' Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul;91(7):929-34. [https://haematologica.org/article/view/4067 link to original article] ''' | + | ## '''Subgroup analysis:''' Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul;91(7):929-34. [https://haematologica.org/article/view/4067 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/16818280/ PubMed] |
## '''Update:''' Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008 Nov;143(4):537-40. Epub 2008 Sep 6. [https://doi.org/10.1111/j.1365-2141.2008.07359.x link to original article] [https://pubmed.ncbi.nlm.nih.gov/18783399/ PubMed] | ## '''Update:''' Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008 Nov;143(4):537-40. Epub 2008 Sep 6. [https://doi.org/10.1111/j.1365-2141.2008.07359.x link to original article] [https://pubmed.ncbi.nlm.nih.gov/18783399/ PubMed] | ||
− | # '''MMY-3001:''' Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007 Sep 1;25(25):3892-901. Epub 2007 Aug 6. [https://doi.org/10.1200/jco.2006.10.5460 link to original article] ''' | + | # '''MMY-3001:''' Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007 Sep 1;25(25):3892-901. Epub 2007 Aug 6. [https://doi.org/10.1200/jco.2006.10.5460 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17679727/ PubMed] [https://clinicaltrials.gov/study/NCT00103506 NCT00103506] |
− | ## '''Update:''' Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009 Jan;144(2):169-75. Epub 2008 Nov 19. [https://doi.org/10.1111/j.1365-2141.2008.07409.x link to original article] ''' | + | ## '''Update:''' Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009 Jan;144(2):169-75. Epub 2008 Nov 19. [https://doi.org/10.1111/j.1365-2141.2008.07409.x link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/19036114/ PubMed] |
## '''Update:''' Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016 Jul 1;122(13):2050-6. Epub 2016 May 18. [https://doi.org/10.1002/cncr.30026 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5701574/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27191689/ PubMed] | ## '''Update:''' Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016 Jul 1;122(13):2050-6. Epub 2016 May 18. [https://doi.org/10.1002/cncr.30026 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5701574/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27191689/ PubMed] | ||
− | # '''MMY-3021:''' Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011 May;12(5):431-40. Epub 2011 Apr 18. [https://doi.org/10.1016/S1470-2045(11)70081-X link to original article] ''' | + | # '''MMY-3021:''' Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011 May;12(5):431-40. Epub 2011 Apr 18. [https://doi.org/10.1016/S1470-2045(11)70081-X link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21507715/ PubMed] [https://clinicaltrials.gov/study/NCT00722566 NCT00722566] |
## '''Update:''' Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012 Dec;97(12):1925-8. Epub 2012 Jun 11. [https://doi.org/10.3324/haematol.2012.067793 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685287/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22689676/ PubMed] | ## '''Update:''' Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012 Dec;97(12):1925-8. Epub 2012 Jun 11. [https://doi.org/10.3324/haematol.2012.067793 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685287/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22689676/ PubMed] | ||
## '''Subgroup analysis:''' Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Rekhtman G, Masliak Z, Robak P, Esseltine DL, Feng H, Deraedt W, van de Velde H, Arnulf B. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica. 2015 May;100(5):e207-10. Epub 2015 Jan 16. [https://doi.org/10.3324/haematol.2014.118182 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420234/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25596270/ PubMed] | ## '''Subgroup analysis:''' Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Rekhtman G, Masliak Z, Robak P, Esseltine DL, Feng H, Deraedt W, van de Velde H, Arnulf B. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica. 2015 May;100(5):e207-10. Epub 2015 Jan 16. [https://doi.org/10.3324/haematol.2014.118182 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420234/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25596270/ PubMed] | ||
− | # '''Retrospective:''' Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Nakajima H, Motoo Y, Umehara H. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res. 2011 Jun;31(6):2297-302. [https://ar.iiarjournals.org/content/31/6/2297/tab-article-info link to original article] ''' | + | # '''Retrospective:''' Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Nakajima H, Motoo Y, Umehara H. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res. 2011 Jun;31(6):2297-302. [https://ar.iiarjournals.org/content/31/6/2297/tab-article-info link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21737655/ PubMed] |
− | # '''NMSG 17/07:''' Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group. Thalidomide and dexamethasone vs bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol. 2012 Jun;88(6):485-96. Epub 2012 Mar 30. [https://doi.org/10.1111/j.1600-0609.2012.01775.x link to original article] ''' | + | # '''NMSG 17/07:''' Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group. Thalidomide and dexamethasone vs bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol. 2012 Jun;88(6):485-96. Epub 2012 Mar 30. [https://doi.org/10.1111/j.1600-0609.2012.01775.x link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492844/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22404182/ PubMed] [https://clinicaltrials.gov/study/NCT00602511 NCT00602511] |
− | # '''CR013165:''' Dimopoulos MA, Beksac M, Benboubker L, Roddie H, Allietta N, Broer E, Couturier C, Mazier MA, Angermund R, Facon T. Phase 2 study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica. 2013 Aug;98(8):1264-72. Epub 2013 May 28. [https://doi.org/10.3324/haematol.2013.084376 link to original article] ''' | + | # '''CR013165:''' Dimopoulos MA, Beksac M, Benboubker L, Roddie H, Allietta N, Broer E, Couturier C, Mazier MA, Angermund R, Facon T. Phase 2 study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica. 2013 Aug;98(8):1264-72. Epub 2013 May 28. [https://doi.org/10.3324/haematol.2013.084376 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729908/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23716559/ PubMed] [https://clinicaltrials.gov/study/NCT00908232 NCT00908232] |
<!-- Presented in abstract form at the American Society of Hematology Annual Meeting, Atlanta, GA, December 8-11, 2012. --> | <!-- Presented in abstract form at the American Society of Hematology Annual Meeting, Atlanta, GA, December 8-11, 2012. --> | ||
− | # '''PANORAMA 1:''' San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1195-206. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. [https://doi.org/10.1016/S1470-2045(14)70440-1 link to original article] ''' | + | # '''PANORAMA 1:''' San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1195-206. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. [https://doi.org/10.1016/S1470-2045(14)70440-1 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25242045/ PubMed] [https://clinicaltrials.gov/study/NCT01023308 NCT01023308] |
## '''Subgroup analysis:''' Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016 Feb 11;127(6):713-21. Epub 2015 Dec 2. [https://doi.org/10.1182/blood-2015-09-665018 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760132/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26631116/ PubMed] | ## '''Subgroup analysis:''' Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016 Feb 11;127(6):713-21. Epub 2015 Dec 2. [https://doi.org/10.1182/blood-2015-09-665018 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760132/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26631116/ PubMed] | ||
## '''Update:''' San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016 Nov;3(11):e506-e515. Epub 2016 Oct 14. [https://doi.org/10.1016/S2352-3026(16)30147-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/27751707/ PubMed] | ## '''Update:''' San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016 Nov;3(11):e506-e515. Epub 2016 Oct 14. [https://doi.org/10.1016/S2352-3026(16)30147-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/27751707/ PubMed] | ||
# '''ENDEAVOR:''' Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27-38. Epub 2015 Dec 5. [https://doi.org/10.1016/S1470-2045(15)00464-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26671818/ PubMed] [https://clinicaltrials.gov/study/NCT01568866 NCT01568866] | # '''ENDEAVOR:''' Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27-38. Epub 2015 Dec 5. [https://doi.org/10.1016/S1470-2045(15)00464-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26671818/ PubMed] [https://clinicaltrials.gov/study/NCT01568866 NCT01568866] | ||
− | ## '''Subgroup analysis:''' Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hájek R. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017 Jun;31(6):1368-1374. Epub 2016 Dec 27. [https://doi.org/10.1038/leu.2016.390 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467042/ link to PMC article] ''' | + | ## '''Subgroup analysis:''' Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hájek R. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017 Jun;31(6):1368-1374. Epub 2016 Dec 27. [https://doi.org/10.1038/leu.2016.390 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467042/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/28025582/ PubMed] |
## '''Update:''' Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1327-1337. Epub 2017 Aug 23. [https://doi.org/10.1016/S1470-2045(17)30578-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28843768/ PubMed] | ## '''Update:''' Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1327-1337. Epub 2017 Aug 23. [https://doi.org/10.1016/S1470-2045(17)30578-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28843768/ PubMed] | ||
## '''Update:''' Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):522-530.e1. Epub 2019 May 2. [https://doi.org/10.1016/j.clml.2019.04.018 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31160237/ PubMed] | ## '''Update:''' Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):522-530.e1. Epub 2019 May 2. [https://doi.org/10.1016/j.clml.2019.04.018 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31160237/ PubMed] | ||
− | # '''CA204-009:''' Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 Jun 9;127(23):2833-40. Epub 2016 Apr 18. [https://doi.org/10.1182/blood-2016-01-694604 link to original article] ''' | + | # '''CA204-009:''' Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 Jun 9;127(23):2833-40. Epub 2016 Apr 18. [https://doi.org/10.1182/blood-2016-01-694604 link to original article] '''dosing details in supplement have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900953/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27091875/ PubMed] [https://clinicaltrials.gov/study/NCT01478048 NCT01478048] |
<!-- # ASCO 2016 Abstract LBA4 --> | <!-- # ASCO 2016 Abstract LBA4 --> | ||
− | # '''CASTOR:''' Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. [https://doi.org/10.1056/NEJMoa1606038 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606038/suppl_file/nejmoa1606038_appendix.pdf link to supplementary appendix] ''' | + | # '''CASTOR:''' Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. [https://doi.org/10.1056/NEJMoa1606038 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606038/suppl_file/nejmoa1606038_appendix.pdf link to supplementary appendix] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27557302/ PubMed] [https://clinicaltrials.gov/study/NCT02136134 NCT02136134] |
## '''Update:''' Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Dec;103(12):2079-87. Epub 2018 Sep 20. [https://doi.org/10.3324/haematol.2018.194118 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6269293/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30237264/ PubMed] | ## '''Update:''' Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Dec;103(12):2079-87. Epub 2018 Sep 20. [https://doi.org/10.3324/haematol.2018.194118 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6269293/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30237264/ PubMed] | ||
## '''Update:''' Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, Corradini P, Min CK, Medvedova E, Weisel K, Chiu C, Schecter JM, Amin H, Qin X, Ukropec J, Kobos R, Spencer A. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):509-518. Epub 2019 Oct 9. [https://doi.org/10.1016/j.clml.2019.09.623 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32482541/ PubMed] | ## '''Update:''' Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, Corradini P, Min CK, Medvedova E, Weisel K, Chiu C, Schecter JM, Amin H, Qin X, Ukropec J, Kobos R, Spencer A. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):509-518. Epub 2019 Oct 9. [https://doi.org/10.1016/j.clml.2019.09.623 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32482541/ PubMed] | ||
Line 1,146: | Line 1,150: | ||
# '''CR015247:''' Kropff M, Vogel M, Bisping G, Schlag R, Weide R, Knauf W, Fiechtner H, Kojouharoff G, Kremers S, Berdel WE. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Ann Hematol. 2017 Nov;96(11):1857-1866. Epub 2017 Sep 14. [https://doi.org/10.1007/s00277-017-3065-z link to original article] [https://pubmed.ncbi.nlm.nih.gov/28905189/ PubMed] [https://clinicaltrials.gov/study/NCT00813150 NCT00813150] | # '''CR015247:''' Kropff M, Vogel M, Bisping G, Schlag R, Weide R, Knauf W, Fiechtner H, Kojouharoff G, Kremers S, Berdel WE. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Ann Hematol. 2017 Nov;96(11):1857-1866. Epub 2017 Sep 14. [https://doi.org/10.1007/s00277-017-3065-z link to original article] [https://pubmed.ncbi.nlm.nih.gov/28905189/ PubMed] [https://clinicaltrials.gov/study/NCT00813150 NCT00813150] | ||
# '''OPTIMRETREAT:''' Terpos E, Gobbi M, Potamianou A, Lahaye M, Couturier C, Cavo M. Retreatmentvand prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: a randomized, controlled, phase III study. Eur J Haematol. 2018 Jan;100(1):10-19. Epub 2017 Oct 30. [https://doi.org/10.1111/ejh.12937 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28801967/ PubMed] [https://clinicaltrials.gov/study/NCT01910987 NCT01910987] | # '''OPTIMRETREAT:''' Terpos E, Gobbi M, Potamianou A, Lahaye M, Couturier C, Cavo M. Retreatmentvand prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: a randomized, controlled, phase III study. Eur J Haematol. 2018 Jan;100(1):10-19. Epub 2017 Oct 30. [https://doi.org/10.1111/ejh.12937 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28801967/ PubMed] [https://clinicaltrials.gov/study/NCT01910987 NCT01910987] | ||
− | # '''BELLINI:''' Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Punnoose EA, Hong WJ, Freise KJ, Yang X, Sood A, Jalaluddin M, Ross JA, Ward JE, Maciag PC, Moreau P. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1630-1642. Epub 2020 Oct 29. [https://doi.org/10.1016/s1470-2045(20)30525-8 link to original article] ''' | + | # '''BELLINI:''' Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Punnoose EA, Hong WJ, Freise KJ, Yang X, Sood A, Jalaluddin M, Ross JA, Ward JE, Maciag PC, Moreau P. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1630-1642. Epub 2020 Oct 29. [https://doi.org/10.1016/s1470-2045(20)30525-8 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/33129376/ PubMed] [https://clinicaltrials.gov/study/NCT02755597 NCT02755597] |
− | # '''BOSTON:''' Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020 Nov 14;396(10262):1563-1573. [https://doi.org/10.1016/s0140-6736(20)32292-3 link to original article] ''' | + | # '''BOSTON:''' Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020 Nov 14;396(10262):1563-1573. [https://doi.org/10.1016/s0140-6736(20)32292-3 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/33189178/ PubMed] [https://clinicaltrials.gov/study/NCT03110562 NCT03110562] |
− | # '''LEPUS:''' Lu J, Fu W, Li W, Hu J, An G, Wang Y, Fu C, Chen L, Jin J, Cen X, Ge Z, Cai Z, Niu T, Qi M, Sun S, Gai X, Liu W, Liu W, Yang X, Huang X. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):e699-e709. Epub 2021 Apr 24. [https://doi.org/10.1016/j.clml.2021.04.012 link to original article] ''' | + | # '''LEPUS:''' Lu J, Fu W, Li W, Hu J, An G, Wang Y, Fu C, Chen L, Jin J, Cen X, Ge Z, Cai Z, Niu T, Qi M, Sun S, Gai X, Liu W, Liu W, Yang X, Huang X. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):e699-e709. Epub 2021 Apr 24. [https://doi.org/10.1016/j.clml.2021.04.012 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34108127/ PubMed] [https://clinicaltrials.gov/study/NCT03234972 NCT03234972] |
# '''BENCH:''' [https://clinicaltrials.gov/study/NCT04939142 NCT04939142] | # '''BENCH:''' [https://clinicaltrials.gov/study/NCT04939142 NCT04939142] | ||
# '''Perifosine 339:''' [https://clinicaltrials.gov/study/NCT01002248 NCT01002248] | # '''Perifosine 339:''' [https://clinicaltrials.gov/study/NCT01002248 NCT01002248] | ||
Line 1,173: | Line 1,177: | ||
*1 to 3 prior lines of therapy, not including bortezomib | *1 to 3 prior lines of therapy, not including bortezomib | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11 | ||
Line 1,183: | Line 1,187: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''MMY-3001:''' Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007 Sep 1;25(25):3892-901. Epub 2007 Aug 6. [https://doi.org/10.1200/jco.2006.10.5460 link to original article] ''' | + | # '''MMY-3001:''' Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007 Sep 1;25(25):3892-901. Epub 2007 Aug 6. [https://doi.org/10.1200/jco.2006.10.5460 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17679727/ PubMed] [https://clinicaltrials.gov/study/NCT00103506 NCT00103506] |
− | ## '''Update:''' Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009 Jan;144(2):169-75. Epub 2008 Nov 19. [https://doi.org/10.1111/j.1365-2141.2008.07409.x link to original article] ''' | + | ## '''Update:''' Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009 Jan;144(2):169-75. Epub 2008 Nov 19. [https://doi.org/10.1111/j.1365-2141.2008.07409.x link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/19036114/ PubMed] |
## '''Update:''' Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016 Jul 1;122(13):2050-6. Epub 2016 May 18. [https://doi.org/10.1002/cncr.30026 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5701574/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27191689/ PubMed] | ## '''Update:''' Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016 Jul 1;122(13):2050-6. Epub 2016 May 18. [https://doi.org/10.1002/cncr.30026 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5701574/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27191689/ PubMed] | ||
==Bortezomib & Vorinostat {{#subobject:2a5b7f|Regimen=1}}== | ==Bortezomib & Vorinostat {{#subobject:2a5b7f|Regimen=1}}== | ||
Line 1,207: | Line 1,211: | ||
*1 to 3 prior lines of therapy | *1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11 | ||
Line 1,214: | Line 1,218: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''VANTAGE 088:''' Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013 Oct;14(11):1129-1140. Epub 2013 Sep 19. [https://doi.org/10.1016/S1470-2045(13)70398-X link to original article] ''' | + | # '''VANTAGE 088:''' Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013 Oct;14(11):1129-1140. Epub 2013 Sep 19. [https://doi.org/10.1016/S1470-2045(13)70398-X link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24055414/ PubMed] [https://clinicaltrials.gov/study/NCT00773747 NCT00773747] |
==Carfilzomib & Dexamethasone (Kd) {{#subobject:0823d6|Regimen=1}}== | ==Carfilzomib & Dexamethasone (Kd) {{#subobject:0823d6|Regimen=1}}== | ||
Kd: '''<u>K</u>'''yprolis (Carfilzomib) & low-dose '''<u>d</u>'''examethasone | Kd: '''<u>K</u>'''yprolis (Carfilzomib) & low-dose '''<u>d</u>'''examethasone | ||
Line 1,238: | Line 1,242: | ||
*2 or 3 lines of therapy, including a proteasome inhibitor and an immunomodulatory agent | *2 or 3 lines of therapy, including a proteasome inhibitor and an immunomodulatory agent | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] as follows: | *[[Carfilzomib (Kyprolis)]] as follows: | ||
Line 1,290: | Line 1,294: | ||
*ENDEAVOR & IKEMA: 1 to 3 prior lines of therapy | *ENDEAVOR & IKEMA: 1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] as follows: | *[[Carfilzomib (Kyprolis)]] as follows: | ||
Line 1,296: | Line 1,300: | ||
**Cycle 2 onwards: 56 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16 | **Cycle 2 onwards: 56 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16 | ||
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
− | *[[Dexamethasone (Decadron)]] 20 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, | + | *[[Dexamethasone (Decadron)]] 20 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23 |
+ | **Some references mention using 40 mg PO or IV once on day 22, instead of 20 mg on days 22 & 23 | ||
'''28-day cycles''' | '''28-day cycles''' | ||
</div></div><br> | </div></div><br> | ||
Line 1,326: | Line 1,331: | ||
*ARROW<sub>MM</sub>: 2 or 3 lines of therapy, including a proteasome inhibitor and an immunomodulatory agent | *ARROW<sub>MM</sub>: 2 or 3 lines of therapy, including a proteasome inhibitor and an immunomodulatory agent | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] as follows: | *[[Carfilzomib (Kyprolis)]] as follows: | ||
Line 1,354: | Line 1,359: | ||
*[[#Carfilzomib_monotherapy|Carfilzomib]] x 2 to 4 cycles (carfilzomib dose escalation attained during this period) | *[[#Carfilzomib_monotherapy|Carfilzomib]] x 2 to 4 cycles (carfilzomib dose escalation attained during this period) | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] 27 mg/m<sup>2</sup> IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16 | *[[Carfilzomib (Kyprolis)]] 27 mg/m<sup>2</sup> IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16 | ||
Line 1,362: | Line 1,367: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''PX-171-005:''' Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013 Aug;27(8):1707-14. Epub 2013 Jan 31. [https://doi.org/10.1038/leu.2013.29 link to original article] ''' | + | # '''PX-171-005:''' Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013 Aug;27(8):1707-14. Epub 2013 Jan 31. [https://doi.org/10.1038/leu.2013.29 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740399/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23364621/ PubMed] [https://clinicaltrials.gov/study/NCT00721734 NCT00721734] |
− | # '''ENDEAVOR:''' Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27-38. Epub 2015 Dec 5. [https://doi.org/10.1016/S1470-2045(15)00464-7 link to original article] ''' | + | # '''ENDEAVOR:''' Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27-38. Epub 2015 Dec 5. [https://doi.org/10.1016/S1470-2045(15)00464-7 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/26671818/ PubMed] [https://clinicaltrials.gov/study/NCT01568866 NCT01568866] |
## '''Subgroup analysis:''' Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hájek R. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017 Jun;31(6):1368-1374. Epub 2016 Dec 27. [https://doi.org/10.1038/leu.2016.390 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467042/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28025582/ PubMed] | ## '''Subgroup analysis:''' Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hájek R. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017 Jun;31(6):1368-1374. Epub 2016 Dec 27. [https://doi.org/10.1038/leu.2016.390 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467042/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28025582/ PubMed] | ||
## '''Update:''' Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1327-1337. Epub 2017 Aug 23. [https://doi.org/10.1016/S1470-2045(17)30578-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28843768/ PubMed] | ## '''Update:''' Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1327-1337. Epub 2017 Aug 23. [https://doi.org/10.1016/S1470-2045(17)30578-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28843768/ PubMed] | ||
## '''Update:''' Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):522-530.e1. Epub 2019 May 2. [https://doi.org/10.1016/j.clml.2019.04.018 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31160237/ PubMed] | ## '''Update:''' Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):522-530.e1. Epub 2019 May 2. [https://doi.org/10.1016/j.clml.2019.04.018 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31160237/ PubMed] | ||
− | # '''CHAMPION-1:''' Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016 Jun 30;127(26):3360-8. Epub 2016 May 12. [https://doi.org/10.1182/blood-2015-11-683854 link to original article] ''' | + | # '''CHAMPION-1:''' Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016 Jun 30;127(26):3360-8. Epub 2016 May 12. [https://doi.org/10.1182/blood-2015-11-683854 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929927/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27207788/ PubMed] [https://clinicaltrials.gov/study/NCT01677858 NCT01677858] |
− | # '''ARROW<sub>MM</sub>:''' Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018 Jul;19(7):953-964. Epub 2018 Jun 1. Erratum in: Lancet Oncol. 2018 Aug;19(8):e382. [https://doi.org/10.1016/S1470-2045(18)30354-1 link to original article] ''' | + | # '''ARROW<sub>MM</sub>:''' Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018 Jul;19(7):953-964. Epub 2018 Jun 1. Erratum in: Lancet Oncol. 2018 Aug;19(8):e382. [https://doi.org/10.1016/S1470-2045(18)30354-1 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29866475/ PubMed] [https://clinicaltrials.gov/study/NCT02412878 NCT02412878] |
− | #'''CANDOR:''' Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 Jul 18;396(10245):186-197. [https://doi.org/10.1016/s0140-6736(20)30734-0 link to original article] ''' | + | #'''CANDOR:''' Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 Jul 18;396(10245):186-197. [https://doi.org/10.1016/s0140-6736(20)30734-0 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32682484/ PubMed] [https://clinicaltrials.gov/study/NCT03158688 NCT03158688] |
##'''Update:''' Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 Jan;23(1):65-76. Epub 2021 Dec 3. [https://doi.org/10.1016/s1470-2045(21)00579-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34871550/ PubMed] | ##'''Update:''' Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 Jan;23(1):65-76. Epub 2021 Dec 3. [https://doi.org/10.1016/s1470-2045(21)00579-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34871550/ PubMed] | ||
− | #'''IKEMA:''' Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 Jun 19;397(10292):2361-2371. Epub 2021 Jun 4. [https://doi.org/10.1016/s0140-6736(21)00592-4 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34097854/ PubMed] [https://clinicaltrials.gov/study/NCT03275285 NCT03275285] | + | #'''IKEMA:''' Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 Jun 19;397(10292):2361-2371. Epub 2021 Jun 4. [https://doi.org/10.1016/s0140-6736(21)00592-4 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34097854/ PubMed] [https://clinicaltrials.gov/study/NCT03275285 NCT03275285] |
<!-- ##'''Abstract:''' Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Casca F, Macé S, Risse ML, Moreau P. MM-064 Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S403-S404. [https://doi.org/10.1016/s2152-2650(22)01586-5 link to original abstract] --> | <!-- ##'''Abstract:''' Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Casca F, Macé S, Risse ML, Moreau P. MM-064 Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S403-S404. [https://doi.org/10.1016/s2152-2650(22)01586-5 link to original abstract] --> | ||
##'''Update:''' Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023 May 9;13(1):72. Erratum in: Blood Cancer J. 2023 Sep 27;13(1):152. [https://doi.org/10.1038/s41408-023-00797-8 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10166682/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37156782/ PubMed] | ##'''Update:''' Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023 May 9;13(1):72. Erratum in: Blood Cancer J. 2023 Sep 27;13(1):152. [https://doi.org/10.1038/s41408-023-00797-8 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10166682/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37156782/ PubMed] | ||
− | #'''KarMMa-3:''' Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. [https://doi.org/10.1056/NEJMoa2213614 link to original article] ''' | + | #'''KarMMa-3:''' Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. [https://doi.org/10.1056/NEJMoa2213614 link to original article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/36762851/ PubMed] [https://clinicaltrials.gov/study/NCT03651128 NCT03651128] |
##'''PRO analysis:''' Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. [https://doi.org/10.1016/s2352-3026(24)00005-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/38423700/ PubMed] | ##'''PRO analysis:''' Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. [https://doi.org/10.1016/s2352-3026(24)00005-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/38423700/ PubMed] | ||
==Carfilzomib & Panobinostat {{#subobject:9d99ab|Regimen=1}}== | ==Carfilzomib & Panobinostat {{#subobject:9d99ab|Regimen=1}}== | ||
Line 1,389: | Line 1,394: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] as follows: | *[[Carfilzomib (Kyprolis)]] as follows: | ||
Line 1,399: | Line 1,404: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''SCRI MM 27:''' Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS, Hainsworth JD, Flinn IW. Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Haematologica. 2015 May;100(5):670-6. Epub 2015 Feb 20. [https://doi.org/10.3324/haematol.2014.119735 link to original article] ''' | + | # '''SCRI MM 27:''' Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS, Hainsworth JD, Flinn IW. Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Haematologica. 2015 May;100(5):670-6. Epub 2015 Feb 20. [https://doi.org/10.3324/haematol.2014.119735 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420216/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25710456/ PubMed] [https://clinicaltrials.gov/study/NCT01496118 NCT01496118] |
==Cyclophosphamide & Dexamethasone {{#subobject:2c713a|Regimen=1}}== | ==Cyclophosphamide & Dexamethasone {{#subobject:2c713a|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 1,422: | Line 1,427: | ||
*At least 3 lines of therapy including bortezomib, lenalidomide or thalidomide, an alkylating agent, and corticosteroids | *At least 3 lines of therapy including bortezomib, lenalidomide or thalidomide, an alkylating agent, and corticosteroids | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day | *[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day | ||
Line 1,430: | Line 1,435: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''FOCUS:''' Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. Epub 2016 Jun 24. [https://doi.org/10.1038/leu.2016.176 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220126/ link to PMC article] ''' | + | # '''FOCUS:''' Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. Epub 2016 Jun 24. [https://doi.org/10.1038/leu.2016.176 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220126/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27416912/ PubMed] [https://clinicaltrials.gov/study/NCT01302392 NCT01302392] |
==Cyclophosphamide & Prednisone {{#subobject:969973|Regimen=1}}== | ==Cyclophosphamide & Prednisone {{#subobject:969973|Regimen=1}}== | ||
CP: '''<u>C</u>'''yclophosphamide & '''<u>P</u>'''rednisone | CP: '''<u>C</u>'''yclophosphamide & '''<u>P</u>'''rednisone | ||
Line 1,455: | Line 1,460: | ||
*At least 3 lines of therapy including bortezomib, lenalidomide or thalidomide, an alkylating agent, and corticosteroids | *At least 3 lines of therapy including bortezomib, lenalidomide or thalidomide, an alkylating agent, and corticosteroids | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day | *[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day | ||
Line 1,474: | Line 1,479: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 100 mg PO once per day | *[[Cyclophosphamide (Cytoxan)]] 100 mg PO once per day | ||
Line 1,482: | Line 1,487: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # de Weerdt O, van de Donk NW, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med. 2001 Aug;59(2):50-6. [https://doi.org/10.1016/s0300-2977(01)00140-1 link to original article] ''' | + | # de Weerdt O, van de Donk NW, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med. 2001 Aug;59(2):50-6. [https://doi.org/10.1016/s0300-2977(01)00140-1 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/11476912/ PubMed] |
− | # '''FOCUS:''' Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. Epub 2016 Jun 24. [https://doi.org/10.1038/leu.2016.176 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220126/ link to PMC article] ''' | + | # '''FOCUS:''' Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. Epub 2016 Jun 24. [https://doi.org/10.1038/leu.2016.176 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220126/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27416912/ PubMed] [https://clinicaltrials.gov/study/NCT01302392 NCT01302392] |
==Ixazomib & Dexamethasone {{#subobject:af43a2|Regimen=1}}== | ==Ixazomib & Dexamethasone {{#subobject:af43a2|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 1,505: | Line 1,510: | ||
*At least 1 prior line of therapy | *At least 1 prior line of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Ixazomib (Ninlaro)]] 4 mg PO once per day on days 1, 8, 15 | *[[Ixazomib (Ninlaro)]] 4 mg PO once per day on days 1, 8, 15 | ||
Line 1,534: | Line 1,539: | ||
*At least 1 prior line of therapy | *At least 1 prior line of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Ixazomib (Ninlaro)]] 5.5 mg PO once per day on days 1, 8, 15 | *[[Ixazomib (Ninlaro)]] 5.5 mg PO once per day on days 1, 8, 15 | ||
Line 1,544: | Line 1,549: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''MC1181 part 2:''' Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. 2016 Nov 17;128(20):2415-2422. Epub 2016 Oct 4. [https://doi.org/10.1182/blood-2016-05-717769 link to original article] ''' | + | # '''MC1181 part 2:''' Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. 2016 Nov 17;128(20):2415-2422. Epub 2016 Oct 4. [https://doi.org/10.1182/blood-2016-05-717769 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114487/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27702799/ PubMed] [https://clinicaltrials.gov/study/NCT01415882 NCT01415882] |
==Lenalidomide & Dexamethasone (Rd) {{#subobject:d6803b|Regimen=1}}== | ==Lenalidomide & Dexamethasone (Rd) {{#subobject:d6803b|Regimen=1}}== | ||
Line 1,611: | Line 1,616: | ||
*ASPIRE, ReLApsE, ELOQUENT-2, TOURMALINE-MM1, POLLUX, TOURMALINE-MM1 China Continuation: 1 to 3 prior lines of therapy | *ASPIRE, ReLApsE, ELOQUENT-2, TOURMALINE-MM1, POLLUX, TOURMALINE-MM1 China Continuation: 1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21 | *[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21 | ||
Line 1,655: | Line 1,660: | ||
*MM-009 & MM-010: At least 1 prior line of therapy | *MM-009 & MM-010: At least 1 prior line of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21 | *[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21 | ||
Line 1,672: | Line 1,677: | ||
|- | |- | ||
|[https://doi.org/10.1111/bjh.14562 Quach et al. 2017 (RevLite)] | |[https://doi.org/10.1111/bjh.14562 Quach et al. 2017 (RevLite)] | ||
− | |2007 | + | |2007 to not reported |
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Lenalidomide (Revlimid)]] 15 mg PO once per day on days 1 to 21 | *[[Lenalidomide (Revlimid)]] 15 mg PO once per day on days 1 to 21 | ||
Line 1,714: | Line 1,719: | ||
*[[#Lenalidomide_monotherapy|Lenalidomide]] x 2 | *[[#Lenalidomide_monotherapy|Lenalidomide]] x 2 | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Lenalidomide (Revlimid)]] 30 mg PO once per day on days 1 to 21 | *[[Lenalidomide (Revlimid)]] 30 mg PO once per day on days 1 to 21 | ||
Line 1,722: | Line 1,727: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15;108(10):3458-64. Epub 2006 Jul 13. [https://doi.org/10.1182/blood-2006-04-015909 link to original article] ''' | + | # Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15;108(10):3458-64. Epub 2006 Jul 13. [https://doi.org/10.1182/blood-2006-04-015909 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895441/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/16840727/ PubMed] |
− | # '''MM-010:''' Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123-32. [https://doi.org/10.1056/NEJMoa070594 link to original article] ''' | + | # '''MM-010:''' Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123-32. [https://doi.org/10.1056/NEJMoa070594 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18032762/ PubMed] [https://clinicaltrials.gov/study/NCT00424047 NCT00424047] |
## '''Pooled update:''' Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Nov;23(11):2147-52. Epub 2009 Jul 23. [https://doi.org/10.1038/leu.2009.147 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19626046/ PubMed] | ## '''Pooled update:''' Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Nov;23(11):2147-52. Epub 2009 Jul 23. [https://doi.org/10.1038/leu.2009.147 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19626046/ PubMed] | ||
− | # '''MM-009:''' Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42. [https://doi.org/10.1056/NEJMoa070596 link to original article] ''' | + | # '''MM-009:''' Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42. [https://doi.org/10.1056/NEJMoa070596 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18032763/ PubMed] [https://clinicaltrials.gov/study/NCT00056160 NCT00056160] |
## '''Pooled update:''' Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Nov;23(11):2147-52. Epub 2009 Jul 23. [https://doi.org/10.1038/leu.2009.147 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19626046/ PubMed] | ## '''Pooled update:''' Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Nov;23(11):2147-52. Epub 2009 Jul 23. [https://doi.org/10.1038/leu.2009.147 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19626046/ PubMed] | ||
− | # '''ASPIRE:''' Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. Epub 2014 Dec 6. [https://doi.org/10.1056/NEJMoa1411321 link to original article] ''' | + | # '''ASPIRE:''' Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. Epub 2014 Dec 6. [https://doi.org/10.1056/NEJMoa1411321 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25482145/ PubMed] [https://clinicaltrials.gov/study/NCT01080391 NCT01080391] |
## '''Subgroup analysis:''' Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80. Epub 2016 Jul 20. [https://doi.org/10.1182/blood-2016-03-707596 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009511/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27439911/ PubMed] | ## '''Subgroup analysis:''' Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80. Epub 2016 Jul 20. [https://doi.org/10.1182/blood-2016-03-707596 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009511/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27439911/ PubMed] | ||
## '''HRQoL analysis:''' Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016 Nov 10;34(32):3921-3930. [https://doi.org/10.1200/JCO.2016.66.9648 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5791840/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27601539/ PubMed] | ## '''HRQoL analysis:''' Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016 Nov 10;34(32):3921-3930. [https://doi.org/10.1200/JCO.2016.66.9648 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5791840/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27601539/ PubMed] | ||
## '''Update:''' Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018 Mar 10;36(8):728-734. Epub 2018 Jan 17. [https://doi.org/10.1200/JCO.2017.76.5032 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29341834/ PubMed] | ## '''Update:''' Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018 Mar 10;36(8):728-734. Epub 2018 Jan 17. [https://doi.org/10.1200/JCO.2017.76.5032 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29341834/ PubMed] | ||
− | # '''ELOQUENT-2:''' Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. Epub 2015 Jun 2. [https://doi.org/10.1056/NEJMoa1505654 link to original article] ''' | + | # '''ELOQUENT-2:''' Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. Epub 2015 Jun 2. [https://doi.org/10.1056/NEJMoa1505654 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/26035255/ PubMed] [https://clinicaltrials.gov/study/NCT01239797 NCT01239797] |
## '''Update:''' Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017 Sep;178(6):896-905. Epub 2017 Jul 5. [https://doi.org/10.1111/bjh.14787 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6084289/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28677826/ PubMed] | ## '''Update:''' Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017 Sep;178(6):896-905. Epub 2017 Jul 5. [https://doi.org/10.1111/bjh.14787 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6084289/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28677826/ PubMed] | ||
## '''Update:''' Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 Oct 15;124(20):4032-4043. Epub 2018 Sep 11. [https://doi.org/10.1002/cncr.31680 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30204239/ PubMed] | ## '''Update:''' Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 Oct 15;124(20):4032-4043. Epub 2018 Sep 11. [https://doi.org/10.1002/cncr.31680 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30204239/ PubMed] | ||
## '''Update:''' Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špička I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu KL, Anderson KC, Jou YM, Ganetsky A, Singhal AK, Richardson PG. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020 Sep 4;10(9):91. [https://doi.org/10.1038/s41408-020-00357-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7474076/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32887873/ PubMed] | ## '''Update:''' Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špička I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu KL, Anderson KC, Jou YM, Ganetsky A, Singhal AK, Richardson PG. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020 Sep 4;10(9):91. [https://doi.org/10.1038/s41408-020-00357-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7474076/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32887873/ PubMed] | ||
<!-- # '''Abstract:''' Philippe Moreau, MD, Tamás Masszi, MD, Norbert Grzasko, MD, PhD, Nizar J Bahlis, MD, Markus Hansson, Ludek Pour, MD, Irwindeep Sandhu, MD, Peter Ganly, BMBCh, PhD, Bartrum W Baker, MBChB, FRACP, FRCPA, Sharon Jackson, MBChB, FRACP, FRCPA, Anne-Marie Stoppa, MD, David R Simpson, MBChB, FRACP, FRCPA, Peter Gimsing, MD, DMSci, Antonio Palumbo, Laurent Garderet, MD, Michele Cavo, Shaji K. Kumar, MD, Cyrille Touzeau, MD, Francis Buadi, MD, Jacob P. Laubach, MD, Jianchang Lin, PhD, Deborah Berg, RN, MSN, Alessandra DiBacco, PhD, Ai-Min Hui, MD, PhD and Paul G. Richardson, MD. Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study ([https://clinicaltrials.gov/study/NCT01564537 NCT01564537]). ASH Annual Meeting 2015 Abstract 727--> | <!-- # '''Abstract:''' Philippe Moreau, MD, Tamás Masszi, MD, Norbert Grzasko, MD, PhD, Nizar J Bahlis, MD, Markus Hansson, Ludek Pour, MD, Irwindeep Sandhu, MD, Peter Ganly, BMBCh, PhD, Bartrum W Baker, MBChB, FRACP, FRCPA, Sharon Jackson, MBChB, FRACP, FRCPA, Anne-Marie Stoppa, MD, David R Simpson, MBChB, FRACP, FRCPA, Peter Gimsing, MD, DMSci, Antonio Palumbo, Laurent Garderet, MD, Michele Cavo, Shaji K. Kumar, MD, Cyrille Touzeau, MD, Francis Buadi, MD, Jacob P. Laubach, MD, Jianchang Lin, PhD, Deborah Berg, RN, MSN, Alessandra DiBacco, PhD, Ai-Min Hui, MD, PhD and Paul G. Richardson, MD. Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study ([https://clinicaltrials.gov/study/NCT01564537 NCT01564537]). ASH Annual Meeting 2015 Abstract 727--> | ||
− | # '''TOURMALINE-MM1:''' Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Apr 28;374(17):1621-1634. [https://doi.org/10.1056/NEJMoa1516282 link to original article] ''' | + | # '''TOURMALINE-MM1:''' Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Apr 28;374(17):1621-1634. [https://doi.org/10.1056/NEJMoa1516282 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27119237/ PubMed] [https://clinicaltrials.gov/study/NCT01564537 NCT01564537] |
## '''Subgroup analysis:''' Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017 Dec 14;130(24):2610-2618. Epub 2017 Oct 20. [https://doi.org/10.1182/blood-2017-06-791228 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29054911/ PubMed] | ## '''Subgroup analysis:''' Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017 Dec 14;130(24):2610-2618. Epub 2017 Oct 20. [https://doi.org/10.1182/blood-2017-06-791228 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29054911/ PubMed] | ||
## '''Update:''' Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Gimsing P, Garderet L, Touzeau C, Buadi FK, Laubach JP, Cavo M, Darif M, Labotka R, Berg D, Moreau P. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021 Aug 1;39(22):2430-2442. Epub 2021 Jun 11. [https://doi.org/10.1200/jco.21.00972 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34111952/ PubMed] | ## '''Update:''' Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Gimsing P, Garderet L, Touzeau C, Buadi FK, Laubach JP, Cavo M, Darif M, Labotka R, Berg D, Moreau P. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021 Aug 1;39(22):2430-2442. Epub 2021 Jun 11. [https://doi.org/10.1200/jco.21.00972 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34111952/ PubMed] | ||
− | # '''POLLUX:''' Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-1331. [https://doi.org/10.1056/NEJMoa1607751 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1607751/suppl_file/nejmoa1607751_protocol.pdf link to original protocol] ''' | + | # '''POLLUX:''' Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-1331. [https://doi.org/10.1056/NEJMoa1607751 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1607751/suppl_file/nejmoa1607751_protocol.pdf link to original protocol] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27705267/ PubMed] [https://clinicaltrials.gov/study/NCT02076009 NCT02076009] |
## '''Update:''' Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O' Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018 Dec;103(12):2088-96. Epub 2018 Sep 20. [https://doi.org/10.3324/haematol.2018.194282 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6269302/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30237262/ PubMed] | ## '''Update:''' Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O' Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018 Dec;103(12):2088-96. Epub 2018 Sep 20. [https://doi.org/10.3324/haematol.2018.194282 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6269302/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30237262/ PubMed] | ||
## '''Update:''' Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Krevvata M, Chiu C, Qin X, Okonkwo L, Trivedi S, Ukropec J, Qi M, San-Miguel J. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020 Jul;34(7):1875-1884. Epub 2020 Jan 30. [https://doi.org/10.1038/s41375-020-0711-6 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7326710/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32001798/ PubMed] | ## '''Update:''' Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Krevvata M, Chiu C, Qin X, Okonkwo L, Trivedi S, Ukropec J, Qi M, San-Miguel J. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020 Jul;34(7):1875-1884. Epub 2020 Jan 30. [https://doi.org/10.1038/s41375-020-0711-6 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7326710/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32001798/ PubMed] | ||
## '''Update:''' Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Moreau P. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 Mar 10;41(8):1590-1599. Epub 2023 Jan 4. [https://doi.org/10.1200/jco.22.00940 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10022849/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/36599114/ PubMed] | ## '''Update:''' Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Moreau P. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 Mar 10;41(8):1590-1599. Epub 2023 Jan 4. [https://doi.org/10.1200/jco.22.00940 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10022849/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/36599114/ PubMed] | ||
− | # '''RevLite:''' Quach H, Fernyhough L, Henderson R, Corbett G, Baker B, Browett P, Blacklock H, Forsyth C, Underhill C, Cannell P, Trotman J, Neylon A, Harrison S, Link E, Swern A, Cowan L, Dimopoulos MA, Miles Prince H. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. Br J Haematol. 2017 May;177(3):441-448. Epub 2017 Feb 15. [https://doi.org/10.1111/bjh.14562 link to original article]''' | + | # '''RevLite:''' Quach H, Fernyhough L, Henderson R, Corbett G, Baker B, Browett P, Blacklock H, Forsyth C, Underhill C, Cannell P, Trotman J, Neylon A, Harrison S, Link E, Swern A, Cowan L, Dimopoulos MA, Miles Prince H. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. Br J Haematol. 2017 May;177(3):441-448. Epub 2017 Feb 15. [https://doi.org/10.1111/bjh.14562 link to original article]'''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/28197996/ PubMed] [https://clinicaltrials.gov/study/NCT00482261 NCT00482261] |
− | # '''TOURMALINE-MM1 China Continuation:''' Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, Lu J, Du X, Chen X, Li J, Liu J, Gupta N, Hanley MJ, Li H, Hua Z, Wang B, Zhang X, Wang H, van de Velde H, Richardson PG, Moreau P. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J Hematol Oncol. 2017 Jul 6;10(1):137. [https://doi.org/10.1186/s13045-017-0501-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500972/ link to PMC article] ''' | + | # '''TOURMALINE-MM1 China Continuation:''' Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, Lu J, Du X, Chen X, Li J, Liu J, Gupta N, Hanley MJ, Li H, Hua Z, Wang B, Zhang X, Wang H, van de Velde H, Richardson PG, Moreau P. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J Hematol Oncol. 2017 Jul 6;10(1):137. [https://doi.org/10.1186/s13045-017-0501-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500972/ link to PMC article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/28683766/ PubMed] [https://clinicaltrials.gov/study/NCT01564537 NCT01564537] |
− | # '''ReLApsE:''' Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T, Raab MS, Hillengass J, Sauer S, Müller-Tidow C, Luntz S, Jauch A, Hose D, Seckinger A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Haenel M, Martin H, Lindemann HW, Scheid C, Nogai A, Salwender H, Noppeney R, Besemer B, Weisel K; German Myeloma Multicenter Group (GMMG). Salvage autologous transplant and lenalidomide maintenance vs lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2021 Apr;35(4):1134-1144. Epub 2020 Jul 21. [https://doi.org/10.1038/s41375-020-0948-0 link to original article] ''' | + | # '''ReLApsE:''' Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T, Raab MS, Hillengass J, Sauer S, Müller-Tidow C, Luntz S, Jauch A, Hose D, Seckinger A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Haenel M, Martin H, Lindemann HW, Scheid C, Nogai A, Salwender H, Noppeney R, Besemer B, Weisel K; German Myeloma Multicenter Group (GMMG). Salvage autologous transplant and lenalidomide maintenance vs lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2021 Apr;35(4):1134-1144. Epub 2020 Jul 21. [https://doi.org/10.1038/s41375-020-0948-0 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32694619/ PubMed] ISRCTN16345835 |
==Melphalan flufenamide & Dexamethasone {{#subobject:0f8gua|Regimen=1}}== | ==Melphalan flufenamide & Dexamethasone {{#subobject:0f8gua|Regimen=1}}== | ||
Line 1,771: | Line 1,776: | ||
|} | |} | ||
''Note: HORIZON should not be confused with the trial by the same name in breast cancer.'' | ''Note: HORIZON should not be confused with the trial by the same name in breast cancer.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Peptide-drug conjugate therapy==== | ====Peptide-drug conjugate therapy==== | ||
*[[Melphalan flufenamide (Pepaxto)]] 40 mg IV over 30 minutes once on day 1 | *[[Melphalan flufenamide (Pepaxto)]] 40 mg IV over 30 minutes once on day 1 | ||
Line 1,781: | Line 1,786: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''HORIZON<sub>RRMM</sub>:''' Richardson PG, Oriol A, Larocca A, Bladé J, Cavo M, Rodriguez-Otero P, Leleu X, Nadeem O, Hiemenz JW, Hassoun H, Touzeau C, Alegre A, Paner A, Maisel C, Mazumder A, Raptis A, Moreb JS, Anderson KC, Laubach JP, Thuresson S, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Mateos MV; HORIZON (OP-106) Investigators. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2021 Mar 1;39(7):757-767. Epub 2020 Dec 9. [https://doi.org/10.1200/jco.20.02259 link to original article] ''' | + | # '''HORIZON<sub>RRMM</sub>:''' Richardson PG, Oriol A, Larocca A, Bladé J, Cavo M, Rodriguez-Otero P, Leleu X, Nadeem O, Hiemenz JW, Hassoun H, Touzeau C, Alegre A, Paner A, Maisel C, Mazumder A, Raptis A, Moreb JS, Anderson KC, Laubach JP, Thuresson S, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Mateos MV; HORIZON (OP-106) Investigators. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2021 Mar 1;39(7):757-767. Epub 2020 Dec 9. [https://doi.org/10.1200/jco.20.02259 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8078327/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33296242/ PubMed] [https://clinicaltrials.gov/study/NCT02963493 NCT02963493] |
− | # '''OCEAN:''' Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R, Mateos MV, Richardson PG, Sonneveld P; OCEAN (OP-103) Investigators. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022 Feb;9(2):e98-e110. Epub 2022 Jan 12. [https://doi.org/10.1016/s2352-3026(21)00381-1 link to original article] ''' | + | # '''OCEAN:''' Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R, Mateos MV, Richardson PG, Sonneveld P; OCEAN (OP-103) Investigators. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022 Feb;9(2):e98-e110. Epub 2022 Jan 12. [https://doi.org/10.1016/s2352-3026(21)00381-1 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/35032434/ PubMed] [https://clinicaltrials.gov/study/NCT03151811 NCT03151811] |
##'''HRQoL analysis:''' Schjesvold FH, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, Pour L, Spicka I, Dimopoulos MA, Masszi T, Chernova NG, Sandberg A, Thuresson M, Norin S, Bakker NA, Mateos MV, Richardson PG, Sonneveld P. Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. Haematologica. 2024 Jul 1;109(7):2331-2336. [https://doi.org/10.3324/haematol.2023.284635 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11215352/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/38426292/ PubMed] | ##'''HRQoL analysis:''' Schjesvold FH, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, Pour L, Spicka I, Dimopoulos MA, Masszi T, Chernova NG, Sandberg A, Thuresson M, Norin S, Bakker NA, Mateos MV, Richardson PG, Sonneveld P. Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. Haematologica. 2024 Jul 1;109(7):2331-2336. [https://doi.org/10.3324/haematol.2023.284635 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11215352/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/38426292/ PubMed] | ||
Line 1,805: | Line 1,810: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962162/ Richardson et al. 2014 (CC-4047-MM-002)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962162/ Richardson et al. 2014 (CC-4047-MM-002)] | ||
− | |2009 | + | |2009 to not reported |
|style="background-color:#1a9851"|Randomized Phase 2 (E-RT-esc) | |style="background-color:#1a9851"|Randomized Phase 2 (E-RT-esc) | ||
|[[#Pomalidomide_monotherapy|Pomalidomide]] | |[[#Pomalidomide_monotherapy|Pomalidomide]] | ||
Line 1,884: | Line 1,889: | ||
*OCEAN: 2 to 4 prior lines of therapy including lenalidomide and a proteasome inhibitor | *OCEAN: 2 to 4 prior lines of therapy including lenalidomide and a proteasome inhibitor | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | *[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | ||
Line 1,929: | Line 1,934: | ||
*IFM 2009-02: At least 1 prior line of therapy | *IFM 2009-02: At least 1 prior line of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 28 | *[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 28 | ||
Line 1,953: | Line 1,958: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pomalidomide (Pomalyst)]] 2 mg PO once per day on days 1 to 28 | *[[Pomalidomide (Pomalyst)]] 2 mg PO once per day on days 1 to 28 | ||
Line 1,964: | Line 1,969: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''MC0789<sub>MM</sub>:''' Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009 Oct 20;27(30):5008-14. Epub 2009 Aug 31. [https://doi.org/10.1200/jco.2009.23.6802 link to original article] ''' | + | # '''MC0789<sub>MM</sub>:''' Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009 Oct 20;27(30):5008-14. Epub 2009 Aug 31. [https://doi.org/10.1200/jco.2009.23.6802 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/19720894/ PubMed] [https://clinicaltrials.gov/study/NCT00558896 NCT00558896] |
− | ## '''Update:''' Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010 Nov;24(11):1934-9. Epub 2010 Sep 9. [https://doi.org/10.1038/leu.2010.190 link to original article] ''' | + | ## '''Update:''' Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010 Nov;24(11):1934-9. Epub 2010 Sep 9. [https://doi.org/10.1038/leu.2010.190 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978257/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20827286/ PubMed] |
− | ## '''Update:''' Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011 Sep 15;118(11):2970-5. Epub 2011 Jun 20. [https://doi.org/10.1182/blood-2011-04-348896 link to original article] ''' | + | ## '''Update:''' Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011 Sep 15;118(11):2970-5. Epub 2011 Jun 20. [https://doi.org/10.1182/blood-2011-04-348896 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291492/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21690557/ PubMed] |
− | # '''IFM 2009-02:''' Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C, Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, Hennache B, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D, Fermand JP, Avet-Loiseau H, Facon T. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02. Blood. 2013 Mar 14;121(11):1968-1975. Epub 2013 Jan 14. [https://doi.org/10.1182/blood-2012-09-452375 link to original article] ''' | + | # '''IFM 2009-02:''' Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C, Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, Hennache B, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D, Fermand JP, Avet-Loiseau H, Facon T. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02. Blood. 2013 Mar 14;121(11):1968-1975. Epub 2013 Jan 14. [https://doi.org/10.1182/blood-2012-09-452375 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/23319574/ PubMed] [https://clinicaltrials.gov/study/NCT01053949 NCT01053949] |
− | # '''NIMBUS:''' San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055-66. Epub 2013 Sep 3. [https://doi.org/10.1016/S1470-2045(13)70380-2 link to original article] ''' | + | # '''NIMBUS:''' San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055-66. Epub 2013 Sep 3. [https://doi.org/10.1016/S1470-2045(13)70380-2 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24007748/ PubMed] [https://clinicaltrials.gov/study/NCT01311687 NCT01311687] |
## '''Update:''' Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015 Oct;100(10):1327-33. Epub 2015 Aug 6. [https://doi.org/10.3324/haematol.2014.117077 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591765/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26250580/ PubMed] | ## '''Update:''' Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015 Oct;100(10):1327-33. Epub 2015 Aug 6. [https://doi.org/10.3324/haematol.2014.117077 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591765/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26250580/ PubMed] | ||
− | # '''CC-4047-MM-002:''' Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson K. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20;123(12):1826-32. Epub 2014 Jan 13. Erratum in: Blood. 2014 May 15;123(20):3208-9. [https://doi.org/10.1182/blood-2013-11-538835 link to original article] ''' | + | # '''CC-4047-MM-002:''' Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson K. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20;123(12):1826-32. Epub 2014 Jan 13. Erratum in: Blood. 2014 May 15;123(20):3208-9. [https://doi.org/10.1182/blood-2013-11-538835 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962162/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24421329/ PubMed] [https://clinicaltrials.gov/study/NCT00833833 NCT00833833] |
− | # '''IFM 2010-02:''' Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood. 2015 Feb 26;125(9):1411-7. Epub 2015 Jan 9. [https://doi.org/10.1182/blood-2014-11-612069 link to original article] ''' | + | # '''IFM 2010-02:''' Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood. 2015 Feb 26;125(9):1411-7. Epub 2015 Jan 9. [https://doi.org/10.1182/blood-2014-11-612069 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25575538/ PubMed] [https://clinicaltrials.gov/study/NCT01745640 NCT01745640] |
<!-- Presented in part at the annual meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2014. --> | <!-- Presented in part at the annual meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2014. --> | ||
− | # '''PO-MM-PI-0039:''' Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May 26;127(21):2561-8. Epub 2016 Mar 1. Erratum in: Blood. 2016 Jul 21;128(3):461. [https://doi.org/10.1182/blood-2015-11-682518 link to original article] ''' | + | # '''PO-MM-PI-0039:''' Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May 26;127(21):2561-8. Epub 2016 Mar 1. Erratum in: Blood. 2016 Jul 21;128(3):461. [https://doi.org/10.1182/blood-2015-11-682518 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/26932802/ PubMed] [https://clinicaltrials.gov/study/NCT01432600 NCT01432600] |
− | # '''STRATUS:''' Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Röllig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016 Jul 28;128(4):497-503. Epub 2016 May 25. [https://doi.org/10.1182/blood-2016-02-700872 link to original article] ''' | + | # '''STRATUS:''' Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Röllig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016 Jul 28;128(4):497-503. Epub 2016 May 25. [https://doi.org/10.1182/blood-2016-02-700872 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009959/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27226434/ PubMed] [https://clinicaltrials.gov/study/NCT01712789 NCT01712789] |
− | # '''ELOQUENT-3:''' Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018 Nov 8;379(19):1811-1822. [https://doi.org/10.1056/NEJMoa1805762 link to original article] ''' | + | # '''ELOQUENT-3:''' Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018 Nov 8;379(19):1811-1822. [https://doi.org/10.1056/NEJMoa1805762 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/30403938/ PubMed] [https://clinicaltrials.gov/study/NCT02654132 NCT02654132] |
##'''Update:''' Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol. 2023 Jan 20;41(3):568-578. Epub 2022 Aug 12. [https://doi.org/10.1200/jco.21.02815 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870233/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35960908/ PubMed] | ##'''Update:''' Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol. 2023 Jan 20;41(3):568-578. Epub 2022 Aug 12. [https://doi.org/10.1200/jco.21.02815 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870233/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35960908/ PubMed] | ||
− | # '''KEYNOTE-183:''' Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019 Sep;6(9):e459-e469. Epub 2019 Jul 18. [https://doi.org/10.1016/S2352-3026(19)30110-3 link to original article] ''' | + | # '''KEYNOTE-183:''' Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019 Sep;6(9):e459-e469. Epub 2019 Jul 18. [https://doi.org/10.1016/S2352-3026(19)30110-3 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/31327687/ PubMed] [https://clinicaltrials.gov/study/NCT02576977 NCT02576977] |
− | # '''ICARIA-MM:''' Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107. Epub 2019 Nov 14. Erratum in: Lancet. 2019 Dec 7;394(10214):2072. [https://doi.org/10.1016/s0140-6736(19)32556-5 link to original article] ''' | + | # '''ICARIA-MM:''' Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107. Epub 2019 Nov 14. Erratum in: Lancet. 2019 Dec 7;394(10214):2072. [https://doi.org/10.1016/s0140-6736(19)32556-5 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/31735560/ PubMed] [https://clinicaltrials.gov/study/NCT02990338 NCT02990338] |
##'''Update:''' Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 Mar;23(3):416-427. Epub 2022 Feb 10. [https://doi.org/10.1016/s1470-2045(22)00019-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35151415/ PubMed] | ##'''Update:''' Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 Mar;23(3):416-427. Epub 2022 Feb 10. [https://doi.org/10.1016/s1470-2045(22)00019-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35151415/ PubMed] | ||
##'''Update:''' Richardson PG, Perrot A, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Macé S, Zhang R, Dubin F, Morisse MC, Anderson KC. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica. 2024 Jul 1;109(7):2239-2249. [https://doi.org/10.3324/haematol.2023.284325 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11215383/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/38299578/ PubMed] | ##'''Update:''' Richardson PG, Perrot A, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Macé S, Zhang R, Dubin F, Morisse MC, Anderson KC. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica. 2024 Jul 1;109(7):2239-2249. [https://doi.org/10.3324/haematol.2023.284325 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11215383/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/38299578/ PubMed] | ||
− | # '''APOLLO:''' Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Jun;22(6):801-812. [https://doi.org/10.1016/s1470-2045(21)00128-5 link to original article] ''' | + | # '''APOLLO:''' Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Jun;22(6):801-812. [https://doi.org/10.1016/s1470-2045(21)00128-5 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34087126/ PubMed] [https://clinicaltrials.gov/study/NCT03180736 NCT03180736] |
##'''Update:''' Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Kampfenkel T, Liu W, Wang J, Kosh M, Tran N, Carson R, Sonneveld P. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. Lancet Haematol. 2023 Oct;10(10):e813-e824. [https://doi.org/10.1016/s2352-3026(23)00218-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37793772/ PubMed] | ##'''Update:''' Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Kampfenkel T, Liu W, Wang J, Kosh M, Tran N, Carson R, Sonneveld P. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. Lancet Haematol. 2023 Oct;10(10):e813-e824. [https://doi.org/10.1016/s2352-3026(23)00218-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37793772/ PubMed] | ||
− | # '''OCEAN:''' Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R, Mateos MV, Richardson PG, Sonneveld P; OCEAN (OP-103) Investigators. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022 Feb;9(2):e98-e110. Epub 2022 Jan 12. [https://doi.org/10.1016/s2352-3026(21)00381-1 link to original article] ''' | + | # '''OCEAN:''' Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R, Mateos MV, Richardson PG, Sonneveld P; OCEAN (OP-103) Investigators. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022 Feb;9(2):e98-e110. Epub 2022 Jan 12. [https://doi.org/10.1016/s2352-3026(21)00381-1 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/35032434/ PubMed] [https://clinicaltrials.gov/study/NCT03151811 NCT03151811] |
##'''HRQoL analysis:''' Schjesvold FH, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, Pour L, Spicka I, Dimopoulos MA, Masszi T, Chernova NG, Sandberg A, Thuresson M, Norin S, Bakker NA, Mateos MV, Richardson PG, Sonneveld P. Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. Haematologica. 2024 Jul 1;109(7):2331-2336. [https://doi.org/10.3324/haematol.2023.284635 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11215352/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/38426292/ PubMed] | ##'''HRQoL analysis:''' Schjesvold FH, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, Pour L, Spicka I, Dimopoulos MA, Masszi T, Chernova NG, Sandberg A, Thuresson M, Norin S, Bakker NA, Mateos MV, Richardson PG, Sonneveld P. Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. Haematologica. 2024 Jul 1;109(7):2331-2336. [https://doi.org/10.3324/haematol.2023.284635 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11215352/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/38426292/ PubMed] | ||
# '''DREAMM-3:''' Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023 Oct;10(10):e801-e812. [https://doi.org/10.1016/s2352-3026(23)00243-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37793771/ PubMed] [https://clinicaltrials.gov/study/NCT04162210 NCT04162210] | # '''DREAMM-3:''' Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023 Oct;10(10):e801-e812. [https://doi.org/10.1016/s2352-3026(23)00243-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37793771/ PubMed] [https://clinicaltrials.gov/study/NCT04162210 NCT04162210] | ||
Line 2,007: | Line 2,012: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Selinexor (Xpovio)]] 80 mg PO once per day on days 1, 3, 8, 10, 15, 17, 22, 24 | *[[Selinexor (Xpovio)]] 80 mg PO once per day on days 1, 3, 8, 10, 15, 17, 22, 24 | ||
Line 2,015: | Line 2,020: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''STORM:''' Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol. 2018 Mar 20;36(9):859-866. Epub 2018 Jan 30. [https://doi.org/10.1200/JCO.2017.75.5207 link to original article] ''' | + | # '''STORM:''' Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol. 2018 Mar 20;36(9):859-866. Epub 2018 Jan 30. [https://doi.org/10.1200/JCO.2017.75.5207 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6905485/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29381435/ PubMed] [https://clinicaltrials.gov/study/NCT02336815 NCT02336815] |
## '''Update:''' Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019 Aug 22;381(8):727-738. [https://doi.org/10.1056/NEJMoa1903455 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31433920/ PubMed] | ## '''Update:''' Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019 Aug 22;381(8):727-738. [https://doi.org/10.1056/NEJMoa1903455 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31433920/ PubMed] | ||
==Thalidomide & Dexamethasone (TD) {{#subobject:13f920|Regimen=1}}== | ==Thalidomide & Dexamethasone (TD) {{#subobject:13f920|Regimen=1}}== | ||
Line 2,043: | Line 2,048: | ||
*CPT-MM301: Two or more prior regimens and not eligible for HSCT | *CPT-MM301: Two or more prior regimens and not eligible for HSCT | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Thalidomide (Thalomid)]] 150 mg PO once per day | *[[Thalidomide (Thalomid)]] 150 mg PO once per day | ||
Line 2,071: | Line 2,076: | ||
*NMSG 17/07: Failure of melphalan with no prior exposure to bortezomib or thalidomide | *NMSG 17/07: Failure of melphalan with no prior exposure to bortezomib or thalidomide | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Thalidomide (Thalomid)]] 50 mg PO once per day, increased by 50 mg every 3 weeks to a maximum of 200 mg PO once per day | *[[Thalidomide (Thalomid)]] 50 mg PO once per day, increased by 50 mg every 3 weeks to a maximum of 200 mg PO once per day | ||
Line 2,100: | Line 2,105: | ||
*At least 1 autologous stem-cell transplant | *At least 1 autologous stem-cell transplant | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Thalidomide (Thalomid)]] 200 mg PO once per day | *[[Thalidomide (Thalomid)]] 200 mg PO once per day | ||
Line 2,122: | Line 2,127: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Thalidomide (Thalomid)]] as follows: | *[[Thalidomide (Thalomid)]] as follows: | ||
Line 2,134: | Line 2,139: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001 Jul;12(7):991-5. [https://doi.org/10.1023/a:1011132808904 link to original article] ''' | + | # Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001 Jul;12(7):991-5. [https://doi.org/10.1023/a:1011132808904 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/11521808/ PubMed] |
− | # '''NMSG 17/07:''' Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group. Thalidomide and dexamethasone vs bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol. 2012 Jun;88(6):485-96. Epub 2012 Mar 30. [https://doi.org/10.1111/j.1600-0609.2012.01775.x link to original article] ''' | + | # '''NMSG 17/07:''' Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group. Thalidomide and dexamethasone vs bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol. 2012 Jun;88(6):485-96. Epub 2012 Mar 30. [https://doi.org/10.1111/j.1600-0609.2012.01775.x link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492844/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22404182/ PubMed] [https://clinicaltrials.gov/study/NCT00602511 NCT00602511] |
<!-- Presented at the 37th Annual Meeting of the European Group for Blood and Marrow Transplantation, Paris, France, April, 3-6, 2011. --> | <!-- Presented at the 37th Annual Meeting of the European Group for Blood and Marrow Transplantation, Paris, France, April, 3-6, 2011. --> | ||
− | # '''MMVAR/IFM 2005-04:''' Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012 Jul 10;30(20):2475-82. Epub 2012 May 14. Erratum in: J Clin Oncol. 2012 Sep 20;30(27):3429. [https://doi.org/10.1200/jco.2011.37.4918 link to original article] ''' | + | # '''MMVAR/IFM 2005-04:''' Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012 Jul 10;30(20):2475-82. Epub 2012 May 14. Erratum in: J Clin Oncol. 2012 Sep 20;30(27):3429. [https://doi.org/10.1200/jco.2011.37.4918 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/22585692/ PubMed] [https://clinicaltrials.gov/study/NCT00256776 NCT00256776] |
− | #'''CPT-MM301:''' Xia Z, Leng Y, Fang B, Liang Y, Li W, Fu C, Yang L, Ke X, Jiang H, Weng J, Liu L, Zhao Y, Zhang X, Huang Z, Liu A, Shi Q, Gao Y, Chen X, Pan L, Cai Z, Wang Z, Wang Y, Fan Y, Hou M, Ma Y, Hu J, Liu J, Zhou J, Zhang X, Meng H, Lu X, Li F, Ren H, Huang B, Shao Z, Zhou H, Hu Y, Yang S, Zheng X, Wei P, Pang H, Yu W, Liu Y, Gao S, Yan L, Ma Y, Jing H, Du J, Ling W, Zhang J, Sui W, Wang F, Li X, Chen W. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial. BMC Cancer. 2023 Oct 14;23(1):980. [https://doi.org/10.1186/s12885-023-11489-8 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10576321/ link to PMC article] ''' | + | #'''CPT-MM301:''' Xia Z, Leng Y, Fang B, Liang Y, Li W, Fu C, Yang L, Ke X, Jiang H, Weng J, Liu L, Zhao Y, Zhang X, Huang Z, Liu A, Shi Q, Gao Y, Chen X, Pan L, Cai Z, Wang Z, Wang Y, Fan Y, Hou M, Ma Y, Hu J, Liu J, Zhou J, Zhang X, Meng H, Lu X, Li F, Ren H, Huang B, Shao Z, Zhou H, Hu Y, Yang S, Zheng X, Wei P, Pang H, Yu W, Liu Y, Gao S, Yan L, Ma Y, Jing H, Du J, Ling W, Zhang J, Sui W, Wang F, Li X, Chen W. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial. BMC Cancer. 2023 Oct 14;23(1):980. [https://doi.org/10.1186/s12885-023-11489-8 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10576321/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37838670/ PubMed] ChiCTR-IPR-15006024 |
=Relapsed or refractory, triplets= | =Relapsed or refractory, triplets= | ||
Line 2,155: | Line 2,160: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Bendamustine]] 70 mg/m<sup>2</sup> IV once per day on days 1 & 4 | *[[Bendamustine]] 70 mg/m<sup>2</sup> IV once per day on days 1 & 4 | ||
Line 2,165: | Line 2,170: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''AFAC BBD:''' Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weißmann A, Adam Z. Bendamustine-bortezomib-dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014 Feb 13;123(7):985-91. Epub 2013 Nov 13. [https://doi.org/10.1182/blood-2013-08-521468 link to original article] ''' | + | # '''AFAC BBD:''' Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weißmann A, Adam Z. Bendamustine-bortezomib-dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014 Feb 13;123(7):985-91. Epub 2013 Nov 13. [https://doi.org/10.1182/blood-2013-08-521468 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924931/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24227817/ PubMed] EudraCT 2008-006421-13 |
==BID {{#subobject:e877g5|Regimen=1}}== | ==BID {{#subobject:e877g5|Regimen=1}}== | ||
BID: '''<u>B</u>'''endamustine, '''<u>I</u>'''xazomib, '''<u>D</u>'''examethasone | BID: '''<u>B</u>'''endamustine, '''<u>I</u>'''xazomib, '''<u>D</u>'''examethasone | ||
Line 2,181: | Line 2,186: | ||
|} | |} | ||
''Note: Dosages listed are the determined maximally tolerated doses (MTD) of this phase 1/2 trial. Note that dexamethasone is not given in week 4; this has been confirmed with the authors.'' | ''Note: Dosages listed are the determined maximally tolerated doses (MTD) of this phase 1/2 trial. Note that dexamethasone is not given in week 4; this has been confirmed with the authors.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Bendamustine]] 80 mg/m<sup>2</sup> IV once per day on days 1 & 2 | *[[Bendamustine]] 80 mg/m<sup>2</sup> IV once per day on days 1 & 2 | ||
Line 2,193: | Line 2,198: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''PRO00024991:''' Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019 Jul 29;9(8):56. [https://doi.org/10.1038/s41408-019-0219-3 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663939/ link to original article] ''' | + | # '''PRO00024991:''' Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019 Jul 29;9(8):56. [https://doi.org/10.1038/s41408-019-0219-3 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663939/ link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/31358733/ PubMed] [https://clinicaltrials.gov/study/NCT02477215 NCT02477215] |
==BLD {{#subobject:e8445|Regimen=1}}== | ==BLD {{#subobject:e8445|Regimen=1}}== | ||
Line 2,210: | Line 2,215: | ||
|} | |} | ||
''Note: Dosages listed are the determined maximally tolerated doses (MTD) of this phase 1/2 trial.'' | ''Note: Dosages listed are the determined maximally tolerated doses (MTD) of this phase 1/2 trial.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Bendamustine]] 75 mg/m<sup>2</sup> IV once per day on days 1 & 2 | *[[Bendamustine]] 75 mg/m<sup>2</sup> IV once per day on days 1 & 2 | ||
Line 2,224: | Line 2,229: | ||
===References=== | ===References=== | ||
<!-- Preliminary results were presented at the 53rd Annual Meeting of the American Society of Hematology, December 12, 2011, Orlando, FL. --> | <!-- Preliminary results were presented at the 53rd Annual Meeting of the American Society of Hematology, December 12, 2011, Orlando, FL. --> | ||
− | # '''UPMC 07-089:''' Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara MY, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012 May 17;119(20):4608-13. Epub 2012 Mar 26. [https://doi.org/10.1182/blood-2011-12-395715 link to original article] ''' | + | # '''UPMC 07-089:''' Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara MY, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012 May 17;119(20):4608-13. Epub 2012 Mar 26. [https://doi.org/10.1182/blood-2011-12-395715 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392072/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22451423/ PubMed] [https://clinicaltrials.gov/study/NCT01042704 NCT01042704] |
==Bortezomib & Dexamethasone (Vd) & Panobinostat {{#subobject:PYR1|Regimen=1}}== | ==Bortezomib & Dexamethasone (Vd) & Panobinostat {{#subobject:PYR1|Regimen=1}}== | ||
Line 2,255: | Line 2,260: | ||
*PANORAMA 1: 1 to 3 prior lines of therapy | *PANORAMA 1: 1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] as follows: | *[[Bortezomib (Velcade)]] as follows: | ||
Line 2,268: | Line 2,273: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''PANORAMA 2:''' Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013 Oct 3;122(14):2331-7. Epub 2013 Aug 15. [https://doi.org/10.1182/blood-2013-01-481325 link to original article] ''' | + | # '''PANORAMA 2:''' Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013 Oct 3;122(14):2331-7. Epub 2013 Aug 15. [https://doi.org/10.1182/blood-2013-01-481325 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/23950178/ PubMed] [https://clinicaltrials.gov/study/NCT01083602 NCT01083602] |
<!-- Presented in abstract form at the American Society of Hematology Annual Meeting, Atlanta, GA, December 8-11, 2012. --> | <!-- Presented in abstract form at the American Society of Hematology Annual Meeting, Atlanta, GA, December 8-11, 2012. --> | ||
− | # '''PANORAMA 1:''' San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1195-206. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. [https://doi.org/10.1016/S1470-2045(14)70440-1 link to original article] ''' | + | # '''PANORAMA 1:''' San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1195-206. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. [https://doi.org/10.1016/S1470-2045(14)70440-1 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25242045/ PubMed] [https://clinicaltrials.gov/study/NCT01023308 NCT01023308] |
## '''Subgroup analysis:''' Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016 Feb 11;127(6):713-21. Epub 2015 Dec 2. [https://doi.org/10.1182/blood-2015-09-665018 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760132/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26631116/ PubMed] | ## '''Subgroup analysis:''' Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016 Feb 11;127(6):713-21. Epub 2015 Dec 2. [https://doi.org/10.1182/blood-2015-09-665018 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760132/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26631116/ PubMed] | ||
## '''Update:''' San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016 Nov;3(11):e506-e515. Epub 2016 Oct 14. [https://doi.org/10.1016/S2352-3026(16)30147-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/27751707/ PubMed] | ## '''Update:''' San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016 Nov;3(11):e506-e515. Epub 2016 Oct 14. [https://doi.org/10.1016/S2352-3026(16)30147-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/27751707/ PubMed] | ||
Line 2,292: | Line 2,297: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] | *[[Bortezomib (Velcade)]] | ||
Line 2,323: | Line 2,328: | ||
''<sup>1</sup>While this study was randomized, it was "not powered to directly compare the two arms for statistically significant superiority."''<br> | ''<sup>1</sup>While this study was randomized, it was "not powered to directly compare the two arms for statistically significant superiority."''<br> | ||
''Note: This study involved two doses of bendamustine but the higher dose was too toxic, leading to premature closure. Note that dosage listed is the lower dose. Also, the abstracts says that thalidomide is given days 1 to 21 but the body of the paper says days 1 to 28.'' | ''Note: This study involved two doses of bendamustine but the higher dose was too toxic, leading to premature closure. Note that dosage listed is the lower dose. Also, the abstracts says that thalidomide is given days 1 to 21 but the body of the paper says days 1 to 28.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Bendamustine]] 60 mg/m<sup>2</sup> IV once per day on days 1 & 8 | *[[Bendamustine]] 60 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
Line 2,336: | Line 2,341: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''MUKone:''' Schey S, Brown SR, Tillotson AL, Yong K, Williams C, Davies F, Morgan G, Cavenagh J, Cook G, Cook M, Orti G, Morris C, Sherratt D, Flanagan L, Gregory W, Cavet J; Myeloma UK Early Phase Clinical Trial Network. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. Br J Haematol. 2015 Aug;170(3):336-48. Epub 2015 Apr 20. [https://doi.org/10.1111/bjh.13435 link to original article] ''' | + | # '''MUKone:''' Schey S, Brown SR, Tillotson AL, Yong K, Williams C, Davies F, Morgan G, Cavenagh J, Cook G, Cook M, Orti G, Morris C, Sherratt D, Flanagan L, Gregory W, Cavet J; Myeloma UK Early Phase Clinical Trial Network. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. Br J Haematol. 2015 Aug;170(3):336-48. Epub 2015 Apr 20. [https://doi.org/10.1111/bjh.13435 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25891006/ PubMed] ISRCTN90889843 |
==CPR {{#subobject:cbf3b8|Regimen=1}}== | ==CPR {{#subobject:cbf3b8|Regimen=1}}== | ||
Line 2,354: | Line 2,359: | ||
|} | |} | ||
''Note: Details are for the MTD/phase 2 portion of the published phase 1/2 trial.'' | ''Note: Details are for the MTD/phase 2 portion of the published phase 1/2 trial.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21 | *[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21 | ||
Line 2,376: | Line 2,381: | ||
|} | |} | ||
''Note: Details are for the phase 2 portion of the published phase 1/2 trial.'' | ''Note: Details are for the phase 2 portion of the published phase 1/2 trial.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> PO on days 1, 8, 15 | *[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> PO on days 1, 8, 15 | ||
Line 2,387: | Line 2,392: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Reece DE, Masih-Khan E, Atenafu EG, Jimenez-Zepeda VH, Anglin P, Chen C, Kukreti V, Mikhael JR, Trudel S. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. Br J Haematol. 2015 Jan;168(1):46-54. Epub 2014 Aug 22. [https://doi.org/10.1111/bjh.13100 link to original article] ''' | + | # Reece DE, Masih-Khan E, Atenafu EG, Jimenez-Zepeda VH, Anglin P, Chen C, Kukreti V, Mikhael JR, Trudel S. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. Br J Haematol. 2015 Jan;168(1):46-54. Epub 2014 Aug 22. [https://doi.org/10.1111/bjh.13100 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25146584/ PubMed] |
− | # '''REPEAT:''' Nijhof IS, Franssen LE, Levin MD, Bos GM, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Ypma PF, Raymakers R, van Spronsen DJ, Westerweel PE, Oostvogels R, van Velzen J, van Kessel B, Mutis T, Sonneveld P, Zweegman S, Lokhorst HM, van de Donk NW. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood. 2016 Nov;128(19), 2297-2306. Epub 2016 Sep 19. [https://doi.org/10.1182/blood-2016-07-729236 link to original article] ''' | + | # '''REPEAT:''' Nijhof IS, Franssen LE, Levin MD, Bos GM, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Ypma PF, Raymakers R, van Spronsen DJ, Westerweel PE, Oostvogels R, van Velzen J, van Kessel B, Mutis T, Sonneveld P, Zweegman S, Lokhorst HM, van de Donk NW. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood. 2016 Nov;128(19), 2297-2306. Epub 2016 Sep 19. [https://doi.org/10.1182/blood-2016-07-729236 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27647864/ PubMed] [https://clinicaltrials.gov/study/NCT01352338 NCT01352338] |
==CRd {{#subobject:c9ad0a|Regimen=1}}== | ==CRd {{#subobject:c9ad0a|Regimen=1}}== | ||
Line 2,405: | Line 2,410: | ||
|} | |} | ||
''Note: This is the MTD of this phase 1/2 trial.'' | ''Note: This is the MTD of this phase 1/2 trial.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 600 mg PO once per day on days 1 & 8 | *[[Cyclophosphamide (Cytoxan)]] 600 mg PO once per day on days 1 & 8 | ||
Line 2,417: | Line 2,422: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Schey SA, Morgan GJ, Ramasamy K, Hazel B, Ladon D, Corderoy S, Jenner M, Phekoo K, Boyd K, Davies FE. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol. 2010 Aug;150(3):326-33. Epub 2010 Jun 10. [https://doi.org/10.1111/j.1365-2141.2010.08250.x link to original article] ''' | + | # Schey SA, Morgan GJ, Ramasamy K, Hazel B, Ladon D, Corderoy S, Jenner M, Phekoo K, Boyd K, Davies FE. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol. 2010 Aug;150(3):326-33. Epub 2010 Jun 10. [https://doi.org/10.1111/j.1365-2141.2010.08250.x link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/20553268/ PubMed] |
==CTD {{#subobject:5d7a75|Regimen=1}}== | ==CTD {{#subobject:5d7a75|Regimen=1}}== | ||
Line 2,433: | Line 2,438: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 150 mg/m<sup>2</sup> PO every 12 hours on days 1 to 5, taken before meals | *[[Cyclophosphamide (Cytoxan)]] 150 mg/m<sup>2</sup> PO every 12 hours on days 1 to 5, taken before meals | ||
Line 2,475: | Line 2,480: | ||
*1 to 3 prior lines of therapy | *1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab (Darzalex)]] as follows: | *[[Daratumumab (Darzalex)]] as follows: | ||
Line 2,511: | Line 2,516: | ||
*1 to 3 prior lines of therapy | *1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab (Darzalex)]] as follows: | *[[Daratumumab (Darzalex)]] as follows: | ||
Line 2,536: | Line 2,541: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6676132/ Chari et al. 2019 (EQUULEUS<sub>cfz</sub>)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6676132/ Chari et al. 2019 (EQUULEUS<sub>cfz</sub>)] | ||
− | |2014 | + | |2014 to not reported |
|style="background-color:#91cf61"|Phase 1b (RT) | |style="background-color:#91cf61"|Phase 1b (RT) | ||
|ORR: 84% | |ORR: 84% | ||
Line 2,542: | Line 2,547: | ||
|} | |} | ||
''Note: this dosing is for patients 75 or younger. EQUULEUS had multiple arms; this one is denoted as cfz (carfilzomib).'' | ''Note: this dosing is for patients 75 or younger. EQUULEUS had multiple arms; this one is denoted as cfz (carfilzomib).'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab (Darzalex)]] as follows: | *[[Daratumumab (Darzalex)]] as follows: | ||
Line 2,569: | Line 2,574: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6676132/ Chari et al. 2019 (EQUULEUS<sub>cfz</sub>)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6676132/ Chari et al. 2019 (EQUULEUS<sub>cfz</sub>)] | ||
− | |2014 | + | |2014 to not reported |
|style="background-color:#91cf61"|Phase 1b (RT) | |style="background-color:#91cf61"|Phase 1b (RT) | ||
|ORR: 84% | |ORR: 84% | ||
Line 2,575: | Line 2,580: | ||
|} | |} | ||
''Note: this dosing is for patients older than 75. EQUULEUS had multiple arms; this one is denoted as cfz (carfilzomib).'' | ''Note: this dosing is for patients older than 75. EQUULEUS had multiple arms; this one is denoted as cfz (carfilzomib).'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab (Darzalex)]] as follows: | *[[Daratumumab (Darzalex)]] as follows: | ||
Line 2,595: | Line 2,600: | ||
===References=== | ===References=== | ||
− | # '''EQUULEUS<sub>cfz</sub>:''' Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019 Aug 1;134(5):421-431. Epub 2019 May 21. [https://doi.org/10.1182/blood.2019000722 link to original article] ''' | + | # '''EQUULEUS<sub>cfz</sub>:''' Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019 Aug 1;134(5):421-431. Epub 2019 May 21. [https://doi.org/10.1182/blood.2019000722 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6676132/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31113777/ PubMed] [https://clinicaltrials.gov/study/NCT01998971 NCT01998971] |
− | ##'''Update:''' Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, Ailawadhi S, Besemer B, de la Rubia Comos J, Encinas C, Mateos MV, Salwender H, Rodriguez-Otero P, Hulin C, Karlin L, Sureda Balari A, Bargay J, Benboubker L, Rosiñol L, Tarantolo S, Terebelo H, Yang S, Wang J, Nnane I, Qi M, Kosh M, Delioukina M, Goldschmidt H. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer J. 2023 Mar 7;13(1):33. [https://doi.org/10.1038/s41408-023-00805-x link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9989580/ link to PMC article] ''' | + | ##'''Update:''' Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, Ailawadhi S, Besemer B, de la Rubia Comos J, Encinas C, Mateos MV, Salwender H, Rodriguez-Otero P, Hulin C, Karlin L, Sureda Balari A, Bargay J, Benboubker L, Rosiñol L, Tarantolo S, Terebelo H, Yang S, Wang J, Nnane I, Qi M, Kosh M, Delioukina M, Goldschmidt H. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer J. 2023 Mar 7;13(1):33. [https://doi.org/10.1038/s41408-023-00805-x link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9989580/ link to PMC article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/36882409/ PubMed] |
− | #'''CANDOR:''' Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 Jul 18;396(10245):186-197. [https://doi.org/10.1016/s0140-6736(20)30734-0 link to original article] ''' | + | #'''CANDOR:''' Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 Jul 18;396(10245):186-197. [https://doi.org/10.1016/s0140-6736(20)30734-0 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32682484/ PubMed] [https://clinicaltrials.gov/study/NCT03158688 NCT03158688] |
##'''Update:''' Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 Jan;23(1):65-76. Epub 2021 Dec 3. [https://doi.org/10.1016/s1470-2045(21)00579-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34871550/ PubMed] | ##'''Update:''' Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 Jan;23(1):65-76. Epub 2021 Dec 3. [https://doi.org/10.1016/s1470-2045(21)00579-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34871550/ PubMed] | ||
#'''REMNANT:''' [https://clinicaltrials.gov/study/NCT04513639 NCT04513639] | #'''REMNANT:''' [https://clinicaltrials.gov/study/NCT04513639 NCT04513639] | ||
Line 2,612: | Line 2,617: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9989580/ Moreau et al. 2023 (PLEIADES)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9989580/ Moreau et al. 2023 (PLEIADES)] | ||
− | |2018 | + | |2018 to not reported |
| style="background-color:#91cf61" |Phase 2 (RT) | | style="background-color:#91cf61" |Phase 2 (RT) | ||
|- | |- | ||
|} | |} | ||
''Note: To our knowledge, Moreau et al. 2023 is the only published manuscript describing PLEIADES.'' | ''Note: To our knowledge, Moreau et al. 2023 is the only published manuscript describing PLEIADES.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab and hyaluronidase (Darzalex Faspro)]] as follows: | *[[Daratumumab and hyaluronidase (Darzalex Faspro)]] as follows: | ||
Line 2,633: | Line 2,638: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''PLEIADES:''' Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, Ailawadhi S, Besemer B, de la Rubia Comos J, Encinas C, Mateos MV, Salwender H, Rodriguez-Otero P, Hulin C, Karlin L, Sureda Balari A, Bargay J, Benboubker L, Rosiñol L, Tarantolo S, Terebelo H, Yang S, Wang J, Nnane I, Qi M, Kosh M, Delioukina M, Goldschmidt H. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer J. 2023 Mar 7;13(1):33. [https://doi.org/10.1038/s41408-023-00805-x link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9989580/ link to PMC article] ''' | + | #'''PLEIADES:''' Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, Ailawadhi S, Besemer B, de la Rubia Comos J, Encinas C, Mateos MV, Salwender H, Rodriguez-Otero P, Hulin C, Karlin L, Sureda Balari A, Bargay J, Benboubker L, Rosiñol L, Tarantolo S, Terebelo H, Yang S, Wang J, Nnane I, Qi M, Kosh M, Delioukina M, Goldschmidt H. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer J. 2023 Mar 7;13(1):33. [https://doi.org/10.1038/s41408-023-00805-x link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9989580/ link to PMC article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/36882409/ PubMed] [https://clinicaltrials.gov/study/NCT03412565 NCT03412565] |
==Dara-Pd {{#subobject:5538a8|Regimen=1}}== | ==Dara-Pd {{#subobject:5538a8|Regimen=1}}== | ||
Line 2,652: | Line 2,657: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5570682/ Chari et al. 2017 (EQUULEUS<sub>pom</sub>)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5570682/ Chari et al. 2017 (EQUULEUS<sub>pom</sub>)] | ||
− | |2014 | + | |2014 to not reported |
|style="background-color:#91cf61"|Phase 1b (RT) | |style="background-color:#91cf61"|Phase 1b (RT) | ||
| | | | ||
Line 2,676: | Line 2,681: | ||
*APOLLO: At least 1 prior line of therapy including lenalidomide and a proteasome inhibitor | *APOLLO: At least 1 prior line of therapy including lenalidomide and a proteasome inhibitor | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab (Darzalex)]] as follows: | *[[Daratumumab (Darzalex)]] as follows: | ||
Line 2,697: | Line 2,702: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''EQUULEUS<sub>pom</sub>:''' Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017 Aug 24;130(8):974-981. Epub 2017 Jun 21. [https://doi.org/10.1182/blood-2017-05-785246 link to original article] ''' | + | # '''EQUULEUS<sub>pom</sub>:''' Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017 Aug 24;130(8):974-981. Epub 2017 Jun 21. [https://doi.org/10.1182/blood-2017-05-785246 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5570682/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28637662/ PubMed] [https://clinicaltrials.gov/study/NCT01998971 NCT01998971] |
− | # '''APOLLO:''' Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Jun;22(6):801-812. [https://doi.org/10.1016/s1470-2045(21)00128-5 link to original article] ''' | + | # '''APOLLO:''' Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Jun;22(6):801-812. [https://doi.org/10.1016/s1470-2045(21)00128-5 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34087126/ PubMed] [https://clinicaltrials.gov/study/NCT03180736 NCT03180736] |
##'''Update:''' Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Kampfenkel T, Liu W, Wang J, Kosh M, Tran N, Carson R, Sonneveld P. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. Lancet Haematol. 2023 Oct;10(10):e813-e824. [https://doi.org/10.1016/s2352-3026(23)00218-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37793772/ PubMed] | ##'''Update:''' Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Kampfenkel T, Liu W, Wang J, Kosh M, Tran N, Carson R, Sonneveld P. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. Lancet Haematol. 2023 Oct;10(10):e813-e824. [https://doi.org/10.1016/s2352-3026(23)00218-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37793772/ PubMed] | ||
− | #'''KarMMa-3:''' Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. [https://doi.org/10.1056/NEJMoa2213614 link to original article] ''' | + | #'''KarMMa-3:''' Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. [https://doi.org/10.1056/NEJMoa2213614 link to original article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/36762851/ PubMed] [https://clinicaltrials.gov/study/NCT03651128 NCT03651128] |
##'''PRO analysis:''' Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. [https://doi.org/10.1016/s2352-3026(24)00005-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/38423700/ PubMed] | ##'''PRO analysis:''' Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. [https://doi.org/10.1016/s2352-3026(24)00005-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/38423700/ PubMed] | ||
− | |||
#'''MAGNETISMM-5:''' [https://clinicaltrials.gov/study/NCT05020236 NCT05020236] | #'''MAGNETISMM-5:''' [https://clinicaltrials.gov/study/NCT05020236 NCT05020236] | ||
==Dara-Pd (SC daratumumab) {{#subobject:5gj2g8|Regimen=1}}== | ==Dara-Pd (SC daratumumab) {{#subobject:5gj2g8|Regimen=1}}== | ||
Line 2,720: | Line 2,724: | ||
|[[#Pomalidomide_.26_Dexamethasone_.28Pd.29|Pd]] | |[[#Pomalidomide_.26_Dexamethasone_.28Pd.29|Pd]] | ||
| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 12.4 vs 6.9 mo<br>(HR 0.63, 95% CI 0.47-0.85)<br><br>Did not meet secondary endpoint of OS<sup>1</sup> | | style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 12.4 vs 6.9 mo<br>(HR 0.63, 95% CI 0.47-0.85)<br><br>Did not meet secondary endpoint of OS<sup>1</sup> | ||
+ | |- | ||
+ | |[https://doi.org/10.1056/nejmoa2303379 San-Miguel et al. 2023 (CARTITUDE-4)] | ||
+ | |2020-07-10 to 2021-11-17 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Ciltacabtagene_autoleucel_monotherapy|Cilta-cel]] | ||
+ | | style="background-color:#d73027" |Inferior PFS | ||
|- | |- | ||
|} | |} | ||
Line 2,727: | Line 2,737: | ||
*APOLLO: At least 1 prior line of therapy including lenalidomide and a proteasome inhibitor | *APOLLO: At least 1 prior line of therapy including lenalidomide and a proteasome inhibitor | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab and hyaluronidase (Darzalex Faspro)]] as follows: | *[[Daratumumab and hyaluronidase (Darzalex Faspro)]] as follows: | ||
Line 2,735: | Line 2,745: | ||
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | *[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | ||
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
− | *[[Dexamethasone (Decadron)]] by the following criteria: | + | *[[Dexamethasone (Decadron)]] by the following study-specific criteria: |
− | ** | + | **APOLLO, standard patients: 40 mg PO once per day on days 1, 8, 15, 22 |
− | ** | + | **APOLLO, patients older than 75 years: 20 mg PO once per day on days 1, 8, 15, 22 |
+ | **CARTITUDE-4: 40 mg IV or PO once per day on days 1, 8, 15, 22 or 20 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23 | ||
'''28-day cycles''' | '''28-day cycles''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''APOLLO:''' Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Jun;22(6):801-812. [https://doi.org/10.1016/s1470-2045(21)00128-5 link to original article] ''' | + | # '''APOLLO:''' Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Jun;22(6):801-812. [https://doi.org/10.1016/s1470-2045(21)00128-5 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34087126/ PubMed] [https://clinicaltrials.gov/study/NCT03180736 NCT03180736] |
##'''Update:''' Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Kampfenkel T, Liu W, Wang J, Kosh M, Tran N, Carson R, Sonneveld P. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. Lancet Haematol. 2023 Oct;10(10):e813-e824. [https://doi.org/10.1016/s2352-3026(23)00218-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37793772/ PubMed] | ##'''Update:''' Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Kampfenkel T, Liu W, Wang J, Kosh M, Tran N, Carson R, Sonneveld P. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. Lancet Haematol. 2023 Oct;10(10):e813-e824. [https://doi.org/10.1016/s2352-3026(23)00218-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37793772/ PubMed] | ||
+ | #'''CARTITUDE-4:''' San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023 Jul 27;389(4):335-347. Epub 2023 Jun 5. [https://doi.org/10.1056/nejmoa2303379 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37272512/ PubMed] [https://clinicaltrials.gov/study/NCT04181827 NCT04181827] | ||
#'''MajesTEC-3:''' [https://clinicaltrials.gov/study/NCT05083169 NCT05083169] | #'''MajesTEC-3:''' [https://clinicaltrials.gov/study/NCT05083169 NCT05083169] | ||
==Dara-Rd {{#subobject:0e17f7|Regimen=1}}== | ==Dara-Rd {{#subobject:0e17f7|Regimen=1}}== | ||
Line 2,755: | Line 2,767: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054695/ Plesner et al. 2016 (GEN503)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054695/ Plesner et al. 2016 (GEN503)] | ||
− | |2012 | + | |2012 to not reported |
|style="background-color:#91cf61"|Phase 1/2 | |style="background-color:#91cf61"|Phase 1/2 | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab (Darzalex)]] as follows: | *[[Daratumumab (Darzalex)]] as follows: | ||
Line 2,792: | Line 2,804: | ||
*1 to 3 prior lines of therapy | *1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab (Darzalex)]] as follows: | *[[Daratumumab (Darzalex)]] as follows: | ||
Line 2,810: | Line 2,822: | ||
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Torben Plesner, MD, Hendrik-Tobias Arkenau, MD, Henk M. Lokhorst, MD PhD, Peter Gimsing, MD, PhD, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MD PhD, Ulrik Lassen, MD PhD, Jacob P. Laubach, MD, Tahamtan Ahmadi, MD, PhD, Howard Yeh, MD, Mary E Guckert, MSN, RN, Huaibao Feng, Nikolai Constantin Brun, MD PhD, Steen Lisby, Linda Basse, MD DMSc, Antonio Palumbo, MD. Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma. ASH 2014 Abstract 84.--> | <!-- # '''Abstract:''' Torben Plesner, MD, Hendrik-Tobias Arkenau, MD, Henk M. Lokhorst, MD PhD, Peter Gimsing, MD, PhD, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MD PhD, Ulrik Lassen, MD PhD, Jacob P. Laubach, MD, Tahamtan Ahmadi, MD, PhD, Howard Yeh, MD, Mary E Guckert, MSN, RN, Huaibao Feng, Nikolai Constantin Brun, MD PhD, Steen Lisby, Linda Basse, MD DMSc, Antonio Palumbo, MD. Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma. ASH 2014 Abstract 84.--> | ||
− | # '''GEN503:''' Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016 Oct 6;128(14):1821-8. Epub 2016 Aug 16. [https://doi.org/10.1182/blood-2016-07-726729 link to original article] ''' | + | # '''GEN503:''' Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016 Oct 6;128(14):1821-8. Epub 2016 Aug 16. [https://doi.org/10.1182/blood-2016-07-726729 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054695/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27531679/ PubMed] [https://clinicaltrials.gov/study/NCT01615029 NCT01615029] |
− | # '''POLLUX:''' Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-1331. [https://doi.org/10.1056/NEJMoa1607751 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1607751/suppl_file/nejmoa1607751_protocol.pdf link to original protocol] ''' | + | # '''POLLUX:''' Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-1331. [https://doi.org/10.1056/NEJMoa1607751 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1607751/suppl_file/nejmoa1607751_protocol.pdf link to original protocol] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27705267/ PubMed] [https://clinicaltrials.gov/study/NCT02076009 NCT02076009] |
## '''Update:''' Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O' Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018 Dec;103(12):2088-96. Epub 2018 Sep 20. [https://doi.org/10.3324/haematol.2018.194282 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6269302/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30237262/ PubMed] | ## '''Update:''' Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O' Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018 Dec;103(12):2088-96. Epub 2018 Sep 20. [https://doi.org/10.3324/haematol.2018.194282 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6269302/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30237262/ PubMed] | ||
## '''Update:''' Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Krevvata M, Chiu C, Qin X, Okonkwo L, Trivedi S, Ukropec J, Qi M, San-Miguel J. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020 Jul;34(7):1875-1884. Epub 2020 Jan 30. [https://doi.org/10.1038/s41375-020-0711-6 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7326710/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32001798/ PubMed] | ## '''Update:''' Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Krevvata M, Chiu C, Qin X, Okonkwo L, Trivedi S, Ukropec J, Qi M, San-Miguel J. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020 Jul;34(7):1875-1884. Epub 2020 Jan 30. [https://doi.org/10.1038/s41375-020-0711-6 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7326710/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32001798/ PubMed] | ||
Line 2,828: | Line 2,840: | ||
|- | |- | ||
|[https://doi.org/10.1111/bjh.16980 Chari et al. 2020 (PLEIADES)] | |[https://doi.org/10.1111/bjh.16980 Chari et al. 2020 (PLEIADES)] | ||
− | |2018 | + | |2018 to not reported |
| style="background-color:#91cf61" |Phase 2 (RT) | | style="background-color:#91cf61" |Phase 2 (RT) | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab and hyaluronidase (Darzalex Faspro)]] as follows: | *[[Daratumumab and hyaluronidase (Darzalex Faspro)]] as follows: | ||
Line 2,844: | Line 2,856: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''PLEIADES:''' Chari A, Rodriguez-Otero P, McCarthy H, Suzuki K, Hungria V, Sureda Balari A, Perrot A, Hulin C, Magen H, Iida S, Maisnar V, Karlin L, Pour L, Parasrampuria DA, Masterson T, Kosh M, Yang S, Delioukina M, Qi M, Carson R, Touzeau C. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. Br J Haematol. 2021 Mar;192(5):869-878. Epub 2020 Jul 30. [https://doi.org/10.1111/bjh.16980 link to original article] ''' | + | #'''PLEIADES:''' Chari A, Rodriguez-Otero P, McCarthy H, Suzuki K, Hungria V, Sureda Balari A, Perrot A, Hulin C, Magen H, Iida S, Maisnar V, Karlin L, Pour L, Parasrampuria DA, Masterson T, Kosh M, Yang S, Delioukina M, Qi M, Carson R, Touzeau C. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. Br J Haematol. 2021 Mar;192(5):869-878. Epub 2020 Jul 30. [https://doi.org/10.1111/bjh.16980 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/33216361/ PubMed] [https://clinicaltrials.gov/study/NCT03412565 NCT03412565] |
==Dara-Vd {{#subobject:5770be|Regimen=1}}== | ==Dara-Vd {{#subobject:5770be|Regimen=1}}== | ||
Dara-Vd: '''<u>Dara</u>'''tumumab, '''<u>V</u>'''elcade (Bortezomib), low-dose '''<u>d</u>'''examethasone | Dara-Vd: '''<u>Dara</u>'''tumumab, '''<u>V</u>'''elcade (Bortezomib), low-dose '''<u>d</u>'''examethasone | ||
Line 2,883: | Line 2,895: | ||
*CASTOR & LEPUS: At least 1 prior line of therapy | *CASTOR & LEPUS: At least 1 prior line of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab (Darzalex)]] as follows: | *[[Daratumumab (Darzalex)]] as follows: | ||
Line 2,901: | Line 2,913: | ||
===References=== | ===References=== | ||
<!-- # ASCO 2016 Abstract LBA4 --> | <!-- # ASCO 2016 Abstract LBA4 --> | ||
− | # '''CASTOR:''' Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. [https://doi.org/10.1056/NEJMoa1606038 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606038/suppl_file/nejmoa1606038_appendix.pdf link to supplementary appendix] ''' | + | # '''CASTOR:''' Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. [https://doi.org/10.1056/NEJMoa1606038 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606038/suppl_file/nejmoa1606038_appendix.pdf link to supplementary appendix] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27557302/ PubMed] [https://clinicaltrials.gov/study/NCT02136134 NCT02136134] |
## '''Update:''' Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Dec;103(12):2079-87. Epub 2018 Sep 20. [https://doi.org/10.3324/haematol.2018.194118 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6269293/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30237264/ PubMed] | ## '''Update:''' Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Dec;103(12):2079-87. Epub 2018 Sep 20. [https://doi.org/10.3324/haematol.2018.194118 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6269293/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30237264/ PubMed] | ||
## '''Update:''' Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, Corradini P, Min CK, Medvedova E, Weisel K, Chiu C, Schecter JM, Amin H, Qin X, Ukropec J, Kobos R, Spencer A. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):509-518. Epub 2019 Oct 9. [https://doi.org/10.1016/j.clml.2019.09.623 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32482541/ PubMed] | ## '''Update:''' Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, Corradini P, Min CK, Medvedova E, Weisel K, Chiu C, Schecter JM, Amin H, Qin X, Ukropec J, Kobos R, Spencer A. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):509-518. Epub 2019 Oct 9. [https://doi.org/10.1016/j.clml.2019.09.623 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32482541/ PubMed] | ||
##'''Update:''' Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Levin MD, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Spencer A. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 Mar 10;41(8):1600-1609. Epub 2022 Nov 22. [https://doi.org/10.1200/jco.21.02734 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10022857/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/36413710/ PubMed] | ##'''Update:''' Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Levin MD, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Spencer A. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 Mar 10;41(8):1600-1609. Epub 2022 Nov 22. [https://doi.org/10.1200/jco.21.02734 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10022857/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/36413710/ PubMed] | ||
− | # '''LEPUS:''' Lu J, Fu W, Li W, Hu J, An G, Wang Y, Fu C, Chen L, Jin J, Cen X, Ge Z, Cai Z, Niu T, Qi M, Sun S, Gai X, Liu W, Liu W, Yang X, Huang X. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):e699-e709. Epub 2021 Apr 24. [https://doi.org/10.1016/j.clml.2021.04.012 link to original article] ''' | + | # '''LEPUS:''' Lu J, Fu W, Li W, Hu J, An G, Wang Y, Fu C, Chen L, Jin J, Cen X, Ge Z, Cai Z, Niu T, Qi M, Sun S, Gai X, Liu W, Liu W, Yang X, Huang X. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):e699-e709. Epub 2021 Apr 24. [https://doi.org/10.1016/j.clml.2021.04.012 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34108127/ PubMed] [https://clinicaltrials.gov/study/NCT03234972 NCT03234972] |
− | #'''KarMMa-3:''' Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. [https://doi.org/10.1056/NEJMoa2213614 link to original article] ''' | + | #'''KarMMa-3:''' Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. [https://doi.org/10.1056/NEJMoa2213614 link to original article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/36762851/ PubMed] [https://clinicaltrials.gov/study/NCT03651128 NCT03651128] |
##'''PRO analysis:''' Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. [https://doi.org/10.1016/s2352-3026(24)00005-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/38423700/ PubMed] | ##'''PRO analysis:''' Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. [https://doi.org/10.1016/s2352-3026(24)00005-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/38423700/ PubMed] | ||
#'''EXCALIBER-RRMM:''' [https://clinicaltrials.gov/study/NCT04975997 NCT04975997] | #'''EXCALIBER-RRMM:''' [https://clinicaltrials.gov/study/NCT04975997 NCT04975997] | ||
Line 2,927: | Line 2,939: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Daratumumab and hyaluronidase (Darzalex Faspro)]] | *[[Daratumumab and hyaluronidase (Darzalex Faspro)]] | ||
Line 2,968: | Line 2,980: | ||
*2 or more prior lines of therapy, including lenalidomide and a proteasome inhibitor | *2 or more prior lines of therapy, including lenalidomide and a proteasome inhibitor | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Elotuzumab (Empliciti)]] as follows: | *[[Elotuzumab (Empliciti)]] as follows: | ||
Line 3,014: | Line 3,026: | ||
*2 or more prior lines of therapy, including lenalidomide and a proteasome inhibitor | *2 or more prior lines of therapy, including lenalidomide and a proteasome inhibitor | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Elotuzumab (Empliciti)]] as follows: | *[[Elotuzumab (Empliciti)]] as follows: | ||
Line 3,033: | Line 3,045: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''ELOQUENT-3:''' Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018 Nov 8;379(19):1811-1822. [https://doi.org/10.1056/NEJMoa1805762 link to original article] ''' | + | # '''ELOQUENT-3:''' Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018 Nov 8;379(19):1811-1822. [https://doi.org/10.1056/NEJMoa1805762 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/30403938/ PubMed] [https://clinicaltrials.gov/study/NCT02654132 NCT02654132] |
##'''Update:''' Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol. 2023 Jan 20;41(3):568-578. Epub 2022 Aug 12. [https://doi.org/10.1200/jco.21.02815 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870233/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35960908/ PubMed] | ##'''Update:''' Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol. 2023 Jan 20;41(3):568-578. Epub 2022 Aug 12. [https://doi.org/10.1200/jco.21.02815 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870233/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35960908/ PubMed] | ||
− | #'''KarMMa-3:''' Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. [https://doi.org/10.1056/NEJMoa2213614 link to original article] ''' | + | #'''KarMMa-3:''' Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. [https://doi.org/10.1056/NEJMoa2213614 link to original article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/36762851/ PubMed] [https://clinicaltrials.gov/study/NCT03651128 NCT03651128] |
##'''PRO analysis:''' Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. [https://doi.org/10.1016/s2352-3026(24)00005-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/38423700/ PubMed] | ##'''PRO analysis:''' Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. [https://doi.org/10.1016/s2352-3026(24)00005-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/38423700/ PubMed] | ||
#'''EMN29:''' [https://clinicaltrials.gov/study/NCT05028348 NCT05028348] | #'''EMN29:''' [https://clinicaltrials.gov/study/NCT05028348 NCT05028348] | ||
Line 3,052: | Line 3,064: | ||
|- | |- | ||
|[https://doi.org/10.1200/jco.2011.37.2649 Lonial et al. 2012 (1703 Study)] | |[https://doi.org/10.1200/jco.2011.37.2649 Lonial et al. 2012 (1703 Study)] | ||
− | |2008 | + | |2008 to not reported |
|style="background-color:#1a9851"|Phase 1b/2 | |style="background-color:#1a9851"|Phase 1b/2 | ||
| style="background-color:#d3d3d3" | | | style="background-color:#d3d3d3" | | ||
Line 3,069: | Line 3,081: | ||
*ELOQUENT-2: 1 to 3 prior lines of therapy | *ELOQUENT-2: 1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Elotuzumab (Empliciti)]] as follows: | *[[Elotuzumab (Empliciti)]] as follows: | ||
Line 3,089: | Line 3,101: | ||
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Richardson, Paul G., Jagannath, Sundar, Moreau, Philippe, Jakubowiak, Andrzej, Raab, Marc S, Facon, Thierry, Vij, Ravi, White, Darrell J., Reece, Donna, Benboubker, Lotfi, Zonder, Jeffrey A., Deng, Wei, Kroog, Glenn, Singhal, Anil K, Lonial, Sagar. A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. ASH Annual Meeting Abstracts 2012 120: 202 --> | <!-- # '''Abstract:''' Richardson, Paul G., Jagannath, Sundar, Moreau, Philippe, Jakubowiak, Andrzej, Raab, Marc S, Facon, Thierry, Vij, Ravi, White, Darrell J., Reece, Donna, Benboubker, Lotfi, Zonder, Jeffrey A., Deng, Wei, Kroog, Glenn, Singhal, Anil K, Lonial, Sagar. A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. ASH Annual Meeting Abstracts 2012 120: 202 --> | ||
− | # '''1703 Study:''' Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012 Jun 1;30(16):1953-9. Epub 2012 Apr 30. [https://doi.org/10.1200/jco.2011.37.2649 link to original article] ''' | + | # '''1703 Study:''' Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012 Jun 1;30(16):1953-9. Epub 2012 Apr 30. [https://doi.org/10.1200/jco.2011.37.2649 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/22547589/ PubMed] [https://clinicaltrials.gov/study/NCT00742560 NCT00742560] |
<!-- ## '''Abstract: Update:''' Paul G. Richardson, Sundar Jagannath, MD, Philippe Moreau, MD, Andrzej Jakubowiak, MD, PhD, Marc S Raab, MD, PhD, Thierry Facon, MD, Ravi Vij, MBBS, MD, Darrell White, MD, Donna E. Reece, MD, Lotfi Benboubker, MD, PhD, Jeffrey Zonder, MD, L. Claire Tsao, PhD, Kenneth C. Anderson, MD, Eric Bleickardt, MD, Anil K Singhal, MD and Sagar Lonial, MD. Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. ASH 2014 Abstract 302--> | <!-- ## '''Abstract: Update:''' Paul G. Richardson, Sundar Jagannath, MD, Philippe Moreau, MD, Andrzej Jakubowiak, MD, PhD, Marc S Raab, MD, PhD, Thierry Facon, MD, Ravi Vij, MBBS, MD, Darrell White, MD, Donna E. Reece, MD, Lotfi Benboubker, MD, PhD, Jeffrey Zonder, MD, L. Claire Tsao, PhD, Kenneth C. Anderson, MD, Eric Bleickardt, MD, Anil K Singhal, MD and Sagar Lonial, MD. Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. ASH 2014 Abstract 302--> | ||
− | ## '''Update:''' Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S; 1703 study investigators. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015 Dec;2(12):e516-27. Epub 2015 Nov 16. [https://doi.org/10.1016/S2352-3026(15)00197-0 link to original article] ''' | + | ## '''Update:''' Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S; 1703 study investigators. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015 Dec;2(12):e516-27. Epub 2015 Nov 16. [https://doi.org/10.1016/S2352-3026(15)00197-0 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6871650/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26686406/ PubMed] |
− | # '''ELOQUENT-2:''' Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. Epub 2015 Jun 2. [https://doi.org/10.1056/NEJMoa1505654 link to original article] ''' | + | # '''ELOQUENT-2:''' Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. Epub 2015 Jun 2. [https://doi.org/10.1056/NEJMoa1505654 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/26035255/ PubMed] [https://clinicaltrials.gov/study/NCT01239797 NCT01239797] |
## '''Update:''' Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017 Sep;178(6):896-905. Epub 2017 Jul 5. [https://doi.org/10.1111/bjh.14787 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6084289/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28677826/ PubMed] | ## '''Update:''' Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017 Sep;178(6):896-905. Epub 2017 Jul 5. [https://doi.org/10.1111/bjh.14787 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6084289/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28677826/ PubMed] | ||
## '''Update:''' Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 Oct 15;124(20):4032-4043. Epub 2018 Sep 11. [https://doi.org/10.1002/cncr.31680 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30204239/ PubMed] | ## '''Update:''' Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 Oct 15;124(20):4032-4043. Epub 2018 Sep 11. [https://doi.org/10.1002/cncr.31680 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30204239/ PubMed] | ||
Line 3,120: | Line 3,132: | ||
*CA204-009: 1 to 3 prior lines of therapy | *CA204-009: 1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Elotuzumab (Empliciti)]] as follows: | *[[Elotuzumab (Empliciti)]] as follows: | ||
Line 3,150: | Line 3,162: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''CA204-009:''' Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 Jun 9;127(23):2833-40. Epub 2016 Apr 18. [https://doi.org/10.1182/blood-2016-01-694604 link to original article] ''' | + | # '''CA204-009:''' Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 Jun 9;127(23):2833-40. Epub 2016 Apr 18. [https://doi.org/10.1182/blood-2016-01-694604 link to original article] '''dosing details in supplement have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900953/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27091875/ PubMed] [https://clinicaltrials.gov/study/NCT01478048 NCT01478048] |
==FRD {{#subobject:69c2ac|Regimen=1}}== | ==FRD {{#subobject:69c2ac|Regimen=1}}== | ||
FRD: '''<u>F</u>'''arydak (Panobinostat), '''<u>R</u>'''evlimid (Lenalidomide), '''<u>D</u>'''examethasone | FRD: '''<u>F</u>'''arydak (Panobinostat), '''<u>R</u>'''evlimid (Lenalidomide), '''<u>D</u>'''examethasone | ||
Line 3,161: | Line 3,173: | ||
|- | |- | ||
|[https://doi.org/10.1182/bloodadvances.2017007427 Chari et al. 2017 (GCO 12-0469)] | |[https://doi.org/10.1182/bloodadvances.2017007427 Chari et al. 2017 (GCO 12-0469)] | ||
− | |2012 | + | |2012 to not reported |
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Panobinostat (Farydak)]] 20 mg PO once per day on days 1, 3, 5, 15, 17, 19 | *[[Panobinostat (Farydak)]] 20 mg PO once per day on days 1, 3, 5, 15, 17, 19 | ||
Line 3,174: | Line 3,186: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''GCO 12-0469:''' Chari A, Cho HJ, Dhadwal A, Morgan G, La L, Zarychta K, Catamero D, Florendo E, Stevens N, Verina D, Chan E, Leshchenko V, Laganà A, Perumal D, Mei AH, Tung K, Fukui J, Jagannath S, Parekh S. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 2017 Aug 21;1(19):1575-1583. eCollection 2017 Aug 22. [https://doi.org/10.1182/bloodadvances.2017007427 link to original article] ''' | + | # '''GCO 12-0469:''' Chari A, Cho HJ, Dhadwal A, Morgan G, La L, Zarychta K, Catamero D, Florendo E, Stevens N, Verina D, Chan E, Leshchenko V, Laganà A, Perumal D, Mei AH, Tung K, Fukui J, Jagannath S, Parekh S. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 2017 Aug 21;1(19):1575-1583. eCollection 2017 Aug 22. [https://doi.org/10.1182/bloodadvances.2017007427 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728465/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29296798/ PubMed] [https://clinicaltrials.gov/study/NCT01651039 NCT01651039] |
==IRd {{#subobject:PYR3|Regimen=1}}== | ==IRd {{#subobject:PYR3|Regimen=1}}== | ||
IRd: '''<u>I</u>'''xazomib, '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone | IRd: '''<u>I</u>'''xazomib, '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone | ||
Line 3,203: | Line 3,215: | ||
*TOURMALINE-MM1 & TOURMALINE-MM1 China Continuation: 1 to 3 prior lines of therapy | *TOURMALINE-MM1 & TOURMALINE-MM1 China Continuation: 1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Ixazomib (Ninlaro)]] 4 mg PO once per day on days 1, 8, 15, taken at least one hour before or at least two hours after food | *[[Ixazomib (Ninlaro)]] 4 mg PO once per day on days 1, 8, 15, taken at least one hour before or at least two hours after food | ||
Line 3,231: | Line 3,243: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Ixazomib (Ninlaro)]] 4 mg PO once per day on days 1, 8, 15 | *[[Ixazomib (Ninlaro)]] 4 mg PO once per day on days 1, 8, 15 | ||
Line 3,241: | Line 3,253: | ||
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Philippe Moreau, MD, Tamás Masszi, MD, Norbert Grzasko, MD, PhD, Nizar J Bahlis, MD, Markus Hansson, Ludek Pour, MD, Irwindeep Sandhu, MD, Peter Ganly, BMBCh, PhD, Bartrum W Baker, MBChB, FRACP, FRCPA, Sharon Jackson, MBChB, FRACP, FRCPA, Anne-Marie Stoppa, MD, David R Simpson, MBChB, FRACP, FRCPA, Peter Gimsing, MD, DMSci, Antonio Palumbo, Laurent Garderet, MD, Michele Cavo, Shaji K. Kumar, MD, Cyrille Touzeau, MD, Francis Buadi, MD, Jacob P. Laubach, MD, Jianchang Lin, PhD, Deborah Berg, RN, MSN, Alessandra DiBacco, PhD, Ai-Min Hui, MD, PhD and Paul G. Richardson, MD. Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study ([https://clinicaltrials.gov/study/NCT01564537 NCT01564537]). ASH Annual Meeting 2015 Abstract 727--> | <!-- # '''Abstract:''' Philippe Moreau, MD, Tamás Masszi, MD, Norbert Grzasko, MD, PhD, Nizar J Bahlis, MD, Markus Hansson, Ludek Pour, MD, Irwindeep Sandhu, MD, Peter Ganly, BMBCh, PhD, Bartrum W Baker, MBChB, FRACP, FRCPA, Sharon Jackson, MBChB, FRACP, FRCPA, Anne-Marie Stoppa, MD, David R Simpson, MBChB, FRACP, FRCPA, Peter Gimsing, MD, DMSci, Antonio Palumbo, Laurent Garderet, MD, Michele Cavo, Shaji K. Kumar, MD, Cyrille Touzeau, MD, Francis Buadi, MD, Jacob P. Laubach, MD, Jianchang Lin, PhD, Deborah Berg, RN, MSN, Alessandra DiBacco, PhD, Ai-Min Hui, MD, PhD and Paul G. Richardson, MD. Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study ([https://clinicaltrials.gov/study/NCT01564537 NCT01564537]). ASH Annual Meeting 2015 Abstract 727--> | ||
− | # '''TOURMALINE-MM1:''' Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Apr 28;374(17):1621-1634. [https://doi.org/10.1056/NEJMoa1516282 link to original article] ''' | + | # '''TOURMALINE-MM1:''' Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Apr 28;374(17):1621-1634. [https://doi.org/10.1056/NEJMoa1516282 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27119237/ PubMed] [https://clinicaltrials.gov/study/NCT01564537 NCT01564537] |
## '''Subgroup analysis:''' Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017 Dec 14;130(24):2610-2618. Epub 2017 Oct 20. [https://doi.org/10.1182/blood-2017-06-791228 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29054911/ PubMed] | ## '''Subgroup analysis:''' Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017 Dec 14;130(24):2610-2618. Epub 2017 Oct 20. [https://doi.org/10.1182/blood-2017-06-791228 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29054911/ PubMed] | ||
## '''Update:''' Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Gimsing P, Garderet L, Touzeau C, Buadi FK, Laubach JP, Cavo M, Darif M, Labotka R, Berg D, Moreau P. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021 Aug 1;39(22):2430-2442. Epub 2021 Jun 11. [https://doi.org/10.1200/jco.21.00972 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34111952/ PubMed] | ## '''Update:''' Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Gimsing P, Garderet L, Touzeau C, Buadi FK, Laubach JP, Cavo M, Darif M, Labotka R, Berg D, Moreau P. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021 Aug 1;39(22):2430-2442. Epub 2021 Jun 11. [https://doi.org/10.1200/jco.21.00972 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34111952/ PubMed] | ||
− | # '''TOURMALINE-MM1 China Continuation:''' Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, Lu J, Du X, Chen X, Li J, Liu J, Gupta N, Hanley MJ, Li H, Hua Z, Wang B, Zhang X, Wang H, van de Velde H, Richardson PG, Moreau P. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J Hematol Oncol. 2017 Jul 6;10(1):137. [https://doi.org/10.1186/s13045-017-0501-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500972/ link to PMC article] ''' | + | # '''TOURMALINE-MM1 China Continuation:''' Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, Lu J, Du X, Chen X, Li J, Liu J, Gupta N, Hanley MJ, Li H, Hua Z, Wang B, Zhang X, Wang H, van de Velde H, Richardson PG, Moreau P. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J Hematol Oncol. 2017 Jul 6;10(1):137. [https://doi.org/10.1186/s13045-017-0501-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500972/ link to PMC article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/28683766/ PubMed] [https://clinicaltrials.gov/study/NCT01564537 NCT01564537] |
− | #'''KarMMa-3:''' Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. [https://doi.org/10.1056/NEJMoa2213614 link to original article] ''' | + | #'''KarMMa-3:''' Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. [https://doi.org/10.1056/NEJMoa2213614 link to original article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/36762851/ PubMed] [https://clinicaltrials.gov/study/NCT03651128 NCT03651128] |
##'''PRO analysis:''' Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. [https://doi.org/10.1016/s2352-3026(24)00005-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/38423700/ PubMed] | ##'''PRO analysis:''' Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. [https://doi.org/10.1016/s2352-3026(24)00005-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/38423700/ PubMed] | ||
==Isa-Kd {{#subobject:06bt45|Regimen=1}}== | ==Isa-Kd {{#subobject:06bt45|Regimen=1}}== | ||
Line 3,266: | Line 3,278: | ||
|} | |} | ||
''<sup>1</sup>Reported efficacy is based on the 2023 update.''<br> | ''<sup>1</sup>Reported efficacy is based on the 2023 update.''<br> | ||
− | |||
<div class="toccolours" style="background-color:#fdcdac"> | <div class="toccolours" style="background-color:#fdcdac"> | ||
====Prior treatment criteria==== | ====Prior treatment criteria==== | ||
*1 to 3 prior lines of therapy | *1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Isatuximab (Sarclisa)]] '''given second''' as follows: | *[[Isatuximab (Sarclisa)]] '''given second''' as follows: | ||
Line 3,277: | Line 3,288: | ||
**Cycle 2 onwards: 10 mg/kg IV once per day on days 1 & 15 | **Cycle 2 onwards: 10 mg/kg IV once per day on days 1 & 15 | ||
*[[Carfilzomib (Kyprolis)]] '''given third''' as follows: | *[[Carfilzomib (Kyprolis)]] '''given third''' as follows: | ||
− | **Cycle 1: 20 mg/m<sup>2</sup> IV | + | **Cycle 1: 20 mg/m<sup>2</sup> IV once per day on days 1 & 2, then 56 mg/m<sup>2</sup> IV once per day on days 8, 9, 15, 16 |
− | **Cycle 2 onwards: 56 mg/m<sup>2</sup> IV | + | **Cycle 2 onwards: 56 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16 |
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
*[[Dexamethasone (Decadron)]] 20 mg PO or IV once per day on days 1, 2, 8, 9, 15, 16, 22, 23, '''given first''' | *[[Dexamethasone (Decadron)]] 20 mg PO or IV once per day on days 1, 2, 8, 9, 15, 16, 22, 23, '''given first''' | ||
Line 3,284: | Line 3,295: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''IKEMA:''' Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 Jun 19;397(10292):2361-2371. Epub 2021 Jun 4. [https://doi.org/10.1016/s0140-6736(21)00592-4 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34097854/ PubMed] [https://clinicaltrials.gov/study/NCT03275285 NCT03275285] | + | #'''IKEMA:''' Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 Jun 19;397(10292):2361-2371. Epub 2021 Jun 4. [https://doi.org/10.1016/s0140-6736(21)00592-4 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34097854/ PubMed] [https://clinicaltrials.gov/study/NCT03275285 NCT03275285] |
<!-- ##'''Abstract:''' Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Casca F, Macé S, Risse ML, Moreau P. MM-064 Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S403-S404. [https://doi.org/10.1016/s2152-2650(22)01586-5 link to original abstract] --> | <!-- ##'''Abstract:''' Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Casca F, Macé S, Risse ML, Moreau P. MM-064 Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S403-S404. [https://doi.org/10.1016/s2152-2650(22)01586-5 link to original abstract] --> | ||
##'''Update:''' Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023 May 9;13(1):72. Erratum in: Blood Cancer J. 2023 Sep 27;13(1):152. [https://doi.org/10.1038/s41408-023-00797-8 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10166682/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37156782/ PubMed] | ##'''Update:''' Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023 May 9;13(1):72. Erratum in: Blood Cancer J. 2023 Sep 27;13(1):152. [https://doi.org/10.1038/s41408-023-00797-8 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10166682/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37156782/ PubMed] | ||
Line 3,310: | Line 3,321: | ||
*ICARIA-MM: At least 2 prior lines of therapy including lenalidomide and a proteasome inhibitor | *ICARIA-MM: At least 2 prior lines of therapy including lenalidomide and a proteasome inhibitor | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Isatuximab (Sarclisa)]] as follows: | *[[Isatuximab (Sarclisa)]] as follows: | ||
Line 3,325: | Line 3,336: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''ICARIA-MM:''' Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107. Epub 2019 Nov 14. Erratum in: Lancet. 2019 Dec 7;394(10214):2072. [https://doi.org/10.1016/s0140-6736(19)32556-5 link to original article] ''' | + | # '''ICARIA-MM:''' Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107. Epub 2019 Nov 14. Erratum in: Lancet. 2019 Dec 7;394(10214):2072. [https://doi.org/10.1016/s0140-6736(19)32556-5 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/31735560/ PubMed] [https://clinicaltrials.gov/study/NCT02990338 NCT02990338] |
##'''Update:''' Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 Mar;23(3):416-427. Epub 2022 Feb 10. [https://doi.org/10.1016/s1470-2045(22)00019-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35151415/ PubMed] | ##'''Update:''' Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 Mar;23(3):416-427. Epub 2022 Feb 10. [https://doi.org/10.1016/s1470-2045(22)00019-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35151415/ PubMed] | ||
##'''Update:''' Richardson PG, Perrot A, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Macé S, Zhang R, Dubin F, Morisse MC, Anderson KC. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica. 2024 Jul 1;109(7):2239-2249. [https://doi.org/10.3324/haematol.2023.284325 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11215383/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/38299578/ PubMed] | ##'''Update:''' Richardson PG, Perrot A, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Macé S, Zhang R, Dubin F, Morisse MC, Anderson KC. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica. 2024 Jul 1;109(7):2239-2249. [https://doi.org/10.3324/haematol.2023.284325 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11215383/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/38299578/ PubMed] | ||
Line 3,340: | Line 3,351: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643003/ Shah et al. 2015 (PO-MM-PI-0034)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643003/ Shah et al. 2015 (PO-MM-PI-0034)] | ||
− | |2011 | + | |2011 to not reported |
|style="background-color:#91cf61"|Phase 1 | |style="background-color:#91cf61"|Phase 1 | ||
|- | |- | ||
|} | |} | ||
''Note: although this is described as a Phase 1 trial, an additional 20 patients were enrolled at the MTD, which is the dose reported here.'' | ''Note: although this is described as a Phase 1 trial, an additional 20 patients were enrolled at the MTD, which is the dose reported here.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] as follows: | *[[Carfilzomib (Kyprolis)]] as follows: | ||
Line 3,367: | Line 3,378: | ||
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Jatin J. Shah, MD, Edward A. Stadtmauer, MD, Rafat Abonour, MD, Adam D. Cohen, MD, William I. Bensinger, MD, Cristina Gasparetto, MD, Jonathan L. Kaufman, MD, Suzanne Lentzsch, MD, Dan T. Vogl, MD, Robert Z. Orlowski, MD, PhD, Erica L. Kim, MPH, Marti McKinley, BSN, MBA, Brian G.M. Durie, MD. A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma. 2013 ASH Annual Meeting abstract 690 --> | <!-- # '''Abstract:''' Jatin J. Shah, MD, Edward A. Stadtmauer, MD, Rafat Abonour, MD, Adam D. Cohen, MD, William I. Bensinger, MD, Cristina Gasparetto, MD, Jonathan L. Kaufman, MD, Suzanne Lentzsch, MD, Dan T. Vogl, MD, Robert Z. Orlowski, MD, PhD, Erica L. Kim, MPH, Marti McKinley, BSN, MBA, Brian G.M. Durie, MD. A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma. 2013 ASH Annual Meeting abstract 690 --> | ||
− | # '''PO-MM-PI-0034:''' Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284-90. Epub 2015 Sep 17. [https://doi.org/10.1182/blood-2015-05-643320 link to original article] ''' | + | # '''PO-MM-PI-0034:''' Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284-90. Epub 2015 Sep 17. [https://doi.org/10.1182/blood-2015-05-643320 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643003/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26384354/ PubMed] [https://clinicaltrials.gov/study/NCT01464034 NCT01464034] |
==KRd {{#subobject:dec1da|Regimen=1}}== | ==KRd {{#subobject:dec1da|Regimen=1}}== | ||
Line 3,403: | Line 3,414: | ||
*ASPIRE: 1 to 3 prior lines of therapy | *ASPIRE: 1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] as follows: | *[[Carfilzomib (Kyprolis)]] as follows: | ||
Line 3,437: | Line 3,448: | ||
|} | |} | ||
''Note: this is the dose that is being explored in phase 3 studies.'' | ''Note: this is the dose that is being explored in phase 3 studies.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] as follows: | *[[Carfilzomib (Kyprolis)]] as follows: | ||
Line 3,450: | Line 3,461: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''PX-171-006:''' Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31;122(18):3122-8. Epub 2013 Sep 6. [https://doi.org/10.1182/blood-2013-07-511170 link to original article] ''' | + | # '''PX-171-006:''' Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31;122(18):3122-8. Epub 2013 Sep 6. [https://doi.org/10.1182/blood-2013-07-511170 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814729/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24014245/ PubMed] [https://clinicaltrials.gov/study/NCT00603447 NCT00603447] |
− | # '''ASPIRE:''' Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. Epub 2014 Dec 6. [https://doi.org/10.1056/NEJMoa1411321 link to original article] ''' | + | # '''ASPIRE:''' Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. Epub 2014 Dec 6. [https://doi.org/10.1056/NEJMoa1411321 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25482145/ PubMed] [https://clinicaltrials.gov/study/NCT01080391 NCT01080391] |
## '''Subgroup analysis:''' Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80. Epub 2016 Jul 20. [https://doi.org/10.1182/blood-2016-03-707596 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009511/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27439911/ PubMed] | ## '''Subgroup analysis:''' Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80. Epub 2016 Jul 20. [https://doi.org/10.1182/blood-2016-03-707596 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009511/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27439911/ PubMed] | ||
## '''HRQoL analysis:''' Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016 Nov 10;34(32):3921-3930. [https://doi.org/10.1200/JCO.2016.66.9648 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5791840/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27601539/ PubMed] | ## '''HRQoL analysis:''' Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016 Nov 10;34(32):3921-3930. [https://doi.org/10.1200/JCO.2016.66.9648 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5791840/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27601539/ PubMed] | ||
## '''Update:''' Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018 Mar 10;36(8):728-734. Epub 2018 Jan 17. [https://doi.org/10.1200/JCO.2017.76.5032 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29341834/ PubMed] | ## '''Update:''' Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018 Mar 10;36(8):728-734. Epub 2018 Jan 17. [https://doi.org/10.1200/JCO.2017.76.5032 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29341834/ PubMed] | ||
− | # '''CFZ013:''' Biran N, Siegel D, Berdeja JG, Raje N, Cornell RF, Alsina M, Kovacsovics T, Fang B, Kimball AS, Landgren O. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a phase 1b study. Am J Hematol. 2019 Jul;94(7):794-802. Epub 2019 May 13. [https://doi.org/10.1002/ajh.25498 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593978/ link to PMC article] ''' | + | # '''CFZ013:''' Biran N, Siegel D, Berdeja JG, Raje N, Cornell RF, Alsina M, Kovacsovics T, Fang B, Kimball AS, Landgren O. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a phase 1b study. Am J Hematol. 2019 Jul;94(7):794-802. Epub 2019 May 13. [https://doi.org/10.1002/ajh.25498 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593978/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/31021005/ PubMed] [https://clinicaltrials.gov/study/NCT02335983 NCT02335983] |
==PAD {{#subobject:0f85ca|Regimen=1}}== | ==PAD {{#subobject:0f85ca|Regimen=1}}== | ||
PAD: '''<u>P</u>'''S-341 (Bortezomib), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone | PAD: '''<u>P</u>'''S-341 (Bortezomib), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone | ||
Line 3,473: | Line 3,484: | ||
|} | |} | ||
''Note: length of cycle is not reported in the manuscript, but presumably is 28 days, similar to other PAD regimens.'' | ''Note: length of cycle is not reported in the manuscript, but presumably is 28 days, similar to other PAD regimens.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11 | ||
Line 3,492: | Line 3,503: | ||
===References=== | ===References=== | ||
# '''NCRI Myeloma X Relapse:''' Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jul;15(8):874-85. Epub 2014 Jun 16. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Dosage error in article text. [https://doi.org/10.1016/S1470-2045(14)70245-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24948586/ PubMed] [https://clinicaltrials.gov/study/NCT00747877 NCT00747877] | # '''NCRI Myeloma X Relapse:''' Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jul;15(8):874-85. Epub 2014 Jun 16. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Dosage error in article text. [https://doi.org/10.1016/S1470-2045(14)70245-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24948586/ PubMed] [https://clinicaltrials.gov/study/NCT00747877 NCT00747877] | ||
− | ## '''Update:''' Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016 Jul;3(7):e340-51. [https://doi.org/10.1016/S2352-3026(16)30049-7 link to original article] ''' | + | ## '''Update:''' Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016 Jul;3(7):e340-51. [https://doi.org/10.1016/S2352-3026(16)30049-7 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27374467/ PubMed] |
## '''Subgroup analysis:''' Cook G, Royle KL, O'Connor S, Cairns DA, Ashcroft AJ, Williams CD, Hockaday A, Cavenagh JD, Snowden JA, Ademokun D, Tholouli E, Andrews VE, Jenner M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Drayson MT, Brown JM, Morris TCM; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Br J Haematol. 2019 May;185(3):450-467. Epub 2019 Feb 6. [https://doi.org/10.1111/bjh.15782 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519200/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30729512/ PubMed] | ## '''Subgroup analysis:''' Cook G, Royle KL, O'Connor S, Cairns DA, Ashcroft AJ, Williams CD, Hockaday A, Cavenagh JD, Snowden JA, Ademokun D, Tholouli E, Andrews VE, Jenner M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Drayson MT, Brown JM, Morris TCM; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Br J Haematol. 2019 May;185(3):450-467. Epub 2019 Feb 6. [https://doi.org/10.1111/bjh.15782 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519200/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30729512/ PubMed] | ||
==PCD {{#subobject:e75204|Regimen=1}}== | ==PCD {{#subobject:e75204|Regimen=1}}== | ||
Line 3,509: | Line 3,520: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | *[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | ||
Line 3,544: | Line 3,555: | ||
*PO-MM-PI-0039: At least 2 prior lines of therapy including an immunomodulator; patients were required to be lenalidomide-refractory | *PO-MM-PI-0039: At least 2 prior lines of therapy including an immunomodulator; patients were required to be lenalidomide-refractory | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | *[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | ||
Line 3,559: | Line 3,570: | ||
===References=== | ===References=== | ||
<!-- Presented in part at the annual meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2014. --> | <!-- Presented in part at the annual meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2014. --> | ||
− | # '''PO-MM-PI-0039:''' Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May 26;127(21):2561-8. Epub 2016 Mar 1. Erratum in: Blood. 2016 Jul 21;128(3):461. [https://doi.org/10.1182/blood-2015-11-682518 link to original article] ''' | + | # '''PO-MM-PI-0039:''' Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May 26;127(21):2561-8. Epub 2016 Mar 1. Erratum in: Blood. 2016 Jul 21;128(3):461. [https://doi.org/10.1182/blood-2015-11-682518 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/26932802/ PubMed] [https://clinicaltrials.gov/study/NCT01432600 NCT01432600] |
− | # '''IC 2013-05:''' Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, Facon T, Leleu X, Karlin L, Perrot A, Moreau P, Marit G, Stoppa AM, Royer B, Chaleteix C, Tiab M, Araujo C, Lenain P, Macro M, Voog E, Benboubker L, Allangba O, Jourdan E, Orsini-Piocelle F, Brechignac S, Eveillard JR, Belhadj K, Wetterwald M, Pegourie B, Jaccard A, Eisenmann JC, Glaisner S, Mohty M, Hulin C, Loiseau HA, Mathiot C, Attal M. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood. 2018 Dec 13;132(24):2555-2563. Epub 2018 Oct 3. [https://doi.org/10.1182/blood-2018-07-863829 link to original article] ''' | + | # '''IC 2013-05:''' Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, Facon T, Leleu X, Karlin L, Perrot A, Moreau P, Marit G, Stoppa AM, Royer B, Chaleteix C, Tiab M, Araujo C, Lenain P, Macro M, Voog E, Benboubker L, Allangba O, Jourdan E, Orsini-Piocelle F, Brechignac S, Eveillard JR, Belhadj K, Wetterwald M, Pegourie B, Jaccard A, Eisenmann JC, Glaisner S, Mohty M, Hulin C, Loiseau HA, Mathiot C, Attal M. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood. 2018 Dec 13;132(24):2555-2563. Epub 2018 Oct 3. [https://doi.org/10.1182/blood-2018-07-863829 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/30282798/ PubMed] [https://clinicaltrials.gov/study/NCT02244125 NCT02244125] |
==PCP {{#subobject:c3aaf2|Regimen=1}}== | ==PCP {{#subobject:c3aaf2|Regimen=1}}== | ||
Line 3,577: | Line 3,588: | ||
|} | |} | ||
''Note: Details are for the phase 2 portion of the published phase 1/2 trial.'' | ''Note: Details are for the phase 2 portion of the published phase 1/2 trial.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pomalidomide (Pomalyst)]] 2.5 mg PO once per day | *[[Pomalidomide (Pomalyst)]] 2.5 mg PO once per day | ||
Line 3,593: | Line 3,604: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''PO0023:''' Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. Pomalidomide, cyclophosphamide and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open label study. Blood. 2013 Oct 17;122(16):2799-806. Epub 2013 Aug 16. [https://doi.org/10.1182/blood-2013-03-488676 link to original article] ''' | + | # '''PO0023:''' Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. Pomalidomide, cyclophosphamide and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open label study. Blood. 2013 Oct 17;122(16):2799-806. Epub 2013 Aug 16. [https://doi.org/10.1182/blood-2013-03-488676 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/23954889/ PubMed] [https://clinicaltrials.gov/study/NCT01166113 NCT01166113] |
==PVD {{#subobject:bf019d|Regimen=1}}== | ==PVD {{#subobject:bf019d|Regimen=1}}== | ||
Line 3,611: | Line 3,622: | ||
|[[#Bortezomib_.26_Dexamethasone_.28Vd.29|Vd]] | |[[#Bortezomib_.26_Dexamethasone_.28Vd.29|Vd]] | ||
| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 11.2 vs 7.1 mo<br>(HR 0.61, 95% CI 0.49-0.77) | | style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 11.2 vs 7.1 mo<br>(HR 0.61, 95% CI 0.49-0.77) | ||
+ | |- | ||
+ | |[https://doi.org/10.1056/nejmoa2303379 San-Miguel et al. 2023 (CARTITUDE-4)] | ||
+ | |2020-07-10 to 2021-11-17 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Ciltacabtagene_autoleucel_monotherapy|Cilta-cel]] | ||
+ | | style="background-color:#d73027" |Inferior PFS | ||
|- | |- | ||
|} | |} | ||
+ | ''Note: CARTITUDE-4 only used the SC route for bortezomib.'' | ||
<div class="toccolours" style="background-color:#fdcdac"> | <div class="toccolours" style="background-color:#fdcdac"> | ||
====Prior treatment criteria==== | ====Prior treatment criteria==== | ||
− | *1 to 3 prior lines of therapy including lenalidomide | + | *OPTIMISMM: 1 to 3 prior lines of therapy including lenalidomide |
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 14 | *[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 14 | ||
Line 3,649: | Line 3,667: | ||
*1 to 3 prior lines of therapy including lenalidomide | *1 to 3 prior lines of therapy including lenalidomide | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 14 | *[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 14 | ||
Line 3,676: | Line 3,694: | ||
|} | |} | ||
''Note: This is the MTD used in the phase 2 portion of the trial.'' | ''Note: This is the MTD used in the phase 2 portion of the trial.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | *[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | ||
Line 3,693: | Line 3,711: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''MC1082:''' Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7;130(10):1198-1204. Epub 2017 Jul 6. [https://doi.org/10.1182/blood-2017-05-782961 link to original article] ''' | + | # '''MC1082:''' Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7;130(10):1198-1204. Epub 2017 Jul 6. [https://doi.org/10.1182/blood-2017-05-782961 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606008/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28684537/ PubMed] [https://clinicaltrials.gov/study/NCT01212952 NCT01212952] |
− | # '''OPTIMISMM:''' Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):781-794. Epub 2019 May 13. [https://doi.org/10.1016/S1470-2045(19)30152-4 link to original article] ''' | + | # '''OPTIMISMM:''' Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):781-794. Epub 2019 May 13. [https://doi.org/10.1016/S1470-2045(19)30152-4 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/31097405/ PubMed] [https://clinicaltrials.gov/study/NCT01734928 NCT01734928] |
− | #'''CARTITUDE-4:''' San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023 Jul 27;389(4):335-347. Epub 2023 Jun 5. [https://doi.org/10.1056/nejmoa2303379 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37272512/ PubMed] [https://clinicaltrials.gov/study/NCT04181827 NCT04181827] | + | #'''CARTITUDE-4:''' San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023 Jul 27;389(4):335-347. Epub 2023 Jun 5. [https://doi.org/10.1056/nejmoa2303379 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37272512/ PubMed] [https://clinicaltrials.gov/study/NCT04181827 NCT04181827] |
==RVD {{#subobject:3f1c8e|Regimen=1}}== | ==RVD {{#subobject:3f1c8e|Regimen=1}}== | ||
Line 3,716: | Line 3,734: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Lenalidomide (Revlimid)]] 15 mg PO once per day on days 1 to 14 | *[[Lenalidomide (Revlimid)]] 15 mg PO once per day on days 1 to 14 | ||
Line 3,734: | Line 3,752: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''DFCI 06-147:''' Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC. A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 6;123(10):1461-9. Epub 2014 Jan 15. [https://doi.org/10.1182/blood-2013-07-517276 link to original article] ''' | + | # '''DFCI 06-147:''' Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC. A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 6;123(10):1461-9. Epub 2014 Jan 15. [https://doi.org/10.1182/blood-2013-07-517276 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123434/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24429336/ PubMed] [https://clinicaltrials.gov/study/NCT00378209 NCT00378209] |
==SDd {{#subobject:ghgjgu|Regimen=1}}== | ==SDd {{#subobject:ghgjgu|Regimen=1}}== | ||
SDd: '''<u>S</u>'''elinexor, '''<u>D</u>'''aratumumab, low-dose '''<u>d</u>'''examethasone | SDd: '''<u>S</u>'''elinexor, '''<u>D</u>'''aratumumab, low-dose '''<u>d</u>'''examethasone | ||
Line 3,750: | Line 3,768: | ||
|} | |} | ||
''Note: this is the dosing used in the expansion cohort.'' | ''Note: this is the dosing used in the expansion cohort.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Selinexor (Xpovio)]] 100 mg PO once per day on days 1, 8, 15, 22 | *[[Selinexor (Xpovio)]] 100 mg PO once per day on days 1, 8, 15, 22 | ||
Line 3,762: | Line 3,780: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''STOMP:''' Gasparetto C, Lentsch S, Schiller G, Callander N, Tuchman S, Chen C, White D, Kotb R, Sutherland H, Sebag M, Baljevic M, Bensinger W, LeBlanc R, Venner C, Bahlis N, Rossi A, Biran N, Sheehan H, Saint Martin JR, Van Domelen D, Kai K, Shah J, Shacham S, Kauffman M, Lipe B. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. eJHaem. 2020 Nov 8;2(1):56-65. [https://doi.org/10.1002/jha2.122 link to original article] ''' | + | # '''STOMP:''' Gasparetto C, Lentsch S, Schiller G, Callander N, Tuchman S, Chen C, White D, Kotb R, Sutherland H, Sebag M, Baljevic M, Bensinger W, LeBlanc R, Venner C, Bahlis N, Rossi A, Biran N, Sheehan H, Saint Martin JR, Van Domelen D, Kai K, Shah J, Shacham S, Kauffman M, Lipe B. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. eJHaem. 2020 Nov 8;2(1):56-65. [https://doi.org/10.1002/jha2.122 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9176052/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35846104/ PubMed] [https://clinicaltrials.gov/study/NCT02343042 NCT02343042] |
==SKd {{#subobject:ghg8e1|Regimen=1}}== | ==SKd {{#subobject:ghg8e1|Regimen=1}}== | ||
SKd: '''<u>S</u>'''elinexor, '''<u>K</u>'''yprolis (Carfilzomib), low-dose '''<u>d</u>'''examethasone | SKd: '''<u>S</u>'''elinexor, '''<u>K</u>'''yprolis (Carfilzomib), low-dose '''<u>d</u>'''examethasone | ||
Line 3,778: | Line 3,796: | ||
|} | |} | ||
''Note: this is the RP2D cohort (2b).'' | ''Note: this is the RP2D cohort (2b).'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Selinexor (Xpovio)]] 60 mg PO once per day on days 1, 3, 8, 10, 15, 17 | *[[Selinexor (Xpovio)]] 60 mg PO once per day on days 1, 3, 8, 10, 15, 17 | ||
Line 3,792: | Line 3,810: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 Aug;186(4):549-560. Epub 2019 May 24. [https://doi.org/10.1111/bjh.15969 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6772147/ link to PMC article] ''' | + | # Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 Aug;186(4):549-560. Epub 2019 May 24. [https://doi.org/10.1111/bjh.15969 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6772147/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/31124580/ PubMed] [https://clinicaltrials.gov/study/NCT02199665 NCT02199665] |
==SVd {{#subobject:auh402|Regimen=1}}== | ==SVd {{#subobject:auh402|Regimen=1}}== | ||
SVd: '''<u>S</u>'''elinexor, '''<u>V</u>'''elcade (Bortezomib), low-dose '''<u>d</u>'''examethasone | SVd: '''<u>S</u>'''elinexor, '''<u>V</u>'''elcade (Bortezomib), low-dose '''<u>d</u>'''examethasone | ||
Line 3,816: | Line 3,834: | ||
*1 to 3 prior lines of therapy, including proteasome inhibitors | *1 to 3 prior lines of therapy, including proteasome inhibitors | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 8, 15, 22 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 8, 15, 22 | ||
Line 3,825: | Line 3,843: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''BOSTON:''' Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020 Nov 14;396(10262):1563-1573. [https://doi.org/10.1016/s0140-6736(20)32292-3 link to original article] ''' | + | # '''BOSTON:''' Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020 Nov 14;396(10262):1563-1573. [https://doi.org/10.1016/s0140-6736(20)32292-3 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/33189178/ PubMed] [https://clinicaltrials.gov/study/NCT03110562 NCT03110562] |
# '''BENCH:''' [https://clinicaltrials.gov/study/NCT04939142 NCT04939142] | # '''BENCH:''' [https://clinicaltrials.gov/study/NCT04939142 NCT04939142] | ||
==VDC {{#subobject:d412fd|Regimen=1}}== | ==VDC {{#subobject:d412fd|Regimen=1}}== | ||
Line 3,852: | Line 3,870: | ||
*1 to 3 prior lines of therapy | *1 to 3 prior lines of therapy | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11 | ||
Line 3,877: | Line 3,895: | ||
*Bortezomib-naive | *Bortezomib-naive | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] as follows: | *[[Bortezomib (Velcade)]] as follows: | ||
Line 3,913: | Line 3,931: | ||
*Bortezomib-naive | *Bortezomib-naive | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] as follows: | *[[Bortezomib (Velcade)]] as follows: | ||
Line 3,927: | Line 3,945: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf HH, Einsele H, Volpert S, Heinecke A, Berdel WE, Kienast J; Deutsche Studiengruppe Multiples Myelom,. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007 Aug;138(3):330-7. [https://doi.org/10.1111/j.1365-2141.2007.06656.x link to original article] ''' | + | # Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf HH, Einsele H, Volpert S, Heinecke A, Berdel WE, Kienast J; Deutsche Studiengruppe Multiples Myelom,. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007 Aug;138(3):330-7. [https://doi.org/10.1111/j.1365-2141.2007.06656.x link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17614819/ PubMed] |
− | # de Waal EG, de Munck L, Hoogendoorn M, Woolthuis G, van der Velden A, Tromp Y, Vellenga E, Hovenga S. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. Br J Haematol. 2015 Dec;171(5):720-5. Epub 2015 Sep 11. [https://doi.org/10.1111/bjh.13653 link to original article] ''' | + | # de Waal EG, de Munck L, Hoogendoorn M, Woolthuis G, van der Velden A, Tromp Y, Vellenga E, Hovenga S. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. Br J Haematol. 2015 Dec;171(5):720-5. Epub 2015 Sep 11. [https://doi.org/10.1111/bjh.13653 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/26358087/ PubMed] |
# '''CR015247:''' Kropff M, Vogel M, Bisping G, Schlag R, Weide R, Knauf W, Fiechtner H, Kojouharoff G, Kremers S, Berdel WE. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Ann Hematol. 2017 Nov;96(11):1857-1866. Epub 2017 Sep 14. [https://doi.org/10.1007/s00277-017-3065-z link to original article] [https://pubmed.ncbi.nlm.nih.gov/28905189/ PubMed] [https://clinicaltrials.gov/study/NCT00813150 NCT00813150] | # '''CR015247:''' Kropff M, Vogel M, Bisping G, Schlag R, Weide R, Knauf W, Fiechtner H, Kojouharoff G, Kremers S, Berdel WE. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Ann Hematol. 2017 Nov;96(11):1857-1866. Epub 2017 Sep 14. [https://doi.org/10.1007/s00277-017-3065-z link to original article] [https://pubmed.ncbi.nlm.nih.gov/28905189/ PubMed] [https://clinicaltrials.gov/study/NCT00813150 NCT00813150] | ||
Line 3,953: | Line 3,971: | ||
*At least 1 autologous stem-cell transplant | *At least 1 autologous stem-cell transplant | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] as follows: | *[[Bortezomib (Velcade)]] as follows: | ||
Line 3,969: | Line 3,987: | ||
===References=== | ===References=== | ||
<!-- Presented at the 37th Annual Meeting of the European Group for Blood and Marrow Transplantation, Paris, France, April, 3-6, 2011. --> | <!-- Presented at the 37th Annual Meeting of the European Group for Blood and Marrow Transplantation, Paris, France, April, 3-6, 2011. --> | ||
− | # '''MMVAR/IFM 2005-04:''' Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012 Jul 10;30(20):2475-82. Epub 2012 May 14. Erratum in: J Clin Oncol. 2012 Sep 20;30(27):3429. [https://doi.org/10.1200/jco.2011.37.4918 link to original article] ''' | + | # '''MMVAR/IFM 2005-04:''' Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012 Jul 10;30(20):2475-82. Epub 2012 May 14. Erratum in: J Clin Oncol. 2012 Sep 20;30(27):3429. [https://doi.org/10.1200/jco.2011.37.4918 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/22585692/ PubMed] [https://clinicaltrials.gov/study/NCT00256776 NCT00256776] |
==Ven-Kd {{#subobject:vncug87|Regimen=1}}== | ==Ven-Kd {{#subobject:vncug87|Regimen=1}}== | ||
Ven-Kd: '''<u>Ven</u>'''etoclax, '''<u>K</u>'''yprolis (Carfilzomib), low-dose '''<u>d</u>'''examethasone | Ven-Kd: '''<u>Ven</u>'''etoclax, '''<u>K</u>'''yprolis (Carfilzomib), low-dose '''<u>d</u>'''examethasone | ||
Line 3,985: | Line 4,003: | ||
|} | |} | ||
''Note: this was the dosing used in the dose expansion cohort.'' | ''Note: this was the dosing used in the dose expansion cohort.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Venetoclax (Venclexta)]] 800 mg PO once per day on days 1 to 28 | *[[Venetoclax (Venclexta)]] 800 mg PO once per day on days 1 to 28 | ||
Line 3,997: | Line 4,015: | ||
===References=== | ===References=== | ||
− | # '''M15-538:''' Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A, Kaufman JL, Hong WJ, Dail M, Salem AH, Yang X, Masud AA, Munasinghe W, Ross JA, Bueno OF, Kumar SK, Stadtmauer EA. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv. 2021 Oct 12;5(19):3748-3759. [https://doi.org/10.1182/bloodadvances.2020004146 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679663/ link to PMC article] ''' | + | # '''M15-538:''' Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A, Kaufman JL, Hong WJ, Dail M, Salem AH, Yang X, Masud AA, Munasinghe W, Ross JA, Bueno OF, Kumar SK, Stadtmauer EA. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv. 2021 Oct 12;5(19):3748-3759. [https://doi.org/10.1182/bloodadvances.2020004146 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679663/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34470049/ PubMed] [https://clinicaltrials.gov/study/NCT02899052 NCT02899052] |
==ZRd {{#subobject:4e6061|Regimen=1}}== | ==ZRd {{#subobject:4e6061|Regimen=1}}== | ||
Line 4,013: | Line 4,031: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Vorinostat (Zolinza)]] 400 mg PO once per day on days 1 to 7, 15 to 21 | *[[Vorinostat (Zolinza)]] 400 mg PO once per day on days 1 to 7, 15 to 21 | ||
Line 4,022: | Line 4,040: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''PRO-2580:''' Sanchez L, Vesole DH, Richter JR, Biran N, Bilotti E, McBride L, Anand P, Ivanovski K, Siegel DS. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. Br J Haematol. 2017 Feb;176(3):440-447. Epub 2016 Nov 18. [https://doi.org/10.1111/bjh.14429 link to original article] ''' | + | # '''PRO-2580:''' Sanchez L, Vesole DH, Richter JR, Biran N, Bilotti E, McBride L, Anand P, Ivanovski K, Siegel DS. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. Br J Haematol. 2017 Feb;176(3):440-447. Epub 2016 Nov 18. [https://doi.org/10.1111/bjh.14429 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27859001/ PubMed] [https://clinicaltrials.gov/study/NCT01502085 NCT01502085] |
=Relapsed or refractory, other combinations= | =Relapsed or refractory, other combinations= | ||
Line 4,039: | Line 4,057: | ||
|} | |} | ||
''Note: this is the dose used in the phase 2 portion of the trial.'' | ''Note: this is the dose used in the phase 2 portion of the trial.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1 & 8 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1 & 8 | ||
Line 4,049: | Line 4,067: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''MUK-six:''' Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network.. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Lancet Haematol. 2016 Dec;3(12):e572-e580. Epub 2016 Nov 12. [https://doi.org/10.1016/S2352-3026(16)30165-X link to original article] ''' | + | # '''MUK-six:''' Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network.. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Lancet Haematol. 2016 Dec;3(12):e572-e580. Epub 2016 Nov 12. [https://doi.org/10.1016/S2352-3026(16)30165-X link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27843120/ PubMed] [https://clinicaltrials.gov/study/NCT02145715 NCT02145715] |
==DCEP {{#subobject:6dd02a|Regimen=1}}== | ==DCEP {{#subobject:6dd02a|Regimen=1}}== | ||
Line 4,066: | Line 4,084: | ||
|} | |} | ||
''Note: this protocol is reported as a mobilization regimen prior to high dose autologous transplant; all patients had received prior therapy.'' | ''Note: this protocol is reported as a mobilization regimen prior to high dose autologous transplant; all patients had received prior therapy.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4 | *[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4 | ||
Line 4,090: | Line 4,108: | ||
|} | |} | ||
''Note: These limited details are based on the abstract's description only. Full article was not available for review.'' | ''Note: These limited details are based on the abstract's description only. Full article was not available for review.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
*[[Dexamethasone (Decadron)]] 40 mg IV bolus once per day on days 1 to 4 | *[[Dexamethasone (Decadron)]] 40 mg IV bolus once per day on days 1 to 4 | ||
Line 4,102: | Line 4,120: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Lazzarino M, Corso A, Barbarano L, Alessandrino EP, Cairoli R, Pinotti G, Ucci G, Uziel L, Rodeghiero F, Fava S, Ferrari D, Fiumanò M, Frigerio G, Isa L, Luraschi A, Montanara S, Morandi S, Perego D, Santagostino A, Savarè M, Vismara A, Morra E. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant. 2001 Nov;28(9):835-9. [https://doi.org/10.1038/sj.bmt.1703240 link to original article] ''' | + | # Lazzarino M, Corso A, Barbarano L, Alessandrino EP, Cairoli R, Pinotti G, Ucci G, Uziel L, Rodeghiero F, Fava S, Ferrari D, Fiumanò M, Frigerio G, Isa L, Luraschi A, Montanara S, Morandi S, Perego D, Santagostino A, Savarè M, Vismara A, Morra E. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant. 2001 Nov;28(9):835-9. [https://doi.org/10.1038/sj.bmt.1703240 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/11781643/ PubMed] |
# Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Mitsouli-Mentzikof C. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON. 2007 Jan-Mar;12(1):41 to 4. [https://pubmed.ncbi.nlm.nih.gov/17436400/ PubMed] | # Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Mitsouli-Mentzikof C. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON. 2007 Jan-Mar;12(1):41 to 4. [https://pubmed.ncbi.nlm.nih.gov/17436400/ PubMed] | ||
Line 4,119: | Line 4,137: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Thalidomide (Thalomid)]] 400 mg PO once per day, taken at night | *[[Thalidomide (Thalomid)]] 400 mg PO once per day, taken at night | ||
Line 4,139: | Line 4,157: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''UARK-98035:''' Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003 Jul 15;21(14):2732-9. Erratum in: J Clin Oncol. 2008 Apr 20;26(12): 2066. [https://doi.org/10.1200/jco.2003.01.055 link to original article] ''' | + | # '''UARK-98035:''' Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003 Jul 15;21(14):2732-9. Erratum in: J Clin Oncol. 2008 Apr 20;26(12): 2066. [https://doi.org/10.1200/jco.2003.01.055 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/12860952/ PubMed] |
==Hyper-CVAD {{#subobject:0df285|Regimen=1}}== | ==Hyper-CVAD {{#subobject:0df285|Regimen=1}}== | ||
Hyper-CVAD: '''<u>Hyper</u>'''fractionated '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone | Hyper-CVAD: '''<u>Hyper</u>'''fractionated '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone | ||
Line 4,154: | Line 4,172: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> IV over 3 hours every 12 hours on days 1 to 3 (total dose per cycle: 1800 mg/m<sup>2</sup>) | *[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> IV over 3 hours every 12 hours on days 1 to 3 (total dose per cycle: 1800 mg/m<sup>2</sup>) | ||
Line 4,186: | Line 4,204: | ||
|} | |} | ||
''Note: vincristine is a flat dose.'' | ''Note: vincristine is a flat dose.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> IV every 12 hours on days 1 to 4 (total dose per cycle: 2400 mg/m<sup>2</sup>) | *[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> IV every 12 hours on days 1 to 4 (total dose per cycle: 2400 mg/m<sup>2</sup>) | ||
Line 4,201: | Line 4,219: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol. 1996 Jun;52(2):77-81. [https://doi.org/10.1002/(SICI)1096-8652(199606)52:2%3C77::AID-AJH2%3E3.0.CO;2-2 link to original article] ''' | + | # Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol. 1996 Jun;52(2):77-81. [https://doi.org/10.1002/(SICI)1096-8652(199606)52:2%3C77::AID-AJH2%3E3.0.CO;2-2 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/8638645/ PubMed] |
− | # '''Retrospective:''' Saraceni MM, Scott E, Maziarz RT, Siegel MB, Bassale S, Jiing S, Medvedova E. Modified hyperCVAD versus bortezomib-hyperCAD in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e77-e84. Epub 2017 Nov 2. [https://doi.org/10.1016/j.clml.2017.10.008 link to original article] ''' | + | # '''Retrospective:''' Saraceni MM, Scott E, Maziarz RT, Siegel MB, Bassale S, Jiing S, Medvedova E. Modified hyperCVAD versus bortezomib-hyperCAD in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e77-e84. Epub 2017 Nov 2. [https://doi.org/10.1016/j.clml.2017.10.008 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29169873/ PubMed] |
==KD-PACE {{#subobject:yg72na|Regimen=1}}== | ==KD-PACE {{#subobject:yg72na|Regimen=1}}== | ||
KD-PACE: '''<u>K</u>'''yprolis (Carfilzomib), '''<u>D</u>'''examethasone, '''<u>P</u>'''latinol (Cisplatin), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide (Toposar) | KD-PACE: '''<u>K</u>'''yprolis (Carfilzomib), '''<u>D</u>'''examethasone, '''<u>P</u>'''latinol (Cisplatin), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide (Toposar) | ||
Line 4,217: | Line 4,235: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] as follows: | *[[Carfilzomib (Kyprolis)]] as follows: | ||
Line 4,232: | Line 4,250: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''Retrospective:''' Alsouqi A, Khan M, Dhakal B, Du L, Harrell S, Hari P, Cornell RF. KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):526-535. Epub 2021 Apr 6. [https://doi.org/10.1016/j.clml.2021.03.013 link to original article] ''' | + | #'''Retrospective:''' Alsouqi A, Khan M, Dhakal B, Du L, Harrell S, Hari P, Cornell RF. KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):526-535. Epub 2021 Apr 6. [https://doi.org/10.1016/j.clml.2021.03.013 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/33985931/ PubMed] |
==KRD-PACE {{#subobject:0072na|Regimen=1}}== | ==KRD-PACE {{#subobject:0072na|Regimen=1}}== | ||
Line 4,249: | Line 4,267: | ||
|} | |} | ||
''Note: PACE was administered as a continuous infusion.'' | ''Note: PACE was administered as a continuous infusion.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] 20 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9 | *[[Carfilzomib (Kyprolis)]] 20 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9 | ||
Line 4,274: | Line 4,292: | ||
|} | |} | ||
''Note: PACE was administered as a continuous infusion.'' | ''Note: PACE was administered as a continuous infusion.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] 20 mg/m<sup>2</sup> IV once per day on days 1, 5, 6 | *[[Carfilzomib (Kyprolis)]] 20 mg/m<sup>2</sup> IV once per day on days 1, 5, 6 | ||
Line 4,293: | Line 4,311: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''Retrospective:''' Cowan AJ, Green DJ, Karami M, Becker PS, Tuazon S, Coffey DG, Hyun TS, Libby EN, Gopal AK, Holmberg LA. KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):602-609. Epub 2020 Apr 14. [https://doi.org/10.1016/j.clml.2020.04.002 link to original article] ''' | + | # '''Retrospective:''' Cowan AJ, Green DJ, Karami M, Becker PS, Tuazon S, Coffey DG, Hyun TS, Libby EN, Gopal AK, Holmberg LA. KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):602-609. Epub 2020 Apr 14. [https://doi.org/10.1016/j.clml.2020.04.002 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32457024/ PubMed] |
==V-HyperCAD {{#subobject:00a88b|Regimen=1}}== | ==V-HyperCAD {{#subobject:00a88b|Regimen=1}}== | ||
Line 4,309: | Line 4,327: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1 & 4 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1 & 4 | ||
Line 4,325: | Line 4,343: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''Retrospective:''' Saraceni MM, Scott E, Maziarz RT, Siegel MB, Bassale S, Jiing S, Medvedova E. Modified hyperCVAD versus bortezomib-hyperCAD in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e77-e84. Epub 2017 Nov 2. [https://doi.org/10.1016/j.clml.2017.10.008 link to original article] ''' | + | # '''Retrospective:''' Saraceni MM, Scott E, Maziarz RT, Siegel MB, Bassale S, Jiing S, Medvedova E. Modified hyperCVAD versus bortezomib-hyperCAD in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e77-e84. Epub 2017 Nov 2. [https://doi.org/10.1016/j.clml.2017.10.008 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29169873/ PubMed] |
==VMPT {{#subobject:c7cda5|Regimen=1}}== | ==VMPT {{#subobject:c7cda5|Regimen=1}}== | ||
VMPT: '''<u>V</u>'''elcade (Bortezomib), '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone, '''<u>T</u>'''halidomide | VMPT: '''<u>V</u>'''elcade (Bortezomib), '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone, '''<u>T</u>'''halidomide | ||
Line 4,341: | Line 4,359: | ||
|} | |} | ||
''Note: This is the MTD dosing of this phase 1/2 trial.'' | ''Note: This is the MTD dosing of this phase 1/2 trial.'' | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 15, 22 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 15, 22 | ||
Line 4,352: | Line 4,370: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, Cangialosi C, Caravita T, Morabito F, Musto P, Bringhen S, Falco P, Avonto I, Cavallo F, Boccadoro M; Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007 Apr 1;109(7):2767-72. [https://doi.org/10.1182/blood-2006-08-042275 link to original article] ''' | + | # Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, Cangialosi C, Caravita T, Morabito F, Musto P, Bringhen S, Falco P, Avonto I, Cavallo F, Boccadoro M; Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007 Apr 1;109(7):2767-72. [https://doi.org/10.1182/blood-2006-08-042275 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17148584/ PubMed] |
<section end=rrmm /> | <section end=rrmm /> | ||
<section begin=rrmm-consol /> | <section begin=rrmm-consol /> | ||
Line 4,378: | Line 4,396: | ||
*[[Multiple_myeloma_-_historical#Bortezomib_monotherapy|Bortezomib]] induction | *[[Multiple_myeloma_-_historical#Bortezomib_monotherapy|Bortezomib]] induction | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | ||
Line 4,386: | Line 4,404: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''APEX:''' Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16;352(24):2487-98. [https://doi.org/10.1056/NEJMoa043445 link to original article] ''' | + | # '''APEX:''' Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16;352(24):2487-98. [https://doi.org/10.1056/NEJMoa043445 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15958804/ PubMed] [https://clinicaltrials.gov/study/NCT00048230 NCT00048230] |
## '''Pooled subgroup analysis:''' Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007 Jan;21(1):151-7. Epub 2006 Nov 9. [https://doi.org/10.1038/sj.leu.2404442 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17096017/ PubMed] | ## '''Pooled subgroup analysis:''' Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007 Jan;21(1):151-7. Epub 2006 Nov 9. [https://doi.org/10.1038/sj.leu.2404442 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17096017/ PubMed] | ||
− | ## '''Update:''' Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov 15;110(10):3557-60. Epub 2007 Aug 9. [https://doi.org/10.1182/blood-2006-08-036947 link to original article] ''' | + | ## '''Update:''' Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov 15;110(10):3557-60. Epub 2007 Aug 9. [https://doi.org/10.1182/blood-2006-08-036947 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17690257/ PubMed] |
==Melphalan monotherapy, then auto HSCT {{#subobject:149d91|Regimen=1}}== | ==Melphalan monotherapy, then auto HSCT {{#subobject:149d91|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 4,411: | Line 4,429: | ||
*Salvage [[#PAD|PAD]] x 4 | *Salvage [[#PAD|PAD]] x 4 | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Melphalan (Alkeran)]] 200 mg/m<sup>2</sup> IV once on day -2 | *[[Melphalan (Alkeran)]] 200 mg/m<sup>2</sup> IV once on day -2 | ||
Line 4,418: | Line 4,436: | ||
===References=== | ===References=== | ||
# '''NCRI Myeloma X Relapse:''' Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jul;15(8):874-85. Epub 2014 Jun 16. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Dosage error in article text. [https://doi.org/10.1016/S1470-2045(14)70245-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24948586/ PubMed] [https://clinicaltrials.gov/study/NCT00747877 NCT00747877] | # '''NCRI Myeloma X Relapse:''' Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jul;15(8):874-85. Epub 2014 Jun 16. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Dosage error in article text. [https://doi.org/10.1016/S1470-2045(14)70245-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24948586/ PubMed] [https://clinicaltrials.gov/study/NCT00747877 NCT00747877] | ||
− | ## '''Update:''' Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016 Jul;3(7):e340-51. [https://doi.org/10.1016/S2352-3026(16)30049-7 link to original article] ''' | + | ## '''Update:''' Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016 Jul;3(7):e340-51. [https://doi.org/10.1016/S2352-3026(16)30049-7 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27374467/ PubMed] |
## '''Subgroup analysis:''' Cook G, Royle KL, O'Connor S, Cairns DA, Ashcroft AJ, Williams CD, Hockaday A, Cavenagh JD, Snowden JA, Ademokun D, Tholouli E, Andrews VE, Jenner M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Drayson MT, Brown JM, Morris TCM; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Br J Haematol. 2019 May;185(3):450-467. Epub 2019 Feb 6. [https://doi.org/10.1111/bjh.15782 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519200/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30729512/ PubMed] | ## '''Subgroup analysis:''' Cook G, Royle KL, O'Connor S, Cairns DA, Ashcroft AJ, Williams CD, Hockaday A, Cavenagh JD, Snowden JA, Ademokun D, Tholouli E, Andrews VE, Jenner M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Drayson MT, Brown JM, Morris TCM; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Br J Haematol. 2019 May;185(3):450-467. Epub 2019 Feb 6. [https://doi.org/10.1111/bjh.15782 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519200/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30729512/ PubMed] | ||
=Maintenance after second-line therapy= | =Maintenance after second-line therapy= | ||
Line 4,438: | Line 4,456: | ||
*Salvage [[#VDC|VDC]] x 6 | *Salvage [[#VDC|VDC]] x 6 | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV or SC once on day 1 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV or SC once on day 1 | ||
Line 4,449: | Line 4,467: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # de Waal EG, de Munck L, Hoogendoorn M, Woolthuis G, van der Velden A, Tromp Y, Vellenga E, Hovenga S. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. Br J Haematol. 2015 Dec;171(5):720-5. Epub 2015 Sep 11. [https://doi.org/10.1111/bjh.13653 link to original article] ''' | + | # de Waal EG, de Munck L, Hoogendoorn M, Woolthuis G, van der Velden A, Tromp Y, Vellenga E, Hovenga S. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. Br J Haematol. 2015 Dec;171(5):720-5. Epub 2015 Sep 11. [https://doi.org/10.1111/bjh.13653 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/26358087/ PubMed] |
==KPD {{#subobject:bfa533|Regimen=1}}== | ==KPD {{#subobject:bfa533|Regimen=1}}== | ||
KPD: '''<u>K</u>'''yprolis (Carfilzomib), '''<u>P</u>'''omalidomide, '''<u>D</u>'''examethasone | KPD: '''<u>K</u>'''yprolis (Carfilzomib), '''<u>P</u>'''omalidomide, '''<u>D</u>'''examethasone | ||
Line 4,461: | Line 4,479: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643003/ Shah et al. 2015 (PO-MM-PI-0034)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643003/ Shah et al. 2015 (PO-MM-PI-0034)] | ||
− | |2011 | + | |2011 to not reported |
|style="background-color:#91cf61"|Phase 1 | |style="background-color:#91cf61"|Phase 1 | ||
|- | |- | ||
Line 4,470: | Line 4,488: | ||
*Salvage [[#KPD|KPD]] x 6 | *Salvage [[#KPD|KPD]] x 6 | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Carfilzomib (Kyprolis)]] 27 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 2, 15, 16 | *[[Carfilzomib (Kyprolis)]] 27 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 2, 15, 16 | ||
Line 4,484: | Line 4,502: | ||
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Jatin J. Shah, MD, Edward A. Stadtmauer, MD, Rafat Abonour, MD, Adam D. Cohen, MD, William I. Bensinger, MD, Cristina Gasparetto, MD, Jonathan L. Kaufman, MD, Suzanne Lentzsch, MD, Dan T. Vogl, MD, Robert Z. Orlowski, MD, PhD, Erica L. Kim, MPH, Marti McKinley, BSN, MBA, Brian G.M. Durie, MD. A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma. 2013 ASH Annual Meeting abstract 690--> | <!-- # '''Abstract:''' Jatin J. Shah, MD, Edward A. Stadtmauer, MD, Rafat Abonour, MD, Adam D. Cohen, MD, William I. Bensinger, MD, Cristina Gasparetto, MD, Jonathan L. Kaufman, MD, Suzanne Lentzsch, MD, Dan T. Vogl, MD, Robert Z. Orlowski, MD, PhD, Erica L. Kim, MPH, Marti McKinley, BSN, MBA, Brian G.M. Durie, MD. A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma. 2013 ASH Annual Meeting abstract 690--> | ||
− | # '''PO-MM-PI-0034:''' Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284-90. Epub 2015 Sep 17. [https://doi.org/10.1182/blood-2015-05-643320 link to original article] ''' | + | # '''PO-MM-PI-0034:''' Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284-90. Epub 2015 Sep 17. [https://doi.org/10.1182/blood-2015-05-643320 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643003/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26384354/ PubMed] [https://clinicaltrials.gov/study/NCT01464034 NCT01464034] |
==Pomalidomide monotherapy {{#subobject:5d4f4d|Regimen=1}}== | ==Pomalidomide monotherapy {{#subobject:5d4f4d|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 4,504: | Line 4,522: | ||
*Salvage [[#PVD|PVD]] x 8 | *Salvage [[#PVD|PVD]] x 8 | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | *[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21 | ||
Line 4,514: | Line 4,532: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''MC1082:''' Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7;130(10):1198-1204. Epub 2017 Jul 6. [https://doi.org/10.1182/blood-2017-05-782961 link to original article] ''' | + | # '''MC1082:''' Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7;130(10):1198-1204. Epub 2017 Jul 6. [https://doi.org/10.1182/blood-2017-05-782961 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606008/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28684537/ PubMed] [https://clinicaltrials.gov/study/NCT01212952 NCT01212952] |
==Pomalidomide & Prednisone {{#subobject:519843|Regimen=1}}== | ==Pomalidomide & Prednisone {{#subobject:519843|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 4,535: | Line 4,553: | ||
*Salvage [[#PCP|PCP]] x 6 | *Salvage [[#PCP|PCP]] x 6 | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pomalidomide (Pomalyst)]] 1 mg PO once per day | *[[Pomalidomide (Pomalyst)]] 1 mg PO once per day | ||
Line 4,545: | Line 4,563: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''PO0023:''' Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. Pomalidomide, cyclophosphamide and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open label study. Blood. 2013 Oct 17;122(16):2799-806. Epub 2013 Aug 16. [https://doi.org/10.1182/blood-2013-03-488676 link to original article] ''' | + | # '''PO0023:''' Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. Pomalidomide, cyclophosphamide and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open label study. Blood. 2013 Oct 17;122(16):2799-806. Epub 2013 Aug 16. [https://doi.org/10.1182/blood-2013-03-488676 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/23954889/ PubMed] [https://clinicaltrials.gov/study/NCT01166113 NCT01166113] |
==RVD {{#subobject:fe8a85|Regimen=1}}== | ==RVD {{#subobject:fe8a85|Regimen=1}}== | ||
RVD: '''<u>R</u>'''evlimid (Lenalidomide), '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone | RVD: '''<u>R</u>'''evlimid (Lenalidomide), '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone | ||
Line 4,567: | Line 4,585: | ||
*[[#RVD|RVD]] salvage | *[[#RVD|RVD]] salvage | ||
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Lenalidomide (Revlimid)]] (at previously tolerated dose) PO once per day on days 1 to 14 | *[[Lenalidomide (Revlimid)]] (at previously tolerated dose) PO once per day on days 1 to 14 | ||
Line 4,579: | Line 4,597: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''DFCI 06-147:''' Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC. A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 6;123(10):1461-9. Epub 2014 Jan 15. [https://doi.org/10.1182/blood-2013-07-517276 link to original article] ''' | + | # '''DFCI 06-147:''' Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC. A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 6;123(10):1461-9. Epub 2014 Jan 15. [https://doi.org/10.1182/blood-2013-07-517276 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123434/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24429336/ PubMed] [https://clinicaltrials.gov/study/NCT00378209 NCT00378209] |
<section end=rrmm-consol /> | <section end=rrmm-consol /> | ||
{{#lst:Multiple myeloma|bottom}} | {{#lst:Multiple myeloma|bottom}} |
Latest revision as of 02:00, 31 July 2024
Page editor | Section editor | ||
---|---|---|---|
Mary L. Kwok, MD, FACP Seattle Cancer Care Alliance Seattle, WA, USA |
Samuel M. Rubinstein, MD University of North Carolina Chapel Hill, NC, USA |
Are you looking for a regimen but can't find it here? It is possible that we've moved it to the historical regimens page. If you still can't find it, please let us know so we can add it!.
Note: due to its size/complexity, multiple myeloma has been split into sub-pages:
- Induction (transplant eligible and ineligible)
- First-line consolidation and maintenance
- Relapsed/refractory, including subsequent consolidation and maintenance [this page]
- Smoldering multiple myeloma
80 regimens on this page
122 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ASCO/CCO
- 2019: Mikhael et al. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline PubMed
- 2018: Anderson et al. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology Clinical Practice Guideline update PubMed
BSH/UKMF
- 2017: Guidelines for the use of imaging in the management of patients with myeloma PubMed
- 2017: Guidelines for screening and management of late and long-term consequences of myeloma and its treatment PubMed
- 2014: Updates to the guidelines for the diagnosis and management of multiple myeloma PubMed
European Myeloma Network (EMN)
- 2020: Ludwig et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network PubMed
- 2018: Caers et al. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when PubMed
- 2018: Gay et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives PubMed
EHA/ESMO
- 2021: Dimopoulos et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2017: Moreau et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2013: Moreau et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2010: Harousseau & Dreyling. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2009: Harousseau & Dreyling. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up PubMed
- 2008: Harousseau & Dreyling. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up PubMed
- 2007: Harousseau. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up PubMed
- 2005: Harousseau et al. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma PubMed
IMWG
- 2021: Moreau et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group PubMed
- 2021: Terpos et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group PubMed
- 2016: Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group PubMed
- 2016: International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment PubMed
- 2014: International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation PubMed
- 2013: International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease PubMed
NCCN
- NCCN Guidelines - Multiple Myeloma
- 2020: Kumar et al. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. PubMed
- 2017: Kumar et al. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology PubMed
- 2016: Anderson et al. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016 PubMed
- 2015: Anderson et al. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology PubMed
- 2011: Anderson et al. Multiple myeloma. PubMed
- 2009: Anderson et al. NCCN clinical practice guidelines in oncology: multiple myeloma. PubMed
- 2007: Anderson et al. Multiple myeloma. Clinical practice guidelines in oncology. PubMed
- 2004: Anderson et al. Multiple myeloma clinical practice guidelines in oncoloqy. PubMed
SITC
- 2020: Shah et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma PubMed
Relapsed or refractory, single agents
Ciltacabtagene autoleucel monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Berdeja et al. 2021 (CARTITUDE-1) | 2018-07-16 to 2019-10-07 | Phase 1b/2 (RT) | ||
San-Miguel et al. 2023 (CARTITUDE-4) | 2020-07-10 to 2021-11-17 | Phase 3 (E-switch-ooc) | 1a. DPd 1b. PVd |
Superior PFS (primary endpoint) Median PFS: NYR vs 11.8 mo (HR 0.26, 95% CI 0.18-0.38) |
Immunotherapy
- Ciltacabtagene autoleucel (Carvykti) 0.75 x 106 CAR-positive viable T cells/kg IV once on day 0
One course
References
- CARTITUDE-1: Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 Jul 24;398(10297):314-324. Epub 2021 Jun 24. Erratum in: Lancet. 2021 Oct 2;398(10307):1216. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT03548207
- Update: Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 Feb 20;41(6):1265-1274. Epub 2022 Jun 4. link to original article link to PMC article PubMed
- CARTITUDE-4: San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023 Jul 27;389(4):335-347. Epub 2023 Jun 5. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT04181827
Carfilzomib monotherapy
Regimen variant #1, 15/20/27 dosing, for renal impairment
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Badros et al. 2013 (PX-171-005) | 2008-2010 | Phase 2 | ORR: 25.5% |
Targeted therapy
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 15 mg/m2 IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16
- Cycle 2: 20 mg/m2 IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16
- Cycle 3 onwards: 27 mg/m2 IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16
Supportive therapy
- Dexamethasone (Decadron) 4 mg (route not specified) before all doses in cycle 1. Continue dexamethasone premedication if patients experience "treatment-related fever, chills, and/or dyspnea."
- "All patients were "required to be well hydrated."
28-day cycle for 12 cycles or longer if deriving clinical benefit
Subsequent treatment
- PX-171-005, patients with less than PR after 2 cycles or less than CR after 4 cycles were allowed to escalate to: Kd
Regimen variant #2, 20/20 dosing
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Vij et al. 2012b (PX-171-004 bortezomib-exposed) | 2007-2008 | Phase 2 | ORR: 17% |
Jagannath et al. 2012 (PX-171-003-A0) | 2007-08 to 2008-12 | Phase 2 | ORR: 17% |
Note: Patients enrolled in PX-171-004 could continue therapy beyond 12 cycles on PX-171-010; results of this extension study have not been published, to our knowledge.
Targeted therapy
- Carfilzomib (Kyprolis) 20 mg/m2 IV once per day on days 1, 2, 8, 9, 15, 16
28-day cycle for up to 12 cycles (see note)
Regimen variant #3, 20/27 dosing, variant #1
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hájek et al. 2016 (FOCUS) | 2010-2012 | Phase 3 (E-switch-ooc) | 1a. Cyclophosphamide & Dexamethasone 1b. CP |
Did not meet primary endpoint of OS (HR 0.98, 95% CI 0.76-1.25) |
Note: This was an experimental arm that did not meet its primary endpoint; included here because other variants of this regimen have ORRs greater than 20%.
Prior treatment criteria
- At least 3 lines of therapy including bortezomib, lenalidomide or thalidomide, an alkylating agent, and corticosteroids
Targeted therapy
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV over 10 minutes once per day on days 1 & 2, then 27 mg/m2 IV over 10 minutes once per day on days 8, 9, 15, 16
- Cycles 2 to 9: 27 mg/m2 IV over 10 minutes once per day on days 1, 2, 8, 9, 15, 16
- Cycle 10 onwards: 27 mg/m2 IV over 10 minutes once per day on days 1, 2, 15, 16
Supportive therapy
- IV and PO hydration required for cycle 1
- Dexamethasone (Decadron) as follows:
- Cycle 1: 4 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, given prior to carfilzomib
- Ciprofloxacin (Cipro) as follows:
- Cycle 1: 500 mg PO once per day
28-day cycles
Regimen variant #4, 20/27 dosing, variant #2
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Watanabe et al. 2016 | 2011-2014 | Phase 1/2 | ORR: 22.5% |
Note: This is the maximum predetermined dose, there was no MTD; ORR is reported for the phase 2 portion.
Targeted therapy
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV once per day on days 1 & 2, then 27 mg/m2 IV once per day on days 8, 9, 15, 16
- Cycle 2 onwards: 27 mg/m2 IV once per day on days 1, 2, 8, 9, 15, 16
Supportive therapy
- IV and PO hydration required for cycle 1, then as needed
- Dexamethasone (Decadron) as follows:
- Cycle 1 (required): 4 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, prior to carfilzomib
- Cycle 2 onwards (prn): 4 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, prior to carfilzomib
- Prophylactic antibiotics (not specified) in cycle 1
- Acyclovir (Zovirax) for patients with history of herpes infection, in cycle 1
28-day cycles
Regimen variant #5, 20/27 dosing, with BSA cap
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Vij et al. 2012a (PX-171-004 bortezomib-naive) | 2007-2010 | Phase 2 (RT) | ORR: 42-52% |
Siegel et al. 2012 (PX-171-003-A1) | 2008-2009 | Phase 2 (RT) | ORR: 24% |
Note: Neither Vij et al. 2012a nor Siegel et al. 2012 specified that carfilzomib was capped at a body surface area of 2.2 m2, but the package insert specifies that: "The dose is calculated using the patient’s actual body surface area at baseline. Patients with a body surface area greater than 2.2 m2 should receive a dose based upon a body surface area of 2.2 m2. Dose adjustments do not need to be made for weight changes of less than or equal to 20%."
Targeted therapy
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 (maximum dose of 44 mg; see note) IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16
- Cycles 2 to 12: 27 mg/m2 (maximum dose of 59.4 mg; see note) IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16
Supportive therapy
- Dexamethasone (Decadron) as follows:
- Cycle 1: 4 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, prior to carfilzomib
- Cycle 2: 4 mg IV or PO once on day 1, prior to carfilzomib (Vij et al. 2012a only)
- Restart dexamethasone premedication if patients experience infusion reactions: "fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina."
- "All patients were to receive oral and intravenous fluids before dosing to assure adequate hydration."
28-day cycle for up to 12 cycles
Dose and schedule modifications
- "Carfilzomib was withheld for grade 3 or 4 hematologic or nonhematologic toxicities and resumed at reduced doses of 15 mg/m2 in cycle 1 or 20 mg/m2 in cycle 2 and above on resolution."
Regimen variant #6, 20/56 dosing
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Papadopoulos et al. 2014 (PX-171-007) | 2009-2013 | Phase 1 (RT) | |
Lendvai et al. 2014 (MSK 10-228) | 2011-2013 | Phase 2 | ORR: 55% |
Targeted therapy
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV over 30 minutes once per day on days 1 & 2, then 56 mg/m2 IV over 30 minutes once per day on days 8, 9, 15, 16
- Cycle 2 onwards: 56 mg/m2 IV over 30 minutes once per day on days 1, 2, 8, 9, 15, 16
Supportive therapy
- Normal saline pre- and post-hydration, tapered over subsequent cycles (see text for details)
- Dexamethasone (Decadron) 8 mg (route not specified) mandated with each cycle 1 dose, then optional
- Palonosetron (Aloxi) 250 mcg (route not specified) mandated with each cycle 1 dose, then optional
- Acyclovir (Zovirax) 400 mg PO once per day
28-day cycles
References
- PX-171-004 bortezomib-naive: Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14;119(24):5661-70. Epub 2012 May 3. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00530816
- PX-171-004 bortezomib-exposed: Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep;158(6):739-48. Epub 2012 Jul 30. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00530816
- PX-171-003-A0: Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):310-8. link to original article dosing details in abstract have been reviewed by our editors PubMed
- PX-171-003-A1: Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 4;120(14):2817-25. Epub 2012 Jul 25. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00511238
- Subgroup analysis: Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec;27(12):2351-6. Epub 2013 May 14. link to original article link to PMC article PubMed
- PX-171-005: Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013 Aug;27(8):1707-14. Epub 2013 Jan 31. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00721734
- MSK 10-228: Lendvai N, Hilden P, Devlin S, Landau H, Hassoun H, Lesokhin AM, Tsakos I, Redling K, Koehne G, Chung DJ, Schaffer WL, Giralt SA. A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 2014 Aug 7;124(6):899-906. Epub 2014 Jun 24. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01351623
- PX-171-007: Papadopoulos KP, Siegel DS, Vesole DH, Lee P, Rosen ST, Zojwalla N, Holahan JR, Lee S, Wang Z, Badros A. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol. 2015 Mar 1;33(7):732-9. Epub 2014 Sep 15. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00531284
- Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2016 Mar;172(5):745-56. Epub 2016 Jan 5. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed
- FOCUS: Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. Epub 2016 Jun 24. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01302392
Daratumumab monotherapy
Regimen variant #1
Study | Dates of enrollment | Evidence |
---|---|---|
Lokhorst et al. 2015 (GEN501 part 2) | 2008 to not reported | Phase 1/2 (RT) |
Lonial et al. 2016 (SIRIUS) | 2013 to not reported | Phase 2 (RT) |
Note: although SIRIUS was a randomized phase 2 trial, the randomization was to choose the dose for further assessment in an expansion cohort; the dose chosen (16 mg/kg from the start) is the one reported here:
Prior treatment criteria
- GEN501 part 2: 2 or more prior therapies, including immunomodulatory agents, proteasome inhibitors, chemotherapy, and autologous stem-cell transplantation
- SIRIUS: at least 3 lines of therapy including proteasome inhibitors and immunomodulatory drugs or refractory to both proteasome inhibitors and immunomodulatory drugs
Targeted therapy
- Daratumumab (Darzalex) as follows:
- Cycles 1 & 2: 16 mg/kg IV once per day on days 1, 8, 15, 22
- Cycles 3 & 4: 16 mg/kg IV once per day on days 1 & 15
- Cycle 5 onwards: 16 mg/kg IV once on day 1
- Note: Per the package insert, daratumumab infusion should complete within 15 hours. In Lokhorst et al. 2015, daratumumab was given over 8 hours.
Supportive therapy
This is a combination of what is listed in the daratumumab package insert and Lokhorst et al. 2015. There were protocol amendments in Lokhorst et al. 2015; listed medications are what was eventually used.
- Prior to all daratumumab infusions:
- Methylprednisolone (Solumedrol) 100 mg IV once per infusion, prior to daratumumab
- Per the package insert, after the second dose of daratumumab, dose may be reduced to 60 mg IV. Per Lokhorst et al. 2015, after the fourth dose of daratumumab, dose "could be reduced to 50 mg."
- Acetaminophen (Tylenol) (paracetamol) 1000 mg (package insert: 650 to 1000 mg) PO once per infusion, 1 to 2 hours prior to daratumumab
- One of the following antihistamines:
- Clemastine (Tavist) 1 mg IV once per infusion, 1 to 2 hours prior to daratumumab
- Cetirizine (Zyrtec) 10 mg PO once per infusion, 1 to 2 hours prior to daratumumab
- Diphenhydramine (Benadryl) (or equivalent) 25 to 50 mg PO or IV once per infusion, 1 to 2 hours prior to daratumumab
- Methylprednisolone (Solumedrol) 100 mg IV once per infusion, prior to daratumumab
- Post-treatment medications:
- Methylprednisolone (Solumedrol) (or equivalent) 20 to 25 mg (package insert: 20 mg) PO once per day for two days after daratumumab
- Package insert: "For patients with a history of obstructive pulmonary disorder, consider prescribing post-infusion medications such as short and long-acting bronchodilators, and inhaled corticosteroids."
- Package insert: "Initiate antiviral prophylaxis to prevent herpes zoster reactivation within 1 week of starting DARZALEX and continue for 3 months following treatment"
28-day cycles
Regimen variant #2
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Mateos et al. 2020 (COLUMBA) | 2017-10-31 to 2018-12-27 | Phase 3 (C) | Daratumumab and hyaluronidase | Non-inferior ORR |
Prior treatment criteria
- At least 3 lines of therapy including proteasome inhibitors and immunomodulatory drugs or refractory to both proteasome inhibitors and immunomodulatory drugs
Targeted therapy
- Daratumumab (Darzalex) as follows:
- Cycles 1 & 2: 16 mg/kg IV once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 16 mg/kg IV once per day on days 1 & 15
- Cycle 7 onwards: 16 mg/kg IV once on day 1
28-day cycles
References
- GEN501 part 2: Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19. Epub 2015 Aug 26. link to original article dosing details in manuscript have been reviewed by our editors link to supplementary appendix link to study protocol PubMed NCT00574288
- Pooled update: Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016 Jul 7;128(1):37-44. Epub 2016 May 23. link to original article link to PMC article PubMed
- Pooled update: Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 Jun;7(6):e447-e455. link to original article PubMed
- SIRIUS: Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 9;387(10027):1551-60. Epub 2016 Jan 7. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT01985126
- Pooled update: Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016 Jul 7;128(1):37-44. Epub 2016 May 23. link to original article link to PMC article PubMed
- Pooled update: Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 Jun;7(6):e447-e455. link to original article PubMed
- COLUMBA: Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020 May;7(5):e370-e380. Epub 2020 Mar 23. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT03277105
- Update: Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV. Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica. 2022 Oct 1;107(10):2408-2417. Epub 2022 Mar 31. link to original article link to PMC article PubMed
Daratumumab and hyaluronidase monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Mateos et al. 2020 (COLUMBA) | 2017-10-31 to 2018-12-27 | Phase 3 (E-RT-switch-ic) | Daratumumab | Non-inferior ORR (co-primary endpoint) ORR: 41% vs 37% (RR 1.11, 95% CI 0.89-1.37) |
Prior treatment criteria
- At least 3 lines of therapy including proteasome inhibitors and immunomodulatory drugs or refractory to both proteasome inhibitors and immunomodulatory drugs
Targeted therapy
- Daratumumab and hyaluronidase (Darzalex Faspro) as follows:
- Cycles 1 & 2: 1800 mg SC once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 1800 mg SC once per day on days 1 & 15
- Cycle 7 onwards: 1800 mg SC once on day 1
28-day cycles
References
- COLUMBA: Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020 May;7(5):e370-e380. Epub 2020 Mar 23. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT03277105
- Update: Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV. Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica. 2022 Oct 1;107(10):2408-2417. Epub 2022 Mar 31. link to original article link to PMC article PubMed
Elranatamab monotherapy
Regimen
FDA-recommended dose |
Study | Dates of enrollment | Evidence |
---|---|---|
Lesokhin et al. 2023 (MagnetisMM-3) | 2021-02-09 to 2022-01-07 | Phase 2 (RT) |
Immunotherapy
- Elranatamab (Elrexfio) as follows:
- Week 1: 12 mg SC once on day 1, then 32 mg SC once on day 4
- Weeks 2 to 24: 76 mg SC once on day 1
7-day cycle for 24 cycles
Subsequent treatment
- MagnetisMM-3, PR or better and maintained response for at least 2 months: Elranatamab maintenance
References
- MagnetisMM-3: Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023 Sep;29(9):2259-2267. Epub 2023 Aug 15. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT04649359
- PRO analysis: Mohty M, Bahlis NJ, Nooka AK, DiBonaventura M, Ren J, Conte U. Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3. Br J Haematol. 2024 May;204(5):1801-1810. Epub 2024 Feb 29. link to original article PubMed
Idecabtagene vicleucel monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Raje et al. 2019 (CRB-401) | 2016-2018 | Phase 1, >20 pts | ||
Munshi et al. 2021 (KarMMa) | 2017-2018 | Phase 2 (RT) | ||
Rodriguez-Otero et al. 2023 (KarMMa-3) | 2019-05 to 2022-04 | Phase 3 (E-switch-ooc) | Investigator's choice of: 1a. Dara-Pd 1b. Dara-Vd 1c. IRd 1d. Kd 1e. Elo-Pd |
Superior PFS (primary endpoint) Median PFS: 13.3 vs 4.4 mo (HR 0.49, 95% CI 0.38-0.65) |
Preceding treatment
- FC lymphodepletion
Immunotherapy
- Idecabtagene vicleucel (Abecma) 150 x 106 to 450 x 106 CAR-positive T cells IV once on day 0
One course
References
- CRB-401: Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019 May 2;380(18):1726-1737. link to original article link to PMC article PubMed NCT02658929
- KarMMa: Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 Feb 25;384(8):705-716. link to original article PubMed NCT03361748
- KarMMa-3: Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03651128
- PRO analysis: Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. link to original article PubMed
Ixazomib monotherapy
Regimen variant #1, bi-weekly, 2 out of 3 weeks
Study | Dates of enrollment | Evidence |
---|---|---|
Richardson et al. 2014 (C16003) | 2009-2012 | Phase 1/2 |
Note: this is the dosing used in the expansion cohort.
Targeted therapy
- Ixazomib (Ninlaro) 2 mg/m2 PO once per day on days 1, 4, 8, 11
21-day cycle for up to 12 cycles
Regimen variant #2, 3 out of 4 weeks
Study | Dates of enrollment | Evidence |
---|---|---|
Kumar et al. 2015 (MC1181) | 2012 | Phase 2 |
Prior treatment criteria
- At least 1 prior line of therapy
Subsequent treatment
- MC1181, patients with no minor response by end of cycle 2, no PR by end of cycle 4, or progression: Ixazomib & Dexamethasone
References
- C16003: Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug 14;124(7):1038-46. Epub 2014 Jun 11. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00932698
- MC1181: Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015 Aug 14;5:e338. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01415882
Lenalidomide monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Richardson et al. 2006 | 2002-2003 | Randomized Phase 2 (E-switch-ic) | Lenalidomide; 15 mg PO twice per day | Did not meet primary endpoint of ORR |
Richardson et al. 2009 (CC-5013-MM-014) | 2003-2004 | Phase 2 |
Note: This regimen is essentially of historical interest, as neither dosing of lenalidomide is in common use now.
Subsequent treatment
- Richardson et al. 2006, patients with SD or progression after 2 cycles: Escalation to Rd
References
- Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15;108(10):3458-64. Epub 2006 Jul 13. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed
- CC-5013-MM-014: Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009 Jul 23;114(4):772-8. Epub 2009 May 26. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00065351
Pomalidomide monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Richardson et al. 2014 (CC-4047-MM-002) | 2009 to not reported | Randomized Phase 2 (C) | Pd | Inferior PFS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
Prior treatment criteria
- At least 2 lines of therapy including lenalidomide and bortezomib
Targeted therapy
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 21
Supportive therapy
- Aspirin 81 to 100 mg PO once per day (unless contraindicated)
28-day cycles
References
- CC-4047-MM-002: Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson K. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20;123(12):1826-32. Epub 2014 Jan 13. Erratum in: Blood. 2014 May 15;123(20):3208-9. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00833833
Talquetamab monotherapy
Regimen variant #1, weekly
FDA-recommended dose |
Study | Dates of enrollment | Evidence |
---|---|---|
Chari et al. 2022 (MonumenTAL-1) | 2018-01-03 to 2021-11-15 | Phase 1b/2 (RT) |
Note: this was one of two recommended phase 2 dose levels. Step-up dosing was used in the first week but the details are not clearly reported in the manuscript or in the appendix; the dosing here is from the Talvey website.
Immunotherapy
- Talquetamab (Talvey) as follows:
- Step-up: 0.01 mg/kg SC once on day 1, then 0.06 mg/kg SC on day 4
- Cycle 1 onwards: 0.4 mg/kg SC once on day 1
6-day course, then 7-day cycles
Regimen variant #2, bi-weekly
FDA-recommended dose |
Study | Dates of enrollment | Evidence |
---|---|---|
Chari et al. 2022 (MonumenTAL-1) | 2018-01-03 to 2021-11-15 | Phase 1b/2 (RT) |
Note: this was one of two recommended phase 2 dose levels. Step-up dosing was used in the first week but the details are not clearly reported in the manuscript or in the appendix; the dosing here is from the Talvey website.
Immunotherapy
- Talquetamab (Talvey) as follows:
- Step-up: 0.01 mg/kg SC once on day 1, then 0.06 mg/kg SC on day 4, then 0.4 mg/kg SC on day 7
- Cycle 1 onwards: 0.8 mg/kg SC once on day 1
9-day course, then 14-day cycles
References
- MonumenTAL-1: Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R, Girgis S, Yang S, Goldsmith RB, Yao X, Pillarisetti K, Hilder BW, Russell J, Goldberg JD, Krishnan A. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022 Dec 15;387(24):2232-2244. Epub 2022 Dec 10. link to original article contains partial dosing details in manuscript PubMed NCT03399799
Teclistamab monotherapy
Regimen
FDA-recommended dose |
Study | Dates of enrollment | Evidence |
---|---|---|
Usmani et al. 2021 (MajesTEC-1 Phase 1) | 2017-2021 | Phase 1 (RT) |
Moreau et al. 2022 (MajesTEC-1 Phase 2) | 2020-2021 | Phase 2 (RT) |
Note: Phase 1 and phase 2 have different clinical trial ID's and are thus recorded separately; Moreau et al. 2022 is an update to the phase 1 portion and the first publication of the phase 2 results.
Immunotherapy
- Teclistamab (Tecvayli) as follows:
- Cycle 1: 0.06 mg/kg SC once on day 1, then 0.3 mg/kg SC once on day 4, then 1.5 mg/kg SC once per day on days 8, 15, 22
- Cycle 2 onwards: 1.5 mg/kg SC once per day on days 1, 8, 15, 22
28-day cycles
References
- MajesTEC-1 Phase 1: Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021 Aug 21;398(10301):665-674. Epub 2021 Aug 10. link to original article PubMed NCT03145181
- Update: Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022 Aug 11;387(6):495-505. Epub 2022 Jun 5. link to original article link to PMC article PubMed
- MajesTEC-1 Phase 2: Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022 Aug 11;387(6):495-505. Epub 2022 Jun 5. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT04557098
Thalidomide monotherapy
Synopsis
Historical Background of Thalidomide
Originally developed and marketed in the late 1950s as a sedative and remedy for morning sickness in pregnant women, thalidomide led to catastrophic birth defects when taken during pregnancy. Due to these teratogenic effects, its usage was banned in many countries by the early 1960s.
Rediscovery and Anticancer Properties
During the late 1990s, the anti-angiogenic and immunomodulatory effects of thalidomide were explored. Researchers hypothesized that these properties could be harnessed against cancers that rely on angiogenesis.
Singhal et al., 1999 ([1] Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine. 1999;341:1565-71): This seminal study reported the effects of thalidomide in patients with refractory multiple myeloma. Thalidomide showed significant antitumor activity, leading to renewed interest in the drug.
Development of Analogues
The success of thalidomide spurred the development of its analogs, designed to retain its therapeutic benefits while minimizing side effects. Lenalidomide and pomalidomide are two such analogs that have shown significant efficacy in multiple myeloma with a better side effect profile.
Current Role in Therapy
While newer agents and combinations have emerged in the treatment landscape of multiple myeloma, thalidomide and its derivatives remain vital components in various treatment regimens, especially in certain settings and geographies.
Conclusion
The repositioning of thalidomide for multiple myeloma is a testament to the importance of re-evaluating existing drugs for new therapeutic indications. Its successful transition from a notorious drug to a vital component in the multiple myeloma treatment arsenal underscores the ever-evolving nature of drug development and therapy.
The draft for this synopsis was generated by a large language model and then manually edited by the page editor for accuracy and style. See this page for more information about this pilot project.
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Singhal et al. 1999 | 1997-1998 | Non-randomized |
Targeted therapy
- Thalidomide (Thalomid) as follows:
- Cycle 1: 200 mg PO once per day on days 1 to 14, then 400 mg PO once per day on days 15 to 28
- Cycle 2: 600 mg PO once per day on days 1 to 14, then 800 mg PO once per day on days 15 to 28
- Cycle 3 onwards: 800 mg PO once per day on days 1 to 28
28-day cycles
References
- Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Siegel D, Crowley J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18;341(21):1565-71. Erratum in: N Engl J Med 2000 Feb 3;342(5):364. link to original article dosing details in abstract have been reviewed by our editors PubMed
- Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM). Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome. Eur J Haematol. 2012 Mar;88(3):249-59. Epub 2012 Jan 4. link to original article PubMed
Vemurafenib monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Hyman et al. 2015 (VE-BASKET) | 2012-2014 | Phase 2, fewer than 20 pts in subgroup |
Note: Andrulis et al. 2013 is a single patient case report with a good response. Sharman et al. reports two patients with good response. In the Hyman et al. 2015 trial, there were 5 patients with multiple myeloma; "No patients with multiple myeloma have had a response to date."
References
- Case report: Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013 Aug;3(8):862-9. Epub 2013 Apr 23. link to original article dosing details in abstract have been reviewed by our editors PubMed
- Case series: Sharman JP, Chmielecki J, Morosini D, Palmer GA, Ross JS, Stephens PJ, Stafl J, Miller VA, Ali SM. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e161-3. Epub 2014 Jun 11. link to original article PubMed
- VE-BASKET: Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015 Aug 20;373(8):726-36. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01524978
Venetoclax monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Kumar et al. 2017 (M13-367) | 2012 to not reported | Phase 1, >20 pts in this cohort |
Note: This is the safety expansion cohort dosing.
Biomarker eligibility criteria
- t(11;14)
Targeted therapy
- Venetoclax (Venclexta) as follows:
- Lead-in: 400 mg PO once per day on days 1 to 7, then 800 mg PO once per day on days 8 to 14
- Cycle 1 onwards: 1200 mg PO once per day on days 1 to 21
14-day lead-in, then 21-day cycles
References
- M13-367: Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017 Nov 30;130(22):2401-2409. Epub 2017 Oct 10. link to original article dosing details in supplement have been reviewed by our editors PubMed NCT01794520
Relapsed or refractory, doublets
Bortezomib & Dexamethasone (Vd)
Vd: Velcade (Bortezomib) & low-dose dexamethasone
BD: Bortezomib & Dexamethasone
Bd: Bortezomib & low-dose dexamethasone
Bort-Dex: Bortezomib & Dexamethasone
Regimen variant #1, indefinite 21-day then 28-day cycles
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Jakubowiak et al. 2016 (CA204-009) | 2012-2013 | Randomized Phase 2 (C) | Elo-Vd | Might have inferior PFS |
Kumar et al. 2020 (BELLINI) | 2016-07-19 to 2017-10-31 | Phase 3 (C) | Vd & Venetoclax | Inferior PFS1 |
1Despite meeting the primary endpoint, there was increased mortality in the experimental group, due to increased infections.
Prior treatment criteria
- CA204-009 & BELLINI: 1 to 3 prior lines of therapy
Targeted therapy
- Bortezomib (Velcade) as follows:
- Cycles 1 to 8: 1.3 mg/m2 IV or SC once per day on days 1, 4, 8, 11
- Cycle 9 onwards: 1.3 mg/m2 IV or SC once per day on days 1, 8, 15
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 8: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
- Cycle 9 onwards: 20 mg PO once per day on days 1, 2, 8, 9, 15, 16
21-day cycle for 8 cycles, then 28-day cycles
Regimen variant #2, SC 21-day cycles (8 total)
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Moreau et al. 2011 (MMY-3021) | 2008-2010 | Phase 3 (E-RT-switch-ic) | Bort-Dex; IV | Non-inferior ORR after 4 cycles (primary endpoint) ORR after 4 cycles: 42% vs 42% |
Terpos et al. 2017 (OPTIMRETREAT) | 2013-2016 | Phase 3 (C) | Bort-Dex x 6, then bortezomib maint. | Did not meet primary endpoint of PFS |
Palumbo et al. 2016 (CASTOR) | 2014-09-04 to 2015-09-24 | Phase 3 (C) | Dara-Vd | Inferior OS1 |
Lu et al. 2021 (LEPUS) | 2017-2019 | Phase 3 (C) | Dara-Vd | Inferior PFS (primary endpoint) |
1Reported efficacy for CASTOR is based on the 2022 update.
Note: In MMY-3021, patients who were "evolving" towards CR after 8 cycles could receive 2 additional cycles.
Prior treatment criteria
- MMY-3021: 1 to 3 prior lines of therapy
- CASTOR: At least 1 prior line of therapy
Preceding treatment
- MMY-3021: Bortezomib x 4
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 SC once per day on days 1, 4, 8, 11
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg IV or PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
21-day cycle for 8 cycles (see note)
Regimen variant #3, IV 21-day cycles (16 total)
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
San-Miguel et al. 2014 (PANORAMA 1) | 2010-2012 | Phase 3 (C) | Vd & Panobinostat | Inferior PFS |
Note: Patients who had clinical benefit per the modified European Group for Blood and Marrow Transplantation [EBMT] criteria on day 1 of cycle 8 proceeded to the last 8 cycles.
Prior treatment criteria
- 1 to 3 prior lines of therapy
Targeted therapy
- Bortezomib (Velcade) as follows:
- Cycles 1 to 8: 1.3 mg/m2 IV once per day on days 1, 4, 8, 11
- Cycles 9 to 16: 1.3 mg/m2 IV once per day on days 1 & 8
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 8: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
- Cycles 9 to 16: 20 mg PO once per day on days 1, 2, 8, 9
21-day cycle for 16 cycles
Regimen variant #4, 21-day cycles, response-adapted
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hjorth et al. 2012 (NMSG 17/07) | 2007-2010 | Phase 3 (E-switch-ooc) | Thal-Dex | Did not meet primary endpoint of PFS |
Dimopoulos et al. 2013 (CR013165) | 2008-2009 | Phase 2 | Not evaluable |
Prior treatment criteria
- NMSG 17/07: Failure of melphalan with no prior exposure to bortezomib or thalidomide
- CR013165: 1 prior line of therapy
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV once per day on days 1, 4, 8, 11
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
Supportive therapy
- "Antithrombotic prophylaxis and acyclovir prophylaxis were not mandatory according to the study protocol but used routinely in an increasing proportion of participating centers during the study period."
21-day cycles until progression or best response, which would then be followed by 1 to 2 additional cycles
Regimen variant #5, IV 21-day cycles (8 total)
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Jagannath et al. 2004 (CREST) | 2001-2002 | Randomized Phase 2 (E-esc) | Bort-Dex; low-dose | Did not meet primary endpoint of ORR |
Moreau et al. 2011 (MMY-3021) | 2008-2010 | Phase 3 (C) | Bort-Dex; SC | Non-inferior ORR after 4 cycles (primary endpoint) |
Kropff et al. 2017 (CR015247) | 2008-2010 | Phase 3 (C) | VCD | Did not meet primary endpoint of TTP |
Note: In MMY-3021, patients who were "evolving" towards CR after 8 cycles could receive 2 additional cycles.
Prior treatment criteria
- CREST: Failure of frontline chemotherapy
- MMY-3021 & CR015247: 1 to 3 prior lines of therapy
Preceding treatment
- CREST: Bortezomib x 2 to 4 cycles
- MMY-3021: Bortezomib x 4
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV bolus once per day on days 1, 4, 8, 11
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
21-day cycle for 8 cycles (see note)
Regimen variant #6, low-dose IV 21-day cycles (8 total)
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Jagannath et al. 2004 (CREST) | 2001-2002 | Randomized Phase 2 (E-de-esc) | Bort-Dex; standard-dose | Did not meet primary endpoint of ORR |
Prior treatment criteria
- CREST: Failure of frontline chemotherapy
Preceding treatment
- Bortezomib x 2 to 4 cycles
Targeted therapy
- Bortezomib (Velcade) 1 mg/m2 IV bolus once per day on days 1, 4, 8, 11
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
21-day cycle for 8 cycles
Regimen variant #7, IV indefinite 21-day cycles
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Richardson et al. 2003 (SUMMIT) | 2001-02 to 2001-12 | Phase 2 (RT) | RR: 35% | |
Dimopoulos et al. 2015 (ENDEAVOR) | 2012-06-20 to 2014-06-30 | Phase 3 (C) | Kd | Inferior OS1 |
1Reported efficacy for ENDEAVOR is based on the 2019 update.
Note: SUMMIT & MMY-3001 specified a total of 8 cycles, but those who were deriving clinical benefit could continue beyond this.
Prior treatment criteria
- ENDEAVOR: 1 to 3 prior lines of therapy
Preceding treatment
- SUMMIT & MMY-3001: Bortezomib x 2 to 4 cycles
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV bolus once per day on days 1, 4, 8, 11
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg IV or PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
21-day cycles
Regimen variant #8, SC indefinite 21-day cycles
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Dimopoulos et al. 2015 (ENDEAVOR) | 2012-06-20 to 2014-06-30 | Phase 3 (C) | Kd | Inferior OS1 |
1Reported efficacy for ENDEAVOR is based on the 2019 update.
Prior treatment criteria
- ENDEAVOR: 1 to 3 prior lines of therapy
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 SC once per day on days 1, 4, 8, 11
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg IV or PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
21-day cycles
Regimen variant #9, SC indefinite 21-day then 35-day cycles
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Grosicki et al. 2020 (BOSTON) | 2017-2019 | Phase 3 (C) | SVd | Inferior PFS |
Prior treatment criteria
- 1 to 3 prior lines of therapy, including proteasome inhibitors
Targeted therapy
- Bortezomib (Velcade) as follows:
- Cycles 1 to 8: 1.3 mg/m2 SC once per day on days 1, 4, 8, 11
- Cycle 9 onwards: 1.3 mg/m2 SC once per day on days 1, 8, 15, 22
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 8: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
- Cycle 9 onwards: 20 mg PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23, 29, 30
21-day cycle for 8 cycles, then 35-day cycles
Regimen variant #10, indefinite 35-day cycles
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Fukushima et al. 2011 | 2007-2010 | Retrospective | ORR: 77% |
Note: treatment could be stopped if CR was achieved.
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV once per day on days 1, 8, 15, 22
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23
35-day cycles
References
- SUMMIT: Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-17. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Subgroup analysis: Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul;91(7):929-34. link to original article dosing details in abstract have been reviewed by our editors PubMed
- Pooled subgroup analysis: Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007 Jan;21(1):151-7. Epub 2006 Nov 9. link to original article PubMed
- CREST: Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004 Oct;127(2):165-72. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Subgroup analysis: Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul;91(7):929-34. link to original article dosing details in abstract have been reviewed by our editors PubMed
- Update: Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008 Nov;143(4):537-40. Epub 2008 Sep 6. link to original article PubMed
- MMY-3001: Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007 Sep 1;25(25):3892-901. Epub 2007 Aug 6. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00103506
- Update: Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009 Jan;144(2):169-75. Epub 2008 Nov 19. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Update: Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016 Jul 1;122(13):2050-6. Epub 2016 May 18. link to original article link to PMC article PubMed
- MMY-3021: Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011 May;12(5):431-40. Epub 2011 Apr 18. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00722566
- Update: Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012 Dec;97(12):1925-8. Epub 2012 Jun 11. link to original article link to PMC article PubMed
- Subgroup analysis: Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Rekhtman G, Masliak Z, Robak P, Esseltine DL, Feng H, Deraedt W, van de Velde H, Arnulf B. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica. 2015 May;100(5):e207-10. Epub 2015 Jan 16. link to original article link to PMC article PubMed
- Retrospective: Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Nakajima H, Motoo Y, Umehara H. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res. 2011 Jun;31(6):2297-302. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- NMSG 17/07: Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group. Thalidomide and dexamethasone vs bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol. 2012 Jun;88(6):485-96. Epub 2012 Mar 30. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00602511
- CR013165: Dimopoulos MA, Beksac M, Benboubker L, Roddie H, Allietta N, Broer E, Couturier C, Mazier MA, Angermund R, Facon T. Phase 2 study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica. 2013 Aug;98(8):1264-72. Epub 2013 May 28. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00908232
- PANORAMA 1: San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1195-206. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01023308
- Subgroup analysis: Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016 Feb 11;127(6):713-21. Epub 2015 Dec 2. link to original article link to PMC article PubMed
- Update: San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016 Nov;3(11):e506-e515. Epub 2016 Oct 14. link to original article PubMed
- ENDEAVOR: Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27-38. Epub 2015 Dec 5. link to original article PubMed NCT01568866
- Subgroup analysis: Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hájek R. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017 Jun;31(6):1368-1374. Epub 2016 Dec 27. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed
- Update: Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1327-1337. Epub 2017 Aug 23. link to original article PubMed
- Update: Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):522-530.e1. Epub 2019 May 2. link to original article PubMed
- CA204-009: Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 Jun 9;127(23):2833-40. Epub 2016 Apr 18. link to original article dosing details in supplement have been reviewed by our editors link to PMC article PubMed NCT01478048
- CASTOR: Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. link to original article link to supplementary appendix dosing details in manuscript have been reviewed by our editors PubMed NCT02136134
- Update: Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Dec;103(12):2079-87. Epub 2018 Sep 20. link to original article link to PMC article PubMed
- Update: Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, Corradini P, Min CK, Medvedova E, Weisel K, Chiu C, Schecter JM, Amin H, Qin X, Ukropec J, Kobos R, Spencer A. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):509-518. Epub 2019 Oct 9. link to original article PubMed
- Update: Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Levin MD, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Spencer A. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 Mar 10;41(8):1600-1609. Epub 2022 Nov 22. link to original article link to PMC article PubMed
- CR015247: Kropff M, Vogel M, Bisping G, Schlag R, Weide R, Knauf W, Fiechtner H, Kojouharoff G, Kremers S, Berdel WE. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Ann Hematol. 2017 Nov;96(11):1857-1866. Epub 2017 Sep 14. link to original article PubMed NCT00813150
- OPTIMRETREAT: Terpos E, Gobbi M, Potamianou A, Lahaye M, Couturier C, Cavo M. Retreatmentvand prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: a randomized, controlled, phase III study. Eur J Haematol. 2018 Jan;100(1):10-19. Epub 2017 Oct 30. link to original article PubMed NCT01910987
- BELLINI: Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Punnoose EA, Hong WJ, Freise KJ, Yang X, Sood A, Jalaluddin M, Ross JA, Ward JE, Maciag PC, Moreau P. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1630-1642. Epub 2020 Oct 29. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02755597
- BOSTON: Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020 Nov 14;396(10262):1563-1573. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03110562
- LEPUS: Lu J, Fu W, Li W, Hu J, An G, Wang Y, Fu C, Chen L, Jin J, Cen X, Ge Z, Cai Z, Niu T, Qi M, Sun S, Gai X, Liu W, Liu W, Yang X, Huang X. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):e699-e709. Epub 2021 Apr 24. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03234972
- BENCH: NCT04939142
- Perifosine 339: NCT01002248
Bortezomib & Pegylated liposomal doxorubicin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Orlowski et al. 2007 (MMY-3001) | 2004-2006 | Phase 3 (E-RT-esc) | Bortezomib | Superior TTP (primary endpoint) Median TTP: 9.3 vs 6.5 mo (HR 0.55, 95% CI 0.43-0.71) |
Prior treatment criteria
- 1 to 3 prior lines of therapy, not including bortezomib
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV bolus once per day on days 1, 4, 8, 11
Chemotherapy
- Pegylated liposomal doxorubicin (Doxil) 30 mg/m2 IV over at least 1 hour once on day 4, given second
Supportive therapy
- Bisphosphonates were used according to established guidelines
21-day cycle for 8 or more cycles
References
- MMY-3001: Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007 Sep 1;25(25):3892-901. Epub 2007 Aug 6. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00103506
- Update: Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009 Jan;144(2):169-75. Epub 2008 Nov 19. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Update: Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016 Jul 1;122(13):2050-6. Epub 2016 May 18. link to original article link to PMC article PubMed
Bortezomib & Vorinostat
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Dimopoulos et al. 2013 (VANTAGE 088) | 2008-2011 | Phase 3 (E-esc) | Bortezomib | Superior PFS (primary endpoint) Median PFS: 7.6 vs 6.8 mo (HR 0.77, 95% CI 0.64-0.94) |
Prior treatment criteria
- 1 to 3 prior lines of therapy
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV bolus once per day on days 1, 4, 8, 11
- Vorinostat (Zolinza) 400 mg PO once per day on days 1 to 14
21-day cycles
References
- VANTAGE 088: Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013 Oct;14(11):1129-1140. Epub 2013 Sep 19. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00773747
Carfilzomib & Dexamethasone (Kd)
Kd: Kyprolis (Carfilzomib) & low-dose dexamethasone
Regimen variant #1, 20/27
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Moreau et al. 2018 (ARROWMM) | 2015-09 to 2016-08 | Phase 3 (C) | Kd; weekly | Inferior PFS |
Note: this trial is denoted as ARROWMM to distinguish from other trials of the same name.
Prior treatment criteria
- 2 or 3 lines of therapy, including a proteasome inhibitor and an immunomodulatory agent
Targeted therapy
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV over 10 minutes once per day on days 1 & 2, then 27 mg/m2 IV over 10 minutes once per day on days 8, 9, 15, 16
- Cycle 2 onwards: 27 mg/m2 IV over 10 minutes once per day on days 1, 2, 8, 9, 15, 16
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 8: 40 mg IV or PO once per day on days 1, 8, 15, 22
- Cycle 10 onwards: 40 mg IV or PO once per day on days 1, 8, 15
28-day cycles
Regimen variant #2, 20/56 dosing
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Dimopoulos et al. 2015 (ENDEAVOR) | 2012-06-20 to 2014-06-30 | Phase 3 (E-RT-switch-ic) | Vd | Superior OS1 (secondary endpoint) Median OS: 47.8 vs 38.8 mo (HR 0.76, 95% CI 0.63-0.92) Superior PFS (primary endpoint) Median PFS: 18.7 vs 9.4 mo (HR 0.53, 95% CI 0.44-0.65) |
Dimopoulos et al. 2020 (CANDOR) | 2017-06-13 to 2018-06-25 | Phase 3 (C) | Dara-Kd | Inferior PFS |
Moreau et al. 2021 (IKEMA) | 2017-11-15 to 2019-03-21 | Phase 3 (C) | Isa-Kd | Inferior PFS |
Rodriguez-Otero et al. 2023 (KarMMa-3) | 2019-05 to 2022-04 | Phase 3 (C) | Ide-cel | Inferior PFS |
1Reported efficacy for ENDEAVOR is based on the 2019 update.
Note: In KarMMA-3, the day 22 dexamethasone was split into 20 mg on days 22 & 23; the total dose per cycle is the same.
Prior treatment criteria
- ENDEAVOR & IKEMA: 1 to 3 prior lines of therapy
Targeted therapy
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV over 30 minutes once per day on days 1 & 2, then 56 mg/m2 IV over 30 minutes once per day on days 8, 9, 15, 16
- Cycle 2 onwards: 56 mg/m2 IV once per day on days 1, 2, 8, 9, 15, 16
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23
- Some references mention using 40 mg PO or IV once on day 22, instead of 20 mg on days 22 & 23
28-day cycles
Regimen variant #3, 20/70 dosing (weekly)
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Berenson et al. 2016 (CHAMPION-1) | 2012-2014 | Phase 1/2 | ||
Moreau et al. 2018 (ARROWMM) | 2015-09 to 2016-08 | Phase 3 (E-RT-switch-ic) | Kd; twice-weekly | Superior PFS (primary endpoint) Median PFS: 11.2 vs 7.6 mo (HR 0.69, 95% CI 0.54-0.83) |
Note: this trial is denoted as ARROWMM to distinguish from other trials of the same name.
Prior treatment criteria
- ARROWMM: 2 or 3 lines of therapy, including a proteasome inhibitor and an immunomodulatory agent
Targeted therapy
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV over 30 minutes once on day 1, then 70 mg/m2 IV over 30 minutes once per day on days 8 & 15
- Cycle 2 onwards: 70 mg/m2 IV over 30 minutes once per day on days 1, 8, 15
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 8: 40 mg IV or PO once per day on days 1, 8, 15, 22
- Cycle 10 onwards: 40 mg IV or PO once per day on days 1, 8, 15
28-day cycles
Regimen variant #4, 27 dosing
Study | Dates of enrollment | Evidence |
---|---|---|
Badros et al. 2013 (PX-171-005) | 2008-2010 | Phase 2 |
Preceding treatment
- Carfilzomib x 2 to 4 cycles (carfilzomib dose escalation attained during this period)
Targeted therapy
- Carfilzomib (Kyprolis) 27 mg/m2 IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg (route not specified) once per day on days 1, 2, 8, 9, 15, 16, given first
28-day cycle for 12 cycles or longer if deriving clinical benefit
References
- PX-171-005: Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013 Aug;27(8):1707-14. Epub 2013 Jan 31. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00721734
- ENDEAVOR: Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27-38. Epub 2015 Dec 5. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01568866
- Subgroup analysis: Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hájek R. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017 Jun;31(6):1368-1374. Epub 2016 Dec 27. link to original article link to PMC article PubMed
- Update: Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1327-1337. Epub 2017 Aug 23. link to original article PubMed
- Update: Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):522-530.e1. Epub 2019 May 2. link to original article PubMed
- CHAMPION-1: Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016 Jun 30;127(26):3360-8. Epub 2016 May 12. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01677858
- ARROWMM: Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018 Jul;19(7):953-964. Epub 2018 Jun 1. Erratum in: Lancet Oncol. 2018 Aug;19(8):e382. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02412878
- CANDOR: Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 Jul 18;396(10245):186-197. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03158688
- Update: Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 Jan;23(1):65-76. Epub 2021 Dec 3. link to original article PubMed
- IKEMA: Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 Jun 19;397(10292):2361-2371. Epub 2021 Jun 4. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03275285
- Update: Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023 May 9;13(1):72. Erratum in: Blood Cancer J. 2023 Sep 27;13(1):152. link to original article link to PMC article PubMed
- KarMMa-3: Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. link to original article dosing details in supplement have been reviewed by our editors PubMed NCT03651128
- PRO analysis: Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. link to original article PubMed
Carfilzomib & Panobinostat
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Berdeja et al. 2015 (SCRI MM 27) | 2012-2013 | Phase 2 |
Targeted therapy
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV once per day on days 1 & 2, then 45 mg/m2 IV over 30 minutes once per day on days 8, 9, 15, 16
- Cycle 2 onwards: 45 mg/m2 IV once per day on days 1, 2, 8, 9, 15, 16
- Panobinostat (Farydak) 30 mg PO once per day on days 1, 3, 5, 15, 17, 19
28-day cycles
References
- SCRI MM 27: Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS, Hainsworth JD, Flinn IW. Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Haematologica. 2015 May;100(5):670-6. Epub 2015 Feb 20. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01496118
Cyclophosphamide & Dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hájek et al. 2016 (FOCUS) | 2010-2012 | Phase 3 (C) | Carfilzomib | Did not meet primary endpoint of OS |
Note: cyclophosphamide was described as optional for the control arm but 95% of patients received it. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Prior treatment criteria
- At least 3 lines of therapy including bortezomib, lenalidomide or thalidomide, an alkylating agent, and corticosteroids
Chemotherapy
- Cyclophosphamide (Cytoxan) 50 mg PO once per day
Glucocorticoid therapy
- Dexamethasone (Decadron) 6 mg PO once every other day
Continued indefinitely
References
- FOCUS: Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. Epub 2016 Jun 24. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01302392
Cyclophosphamide & Prednisone
CP: Cyclophosphamide & Prednisone
CyPred: Cyclophosphamide & Prednisone
Regimen variant #1
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hájek et al. 2016 (FOCUS) | 2010-2012 | Phase 3 (C) | Carfilzomib | Did not meet primary endpoint of OS |
Note: cyclophosphamide was described as optional for the control arm but 95% of patients received it. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Prior treatment criteria
- At least 3 lines of therapy including bortezomib, lenalidomide or thalidomide, an alkylating agent, and corticosteroids
Chemotherapy
- Cyclophosphamide (Cytoxan) 50 mg PO once per day
Glucocorticoid therapy
- Prednisone (Sterapred) 30 mg PO once every other day
Continued indefinitely
Regimen variant #2
Study | Dates of enrollment | Evidence |
---|---|---|
de Weerdt et al. 2001 | 1991-1998 | Non-randomized |
Chemotherapy
- Cyclophosphamide (Cytoxan) 100 mg PO once per day
Glucocorticoid therapy
- Prednisone (Sterapred) 10 to 20 mg PO once per day
Continued indefinitely
References
- de Weerdt O, van de Donk NW, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med. 2001 Aug;59(2):50-6. link to original article dosing details in abstract have been reviewed by our editors PubMed
- FOCUS: Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. Epub 2016 Jun 24. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01302392
Ixazomib & Dexamethasone
Regimen variant #1, 4/20
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kumar et al. 2015 (MC1181 part 2) | 2013-2015 | Randomized Phase 2 (E-de-esc) | Ixazomib & Dexamethasone; 5.5 mg/20 mg | Might have inferior ORR (primary endpoint) |
Prior treatment criteria
- At least 1 prior line of therapy
Targeted therapy
- Ixazomib (Ninlaro) 4 mg PO once per day on days 1, 8, 15
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg PO once per day on days 1, 2, 8, 9, 15, 16
Supportive therapy
- Herpes zoster prophylaxis
28-day cycles
Regimen variant #2, 5.5/20
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kumar et al. 2015 (MC1181 part 2) | 2013-2015 | Randomized Phase 2 (E-esc) | Ixazomib & Dexamethasone; 4 mg/20 mg | Might have superior ORR (primary endpoint) |
Prior treatment criteria
- At least 1 prior line of therapy
Targeted therapy
- Ixazomib (Ninlaro) 5.5 mg PO once per day on days 1, 8, 15
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg PO once per day on days 1, 2, 8, 9, 15, 16
Supportive therapy
- Herpes zoster prophylaxis
28-day cycles
References
- MC1181 part 2: Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. 2016 Nov 17;128(20):2415-2422. Epub 2016 Oct 4. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01415882
Lenalidomide & Dexamethasone (Rd)
Rd: Revlimid (Lenalidomide) & low-dose dexamethasone
RevDex: Revlimid (Lenalidomide) & Dexamethasone
Ld: Lenalidomide & low-dose dexamethasone
LenDex: Lenalidomide & Dexamethasone
Regimen variant #1, Len @ 25 mg 21/28
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Stewart et al. 2014 (ASPIRE) | 2010-2012 | Phase 3 (C) | KRd | Inferior OS1 | Inferior GHS/QoL |
Goldschmidt et al. 2020 (ReLApsE) | 2010-2016 | Phase 3 (C) | Rd x 3, then Melphalan auto HSCT, then Lenalidomide | Did not meet primary endpoint of PFS | |
Lonial et al. 2015 (ELOQUENT-2) | 2011-06 to 2012-11 | Phase 3 (C) | Elo-Rd | Seems to have inferior OS2 | |
Moreau et al. 2016 (TOURMALINE-MM1) | 2012-2014 | Phase 3 (C) | IRd | Inferior PFS | |
Dimopoulos et al. 2016 (POLLUX) | 2014-06-16 to 2015-07-14 | Phase 3 (C) | Dara-Rd | Inferior OS3 | |
Hou et al. 2017 (TOURMALINE-MM1 China Continuation) | 2014-05-08 to 2015-05-08 | Phase 3 (C) | IRd | Inferior OS |
1Reported efficacy for ASPIRE is based on the 2018 update.
2Reported efficacy for ELOQUENT-2 is based on the 2020 update.
3Reported efficacy for POLLUX is based on the 2023 update.
Prior treatment criteria
- ASPIRE, ReLApsE, ELOQUENT-2, TOURMALINE-MM1, POLLUX, TOURMALINE-MM1 China Continuation: 1 to 3 prior lines of therapy
Targeted therapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
- POLLUX: Patients with CrCl of 30 to 60 mL/min/1.73m2 received 10 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
- POLLUX: Patients older than 75 years or underweight (BMI less than 18.5) could receive 20 mg
Supportive therapy
Best described by ASPIRE:
- Valacyclovir (Valtrex) (dose not specified) or equivalent antiviral while taking Lenalidomide (Revlimid)
- Aspirin (dose not specified) or other anticoagulant or antiplatelet medication such as Clopidogrel (Plavix), low-molecular-weight heparin or Warfarin (Coumadin) while taking Lenalidomide (Revlimid)
- Bisphosphonates while taking Dexamethasone (Decadron)
- Lansoprazole (Prevacid) (dose not specified) or other proton pump inhibitor while taking Dexamethasone (Decadron)
- A prophylactic antibiotic (Ciprofloxacin (Cipro), Amoxicillin, Trimethoprim-Sulfamethoxazole (Bactrim DS) are given as examples)
28-day cycles
Regimen variant #2, Len @ 25 mg 21/28, with high-dose dex lead-in
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Weber et al. 2007 (MM-009) | 2003-02-27 to 2004-04-14 | Phase 3 (E-RT-esc) | Dexamethasone | Seems to have superior OS1 (secondary endpoint) Superior TTP (primary endpoint) Median TTP: 11.1 vs 4.7 mo (HR 0.35, 95% CI 0.27-0.47) |
Dimopoulos et al. 2007 (MM-010) | 2003-09-22 to 2004-09-15 | Phase 3 (E-RT-esc) | Dexamethasone | Seems to have superior OS (secondary endpoint) Median OS: NYR vs 20.6 mo (HR 0.66, 95% CI 0.45-0.96) Superior TTP (primary endpoint) Median TTP: 11.3 vs 4.7 mo (HR 0.35, 95% CI 0.27-0.46) |
1Reported efficacy of MM-009 is based on the 2009 pooled update.
Note: MM-009 is "Study 1" and MM-010 is "Study 2" listed in the package insert.
Prior treatment criteria
- MM-009 & MM-010: At least 1 prior line of therapy
Targeted therapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 4: 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
- Cycle 5 onwards: 40 mg PO once per day on days 1 to 4
28-day cycles
Regimen variant #3, Len @ 15 mg 21/28 ("RevLite")
Study | Dates of enrollment | Evidence |
---|---|---|
Quach et al. 2017 (RevLite) | 2007 to not reported | Phase 2 |
Targeted therapy
- Lenalidomide (Revlimid) 15 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 4: 20 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
- Cycle 5 onwards: 20 mg PO once per day on days 1 to 4
28-day cycles
Regimen variant #4, Len @ 30 mg 21/28
Historic variant |
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Richardson et al. 2006 | 2002-2003 | Randomized Phase 2 (E-switch-ic) | Rd; twice-daily Lenalidomide | Did not meet primary endpoint of ORR |
Note: This regimen variant is essentially of historical interest.
Prior treatment criteria
- Relapse after prior chemotherapy
Preceding treatment
- Lenalidomide x 2
Targeted therapy
- Lenalidomide (Revlimid) 30 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4, 15 to 18
28-day cycles
References
- Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15;108(10):3458-64. Epub 2006 Jul 13. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed
- MM-010: Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123-32. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00424047
- Pooled update: Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Nov;23(11):2147-52. Epub 2009 Jul 23. link to original article PubMed
- MM-009: Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00056160
- Pooled update: Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Nov;23(11):2147-52. Epub 2009 Jul 23. link to original article PubMed
- ASPIRE: Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. Epub 2014 Dec 6. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01080391
- Subgroup analysis: Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80. Epub 2016 Jul 20. link to original article link to PMC article PubMed
- HRQoL analysis: Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016 Nov 10;34(32):3921-3930. link to original article link to PMC article PubMed
- Update: Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018 Mar 10;36(8):728-734. Epub 2018 Jan 17. link to original article PubMed
- ELOQUENT-2: Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. Epub 2015 Jun 2. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01239797
- Update: Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017 Sep;178(6):896-905. Epub 2017 Jul 5. link to original article link to PMC article PubMed
- Update: Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 Oct 15;124(20):4032-4043. Epub 2018 Sep 11. link to original article PubMed
- Update: Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špička I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu KL, Anderson KC, Jou YM, Ganetsky A, Singhal AK, Richardson PG. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020 Sep 4;10(9):91. link to original article link to PMC article PubMed
- TOURMALINE-MM1: Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Apr 28;374(17):1621-1634. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01564537
- Subgroup analysis: Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017 Dec 14;130(24):2610-2618. Epub 2017 Oct 20. link to original article PubMed
- Update: Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Gimsing P, Garderet L, Touzeau C, Buadi FK, Laubach JP, Cavo M, Darif M, Labotka R, Berg D, Moreau P. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021 Aug 1;39(22):2430-2442. Epub 2021 Jun 11. link to original article PubMed
- POLLUX: Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-1331. link to original article link to original protocol dosing details in manuscript have been reviewed by our editors PubMed NCT02076009
- Update: Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O' Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018 Dec;103(12):2088-96. Epub 2018 Sep 20. link to original article link to PMC article PubMed
- Update: Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Krevvata M, Chiu C, Qin X, Okonkwo L, Trivedi S, Ukropec J, Qi M, San-Miguel J. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020 Jul;34(7):1875-1884. Epub 2020 Jan 30. link to original article link to PMC article PubMed
- Update: Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Moreau P. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 Mar 10;41(8):1590-1599. Epub 2023 Jan 4. link to original article link to PMC article PubMed
- RevLite: Quach H, Fernyhough L, Henderson R, Corbett G, Baker B, Browett P, Blacklock H, Forsyth C, Underhill C, Cannell P, Trotman J, Neylon A, Harrison S, Link E, Swern A, Cowan L, Dimopoulos MA, Miles Prince H. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. Br J Haematol. 2017 May;177(3):441-448. Epub 2017 Feb 15. link to original articledosing details in manuscript have been reviewed by our editors PubMed NCT00482261
- TOURMALINE-MM1 China Continuation: Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, Lu J, Du X, Chen X, Li J, Liu J, Gupta N, Hanley MJ, Li H, Hua Z, Wang B, Zhang X, Wang H, van de Velde H, Richardson PG, Moreau P. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J Hematol Oncol. 2017 Jul 6;10(1):137. link to original article link to PMC article dosing details in abstract have been reviewed by our editors PubMed NCT01564537
- ReLApsE: Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T, Raab MS, Hillengass J, Sauer S, Müller-Tidow C, Luntz S, Jauch A, Hose D, Seckinger A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Haenel M, Martin H, Lindemann HW, Scheid C, Nogai A, Salwender H, Noppeney R, Besemer B, Weisel K; German Myeloma Multicenter Group (GMMG). Salvage autologous transplant and lenalidomide maintenance vs lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2021 Apr;35(4):1134-1144. Epub 2020 Jul 21. link to original article dosing details in abstract have been reviewed by our editors PubMed ISRCTN16345835
Melphalan flufenamide & Dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Richardson et al. 2020 (HORIZONRRMM) | 2016-2019 | Phase 2 (RT) | ||
Schjesvold et al. 2022 (OCEAN) | 2017-2020 | Phase 3 (E-switch-ooc) | PD | Seems to have superior PFS (primary endpoint) Median PFS: 6.8 vs 4.9 mo (HR 0.79, 95% CI 0.64-0.98) |
Note: HORIZON should not be confused with the trial by the same name in breast cancer.
Peptide-drug conjugate therapy
- Melphalan flufenamide (Pepaxto) 40 mg IV over 30 minutes once on day 1
Glucocorticoid therapy
- Dexamethasone (Decadron) by the following age-based criteria:
- 75 years old or younger: 40 mg PO once per day on days 1, 8, 15, 22
- Older than 75 years old: 20 mg PO once per day on days 1, 8, 15, 22
28-day cycles
References
- HORIZONRRMM: Richardson PG, Oriol A, Larocca A, Bladé J, Cavo M, Rodriguez-Otero P, Leleu X, Nadeem O, Hiemenz JW, Hassoun H, Touzeau C, Alegre A, Paner A, Maisel C, Mazumder A, Raptis A, Moreb JS, Anderson KC, Laubach JP, Thuresson S, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Mateos MV; HORIZON (OP-106) Investigators. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2021 Mar 1;39(7):757-767. Epub 2020 Dec 9. link to original article dosing details in abstract have been reviewed by our editors link to PMC article PubMed NCT02963493
- OCEAN: Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R, Mateos MV, Richardson PG, Sonneveld P; OCEAN (OP-103) Investigators. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022 Feb;9(2):e98-e110. Epub 2022 Jan 12. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03151811
- HRQoL analysis: Schjesvold FH, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, Pour L, Spicka I, Dimopoulos MA, Masszi T, Chernova NG, Sandberg A, Thuresson M, Norin S, Bakker NA, Mateos MV, Richardson PG, Sonneveld P. Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. Haematologica. 2024 Jul 1;109(7):2331-2336. link to original article link to PMC article PubMed
Pomalidomide & Dexamethasone (Pd)
Pd: Pomalidomide & low-dose dexamethasone
PomDex: Pomalidomide & Dexamethasone
Pom + LoDEX: Pomalidomide & Low-dose Dexamethasone
Regimen variant #1, 4 mg 21/28
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Leleu et al. 2013 (IFM 2009-02) | 2009-2010 | Randomized Phase 2 (E-de-esc) | Pd; 28/28 | Did not meet primary endpoint of ORR |
Richardson et al. 2014 (CC-4047-MM-002) | 2009 to not reported | Randomized Phase 2 (E-RT-esc) | Pomalidomide | Superior PFS (primary endpoint) Median PFS: 4.2 vs 2.7 mo (HR 0.68, 95% CI 0.51-0.90) |
San Miguel et al. 2013 (NIMBUS) | 2011-03-18 to 2012-08-30 | Phase 3 (E-RT-esc) | Dexamethasone | Superior PFS (primary endpoint) Median PFS: 4 vs 1.9 mo (HR 0.48, 95% CI 0.39-0.60) Superior OS1 (secondary endpoint) Median OS: 13.1 vs 8.1 mo (HR 0.72) |
Baz et al. 2016 (PO-MM-PI-0039) | 2011-2014 | Randomized Phase 1/2 (C) | PomCyDex | Seems to have inferior ORR |
Leleu et al. 2015 (IFM 2010-02) | 2012-2013 | Phase 2 | ||
Dimopoulos et al. 2016 (STRATUS) | 2012-2014 | Phase 3b | ||
Mateos et al. 2019 (KEYNOTE-183) | 2016-01-18 to 2017-06-07 | Phase 3 (C) | PD & Pembrolizumab | Superior PFS2 Median PFS: 8.4 vs 5.6 mo (HR 0.65, 95% CI 0.45-0.95) |
Dimopoulos et al. 2018 (ELOQUENT-3) | 2016-03 to 2017-04 | Randomized Phase 2 (C) | Elo-Pd | Inferior OS3 |
Attal et al. 2019 (ICARIA-MM) | 2017-01-10 to 2018-02-02 | Phase 3 (C) | Isa-Pd | Might have inferior OS |
Dimopoulos et al. 2021 (APOLLO) | 2017-2019 | Phase 3 (C) | 1a. Dara-Pd 1b. Dara-Pd (SC daratumumab) |
Inferior PFS |
Schjesvold et al. 2022 (OCEAN) | 2017-2020 | Phase 3 (C) | Melflufen flufenamide & Dexamethasone | Seems to have inferior PFS |
Dimopoulos et al. 2023 (DREAMM-3) | 2020-04-02 to 2022-04-18 | Phase 3 (C) | Belantamab mafodotin | Did not meet primary endpoint of PFS |
1efficacy reported for NIMBUS is based on the 2015 update.
2KEYNOTE-183 was not designed to evaluate superiority in the control arm; nevertheless, an unplanned interim analysis found that the control arm had superior PFS.
3Reported efficacy for ELOQUENT-3 is based on the 2022 update.
Prior treatment criteria
- IFM 2009-02: At least 1 prior line of therapy
- CC-4047-MM-002 & NIMBUS: At least 2 prior lines of therapy including lenalidomide and bortezomib
- PO-MM-PI-0039: At least 2 prior lines of therapy including an immunomodulator; patients were required to be lenalidomide-refractory
- KEYNOTE-183: At least 2 prior lines of therapy not including pomalidomide
- ICARIA-MM: At least 2 prior lines of therapy including lenalidomide and a proteasome inhibitor
- APOLLO: At least 1 prior line of therapy including lenalidomide and a proteasome inhibitor
- OCEAN: 2 to 4 prior lines of therapy including lenalidomide and a proteasome inhibitor
Targeted therapy
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) by the following age-based criteria:
- 75 years old or younger: 40 mg PO once per day on days 1, 8, 15, 22
- Older than 75 years old: 20 mg PO once per day on days 1, 8, 15, 22
Supportive therapy
- NIMBUS: Thromboprohpylaxis required. "Choice of thromboprophylaxis and use of myeloid and erythroid growth factors was left to the physician's discretion."
- IFM 2009-02: Thromboprophylaxis "at the physician's discretion"
- CC-4047-MM-002: Aspirin 81 to 100 mg PO once per day unless contraindicated
- PO-MM-PI-0039: Aspirin 81 mg PO once per day unless contraindicated
- STRATUS: Thromboprophylaxis with low-dose Aspirin, |LMWH, or equivalent was required
- IFM 2009-02: G-CSF allowed beginning with cycle 2 and on
- ICARIA-MM: mandatory Aspirin or |LMWH
28-day cycles
Regimen variant #2, 4 mg continuous
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Lacy et al. 2011 (MC0789-2) | 2009 | Phase 2 | ||
Leleu et al. 2013 (IFM 2009-02) | 2009-2010 | Randomized Phase 2, >20 patients (E-esc) | Pd; 21/28 | Did not meet primary endpoint of ORR |
Note: Lacy et al. 2011 is registered under MC0789 but is described as a sequential phase 2 trial, distinct from Lacy et al. 2009.
Prior treatment criteria
- IFM 2009-02: At least 1 prior line of therapy
Targeted therapy
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 28
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
Supportive therapy
- MC0789-2: Aspirin 325 mg PO once per day
- low molecular weight heparin or Warfarin (Coumadin) could be substituted at physician discretion
- IFM 2009-02: Thromboprophylaxis "at the physician's discretion"
- IFM 2009-02: G-CSF allowed beginning with cycle 2 and on
28-day cycles
Regimen variant #3, 2 mg continuous
Study | Dates of enrollment | Evidence |
---|---|---|
Lacy et al. 2009 (MC0789MM) | 2007-2008 | Phase 2 |
Targeted therapy
- Pomalidomide (Pomalyst) 2 mg PO once per day on days 1 to 28
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
Supportive therapy
- Aspirin 325 mg PO once per day
- Low molecular weight heparin or Warfarin (Coumadin) could be substituted at physician discretion
28-day cycles
References
- MC0789MM: Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009 Oct 20;27(30):5008-14. Epub 2009 Aug 31. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00558896
- Update: Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010 Nov;24(11):1934-9. Epub 2010 Sep 9. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed
- Update: Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011 Sep 15;118(11):2970-5. Epub 2011 Jun 20. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed
- IFM 2009-02: Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C, Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, Hennache B, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D, Fermand JP, Avet-Loiseau H, Facon T. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02. Blood. 2013 Mar 14;121(11):1968-1975. Epub 2013 Jan 14. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01053949
- NIMBUS: San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055-66. Epub 2013 Sep 3. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01311687
- Update: Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015 Oct;100(10):1327-33. Epub 2015 Aug 6. link to original article link to PMC article PubMed
- CC-4047-MM-002: Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson K. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20;123(12):1826-32. Epub 2014 Jan 13. Erratum in: Blood. 2014 May 15;123(20):3208-9. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00833833
- IFM 2010-02: Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood. 2015 Feb 26;125(9):1411-7. Epub 2015 Jan 9. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01745640
- PO-MM-PI-0039: Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May 26;127(21):2561-8. Epub 2016 Mar 1. Erratum in: Blood. 2016 Jul 21;128(3):461. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01432600
- STRATUS: Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Röllig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016 Jul 28;128(4):497-503. Epub 2016 May 25. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01712789
- ELOQUENT-3: Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018 Nov 8;379(19):1811-1822. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02654132
- Update: Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol. 2023 Jan 20;41(3):568-578. Epub 2022 Aug 12. link to original article link to PMC article PubMed
- KEYNOTE-183: Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019 Sep;6(9):e459-e469. Epub 2019 Jul 18. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02576977
- ICARIA-MM: Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107. Epub 2019 Nov 14. Erratum in: Lancet. 2019 Dec 7;394(10214):2072. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02990338
- Update: Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 Mar;23(3):416-427. Epub 2022 Feb 10. link to original article PubMed
- Update: Richardson PG, Perrot A, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Macé S, Zhang R, Dubin F, Morisse MC, Anderson KC. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica. 2024 Jul 1;109(7):2239-2249. link to original article link to PMC article PubMed
- APOLLO: Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Jun;22(6):801-812. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT03180736
- Update: Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Kampfenkel T, Liu W, Wang J, Kosh M, Tran N, Carson R, Sonneveld P. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. Lancet Haematol. 2023 Oct;10(10):e813-e824. link to original article PubMed
- OCEAN: Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R, Mateos MV, Richardson PG, Sonneveld P; OCEAN (OP-103) Investigators. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022 Feb;9(2):e98-e110. Epub 2022 Jan 12. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03151811
- HRQoL analysis: Schjesvold FH, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, Pour L, Spicka I, Dimopoulos MA, Masszi T, Chernova NG, Sandberg A, Thuresson M, Norin S, Bakker NA, Mateos MV, Richardson PG, Sonneveld P. Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. Haematologica. 2024 Jul 1;109(7):2331-2336. link to original article link to PMC article PubMed
- DREAMM-3: Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023 Oct;10(10):e801-e812. link to original article PubMed NCT04162210
- CANOVA: NCT03539744
- CheckMate 602: NCT02726581
Selinexor & Dexamethasone (Sd)
Sd: Selinexor & low-dose dexamethasone
Regimen
FDA-recommended dose |
Study | Dates of enrollment | Evidence |
---|---|---|
Vogl et al. 2018 (STORM) | 2015-2018 | Phase 2 (RT) |
Targeted therapy
- Selinexor (Xpovio) 80 mg PO once per day on days 1, 3, 8, 10, 15, 17, 22, 24
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg PO once per day on days 1, 3, 8, 10, 15, 17, 22, 24
28-day cycles
References
- STORM: Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol. 2018 Mar 20;36(9):859-866. Epub 2018 Jan 30. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02336815
- Update: Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019 Aug 22;381(8):727-738. link to original article PubMed
Thalidomide & Dexamethasone (TD)
TD: Thalidomide, Dexamethasone
Thal-Dex: Thalidomide, Dexamethasone
Regimen variant #1, thalidomide 150
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Xia et al. 2023 (CPT-MM301) | 2015-02-25 to 2019-07-03 | Phase 3 (C) | Thal-Dex & Aponermin | Inferior OS (secondary endpoint) Inferior PFS (primary endpoint) |
Note: to our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
Eligibility criteria
- CPT-MM301: 18 to 75 years old
Prior treatment criteria
- CPT-MM301: Two or more prior regimens and not eligible for HSCT
Targeted therapy
- Thalidomide (Thalomid) 150 mg PO once per day
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
28-day cycle for up to 18 cycles
Regimen variant #2, thalidomide 200, with lead-in
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hjorth et al. 2012 (NMSG 17/07) | 2007-2010 | Phase 3 (E-switch-ooc) | Bort-Dex | Did not meet primary endpoint of PFS |
Note: This was an experimental arm that did not meet its primary endpoint, likely due to premature close of the study; included here because it was eventually used to establish this regimen as a standard comparator.
Prior treatment criteria
- NMSG 17/07: Failure of melphalan with no prior exposure to bortezomib or thalidomide
Targeted therapy
- Thalidomide (Thalomid) 50 mg PO once per day, increased by 50 mg every 3 weeks to a maximum of 200 mg PO once per day
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
Supportive therapy
- "Antithrombotic prophylaxis and acyclovir prophylaxis were not mandatory according to the study protocol but used routinely in an increasing proportion of participating centers during the study period."
21-day cycles until progression or best response, which would then be followed by 1 to 2 additional cycles
Regimen variant #3, thalidomide 200
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Garderet et al. 2012 (MMVAR/IFM 2005-04) | 2006-2010 | Phase 3 (C) | VTD | Inferior TTP |
Prior treatment criteria
- At least 1 autologous stem-cell transplant
Targeted therapy
- Thalidomide (Thalomid) 200 mg PO once per day
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
Supportive therapy
- Enoxaparin (Lovenox) 40 mg SC once per day for primary prophylaxis
- Warfarin (Coumadin) for secondary prophylaxis
21-day cycle for 18 cycles (1 year)
Regimen variant #4, thalidomide 400, with lead-in
Study | Dates of enrollment | Evidence |
---|---|---|
Dimopoulos et al. 2001 | 1999-2000 | Phase 2 |
Targeted therapy
- Thalidomide (Thalomid) as follows:
- Cycle 1: 200 mg PO once per day for 14 days, then 400 mg PO once per day
- Cycle 2 onwards: 400 mg PO once per day
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycle 1: 20 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
- Cycle 2 onwards: 20 mg PO once per day on days 1 to 4
1-month cycles
References
- Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001 Jul;12(7):991-5. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- NMSG 17/07: Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group. Thalidomide and dexamethasone vs bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol. 2012 Jun;88(6):485-96. Epub 2012 Mar 30. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00602511
- MMVAR/IFM 2005-04: Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012 Jul 10;30(20):2475-82. Epub 2012 May 14. Erratum in: J Clin Oncol. 2012 Sep 20;30(27):3429. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00256776
- CPT-MM301: Xia Z, Leng Y, Fang B, Liang Y, Li W, Fu C, Yang L, Ke X, Jiang H, Weng J, Liu L, Zhao Y, Zhang X, Huang Z, Liu A, Shi Q, Gao Y, Chen X, Pan L, Cai Z, Wang Z, Wang Y, Fan Y, Hou M, Ma Y, Hu J, Liu J, Zhou J, Zhang X, Meng H, Lu X, Li F, Ren H, Huang B, Shao Z, Zhou H, Hu Y, Yang S, Zheng X, Wei P, Pang H, Yu W, Liu Y, Gao S, Yan L, Ma Y, Jing H, Du J, Ling W, Zhang J, Sui W, Wang F, Li X, Chen W. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial. BMC Cancer. 2023 Oct 14;23(1):980. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed ChiCTR-IPR-15006024
Relapsed or refractory, triplets
BBD
BBD: Bendamustine, Bortezomib, Dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Ludwig et al. 2013 (AFAC BBD) | 2010-2012 | Phase 2 |
Chemotherapy
- Bendamustine 70 mg/m2 IV once per day on days 1 & 4
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg (route not specified) once per day on days 1, 4, 8, 11
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV once per day on days 1, 4, 8, 11
28-day cycle for up to 8 cycles
References
- AFAC BBD: Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weißmann A, Adam Z. Bendamustine-bortezomib-dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014 Feb 13;123(7):985-91. Epub 2013 Nov 13. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed EudraCT 2008-006421-13
BID
BID: Bendamustine, Ixazomib, Dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Dhakal et al. 2019 (PRO00024991) | 2015-2018 | Phase 1/2, fewer than 20 pts in MTD cohort |
Note: Dosages listed are the determined maximally tolerated doses (MTD) of this phase 1/2 trial. Note that dexamethasone is not given in week 4; this has been confirmed with the authors.
Chemotherapy
- Bendamustine 80 mg/m2 IV once per day on days 1 & 2
Glucocorticoid therapy
- Dexamethasone (Decadron) by the following age-based criteria:
- 75 years old or younger: 40 mg PO once per day on days 1, 8, 15
- Older than 75 years old: 20 mg PO once per day on days 1, 8, 15
Targeted therapy
- Ixazomib (Ninlaro) 4 mg PO once per day on days 1, 8, 15
28-day cycle for up to 8 cycles
References
- PRO00024991: Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019 Jul 29;9(8):56. link to original article link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02477215
BLD
BLD: Bendamustine, Lenalidomide, Dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Lentzsch et al. 2012 (UPMC 07-089) | 2008-2011 | Phase 1/2 |
Note: Dosages listed are the determined maximally tolerated doses (MTD) of this phase 1/2 trial.
Chemotherapy
- Bendamustine 75 mg/m2 IV once per day on days 1 & 2
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg (no route specified) once per day on days 1, 8, 15, 22
Targeted therapy
- Lenalidomide (Revlimid) 10 mg PO once per day on days 1 to 21
Supportive therapy
- Aspirin 325 mg PO once per day
- "Gastroprotectant" (H2-blocker or PPI)
28-day cycle for up to 8 cycles
References
- UPMC 07-089: Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara MY, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012 May 17;119(20):4608-13. Epub 2012 Mar 26. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01042704
Bortezomib & Dexamethasone (Vd) & Panobinostat
Vd & Panobinostat: Velcade (Bortezomib), low-dose dexamethasone, Panobinostat
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Richardson et al. 2013 (PANORAMA 2) | 2010-2011 | Phase 2 | ||
San-Miguel et al. 2014 (PANORAMA 1) | 2010-2012 | Phase 3 (E-RT-esc) | Vd | Superior PFS (primary endpoint) Median PFS: 12 vs 8.1 mo (HR 0.63, 95% CI 0.52-0.76) |
Patients who had clinical benefit per the modified European Group for Blood and Marrow Transplantation [EBMT] criteria on day 1 of cycle 8 proceeded to cycle 9:
Prior treatment criteria
- PANORAMA 1: 1 to 3 prior lines of therapy
Targeted therapy
- Bortezomib (Velcade) as follows:
- Cycles 1 to 8: 1.3 mg/m2 IV once per day on days 1, 4, 8, 11
- Cycles 9 to 16: 1.3 mg/m2 IV once per day on days 1 & 8
- Panobinostat (Farydak) 20 mg PO once per day on days 1, 3, 5, 8, 10, 12
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 8: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
- Cycles 9 to 16: 20 mg PO once per day on days 1, 2, 8, 9
21-day cycle for 16 cycles (PANORAMA 1) or indefinitely (PANORAMA 2)
References
- PANORAMA 2: Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013 Oct 3;122(14):2331-7. Epub 2013 Aug 15. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01083602
- PANORAMA 1: San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1195-206. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01023308
- Subgroup analysis: Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016 Feb 11;127(6):713-21. Epub 2015 Dec 2. link to original article link to PMC article PubMed
- Update: San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016 Nov;3(11):e506-e515. Epub 2016 Oct 14. link to original article PubMed
B-Pd
B-Pd: Bortezomib, Pomalidomide, low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Awaiting publication (DREAMM 8) | 2020-2023 | Phase 3 (C) | Pd & Belantamab mafodotin | TBD if different primary endpoint of PFS |
Targeted therapy
Glucocorticoid therapy
References
- DREAMM 8: NCT04484623
BTD
BTD: Bendamustine, Thalidomide, Dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Schey et al. 2015 (MUKone) | 2011-2012 | Randomized Phase 2 (E-de-esc) | BTD; higher-dose benadmustine | Not reported1 |
1While this study was randomized, it was "not powered to directly compare the two arms for statistically significant superiority."
Note: This study involved two doses of bendamustine but the higher dose was too toxic, leading to premature closure. Note that dosage listed is the lower dose. Also, the abstracts says that thalidomide is given days 1 to 21 but the body of the paper says days 1 to 28.
Chemotherapy
- Bendamustine 60 mg/m2 IV once per day on days 1 & 8
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg PO once per day on days 1, 8, 15, 22
Targeted therapy
- Thalidomide (Thalomid) 100 mg PO once per day on days 1 to 21 (see note)
Supportive therapy
- Thromboprophylaxis (not specified)
- Anti-infective prophylaxis (not specified)
28-day cycle for 6 to 9 cycles (2 cycles past best response)
References
- MUKone: Schey S, Brown SR, Tillotson AL, Yong K, Williams C, Davies F, Morgan G, Cavenagh J, Cook G, Cook M, Orti G, Morris C, Sherratt D, Flanagan L, Gregory W, Cavet J; Myeloma UK Early Phase Clinical Trial Network. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. Br J Haematol. 2015 Aug;170(3):336-48. Epub 2015 Apr 20. link to original article dosing details in manuscript have been reviewed by our editors PubMed ISRCTN90889843
CPR
CPR: Cyclophosphamide, Prednisone, Revlimid (Lenalidomide)
REP: Revlimid (Lenalidomide), Endoxan (Cyclophosphamide), Prednisone
Regimen variant #1, "REP"
Study | Dates of enrollment | Evidence |
---|---|---|
Nijhof et al. 2016 (REPEAT) | 2011-2014 | Phase 1/2 |
Note: Details are for the MTD/phase 2 portion of the published phase 1/2 trial.
Targeted therapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Chemotherapy
- Cyclophosphamide (Cytoxan) 50 mg PO once per day on days 1 to 28
Glucocorticoid therapy
- Prednisone (Sterapred) 20 mg PO once per day on days 1 to 28
28-day cycles
Regimen variant #2, "CPR"
Study | Dates of enrollment | Evidence |
---|---|---|
Reece et al. 2014 | 2007-2009 | Phase 1/2 |
Note: Details are for the phase 2 portion of the published phase 1/2 trial.
Chemotherapy
- Cyclophosphamide (Cytoxan) 300 mg/m2 PO on days 1, 8, 15
Glucocorticoid therapy
- Prednisone (Sterapred) 100 mg PO once every other day on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27
Targeted therapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
28-day cycles
References
- Reece DE, Masih-Khan E, Atenafu EG, Jimenez-Zepeda VH, Anglin P, Chen C, Kukreti V, Mikhael JR, Trudel S. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. Br J Haematol. 2015 Jan;168(1):46-54. Epub 2014 Aug 22. link to original article dosing details in abstract have been reviewed by our editors PubMed
- REPEAT: Nijhof IS, Franssen LE, Levin MD, Bos GM, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Ypma PF, Raymakers R, van Spronsen DJ, Westerweel PE, Oostvogels R, van Velzen J, van Kessel B, Mutis T, Sonneveld P, Zweegman S, Lokhorst HM, van de Donk NW. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood. 2016 Nov;128(19), 2297-2306. Epub 2016 Sep 19. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01352338
CRd
CRd: Cyclophosphamide, Revlimid (Lenalidomide), low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Schey et al. 2010 | Not reported | Phase 1/2 |
Note: This is the MTD of this phase 1/2 trial.
Chemotherapy
- Cyclophosphamide (Cytoxan) 600 mg PO once per day on days 1 & 8
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg PO once per day on days 1 to 4, 8 to 11
Targeted therapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Supportive therapy
- Aspirin 75 mg PO once per day
28-day cycles
References
- Schey SA, Morgan GJ, Ramasamy K, Hazel B, Ladon D, Corderoy S, Jenner M, Phekoo K, Boyd K, Davies FE. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol. 2010 Aug;150(3):326-33. Epub 2010 Jun 10. link to original article dosing details in manuscript have been reviewed by our editors PubMed
CTD
CTD: Cyclophosphamide, Thalidomide, Dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Dimopoulos et al. 2004 | Not reported in abstract | Phase 2 |
Chemotherapy
- Cyclophosphamide (Cytoxan) 150 mg/m2 PO every 12 hours on days 1 to 5, taken before meals
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 3: 20 mg PO once per day on days 1 to 5, 14 to 18, taken every morning after breakfast
- Cycle 4 onwards: 20 mg PO once per day on days 1 to 5, taken every morning after breakfast
Targeted therapy
- Thalidomide (Thalomid) as follows:
- Cycles 1 to 3: 400 mg PO once per day on days 1 to 5, 14 to 18, taken in the evening
- Cycle 4 onwards: 400 mg PO once per day on days 1 to 5, taken in the evening
28-day cycles
References
- Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V, Poziopoulos C, Xilouri I, Zorzou MP, Anagnostopoulos N, Anagnostopoulos A. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004;5(2):112-7. link to original article PubMed
Dara-Kd
Dara-Kd: Daratumumab, Kyprolis (Carfilzomib), low-dose dexamethasone
D-Kd: Daratumumab, Kyprolis (Carfilzomib), low-dose dexamethasone
KdD: Kyprolis (Carfilzomib), low-dose dexamethasone, Daratumumab
Regimen variant #1
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Dimopoulos et al. 2020 (CANDOR) | 2017-06-13 to 2018-06-25 | Phase 3 (E-RT-esc) | Kd | Superior PFS1 (primary endpoint) Median PFS: 28.6 vs 15.2 mo (HR 0.59, 95% CI 0.45-0.78) |
1Reported efficacy is based on the 2021 update.
Note: this dosing if for patients 75 or younger; the steroid dosing is fairly complex; refer to page 45 of the protocol for additional details.
Prior treatment criteria
- 1 to 3 prior lines of therapy
Targeted therapy
- Daratumumab (Darzalex) as follows:
- Cycle 1: 8 mg/kg IV once per day on days 1 & 2, then 16 mg/kg IV once per day on days 8, 15, 22
- Cycle 2: 16 mg/kg IV once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 16 mg/kg IV once per day on days 1 & 15
- Cycle 7 onwards: 16 mg/kg IV once on day 1
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV over 30 minutes once per day on days 1 & 2, then 56 mg/m2 IV over 30 minutes once per day on days 8, 9, 15, 16
- Cycle 2 onwards: 56 mg/m2 IV over 30 minutes once per day on days 1, 2, 8, 9, 15, 16
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23
28-day cycles
Regimen variant #2
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Dimopoulos et al. 2020 (CANDOR) | 2017-06-13 to 2018-06-25 | Phase 3 (E-RT-esc) | Kd | Superior PFS1 (primary endpoint) Median PFS: 28.6 vs 15.2 mo (HR 0.59, 95% CI 0.45-0.78) |
1Reported efficacy is based on the 2021 update.
Note: this dosing is for patients older than 75; the steroid dosing is fairly complex; refer to page 45 of the protocol for additional details.
Prior treatment criteria
- 1 to 3 prior lines of therapy
Targeted therapy
- Daratumumab (Darzalex) as follows:
- Cycle 1: 8 mg/kg IV once per day on days 1 & 2, then 16 mg/kg IV once per day on days 8, 15, 22
- Cycle 2: 16 mg/kg IV once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 16 mg/kg IV once per day on days 1 & 15
- Cycle 7 onwards: 16 mg/kg IV once on day 1
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV over 30 minutes once per day on days 1 & 2, then 56 mg/m2 IV over 30 minutes once per day on days 8, 9, 15, 16
- Cycle 2 onwards: 56 mg/m2 IV over 30 minutes once per day on days 1, 2, 8, 9, 15, 16
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycle 1: 20 mg IV or PO once per day on days 1, 2, 8, then 8 mg IV or PO once on day 9, then 20 mg IV or PO once on day 15, then 8 mg IV or PO once on day 16, then 20 mg IV or PO once on day 22
- Cycle 2 onwards: 20 mg IV or PO once per day on days 1, 8, 15, 22
28-day cycles
Regimen variant #3
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Chari et al. 2019 (EQUULEUScfz) | 2014 to not reported | Phase 1b (RT) | ORR: 84% |
Note: this dosing is for patients 75 or younger. EQUULEUS had multiple arms; this one is denoted as cfz (carfilzomib).
Targeted therapy
- Daratumumab (Darzalex) as follows:
- Cycles 1 & 2: 16 mg/kg IV once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 16 mg/kg IV once per day on days 1 & 15
- Cycle 7 onwards: 16 mg/kg IV once on day 1
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV once on day 1, then 70 mg/m2 IV once per day on days 8 & 15
- Cycle 2 onwards: 70 mg/m2 IV once per day on days 1, 8, 15
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
Supportive therapy
- Dexamethasone (Decadron) 20 mg IV or PO once per infusion, prior to daratumumab
- For patients receiving the 40 mg/wk dose, the remainder is given the day after the infusion
- Acetaminophen (Tylenol) once per infusion, prior to daratumumab
- Diphenhydramine (Benadryl) once per infusion, prior to daratumumab
28-day cycles
Regimen variant #4
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Chari et al. 2019 (EQUULEUScfz) | 2014 to not reported | Phase 1b (RT) | ORR: 84% |
Note: this dosing is for patients older than 75. EQUULEUS had multiple arms; this one is denoted as cfz (carfilzomib).
Targeted therapy
- Daratumumab (Darzalex) as follows:
- Cycles 1 & 2: 16 mg/kg IV once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 16 mg/kg IV once per day on days 1 & 15
- Cycle 7 onwards: 16 mg/kg IV once on day 1
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV once on day 1, then 70 mg/m2 IV once per day on days 8 & 15
- Cycle 2 onwards: 70 mg/m2 IV once per day on days 1, 8, 15
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg PO once per day on days 1, 8, 15, 22
Supportive therapy
- Dexamethasone (Decadron) 20 mg IV or PO once per infusion, prior to daratumumab
- For patients receiving the 40 mg/wk dose, the remainder is given the day after the infusion
- Acetaminophen (Tylenol) once per infusion, prior to daratumumab
- Diphenhydramine (Benadryl) once per infusion, prior to daratumumab
28-day cycles
References
- EQUULEUScfz: Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019 Aug 1;134(5):421-431. Epub 2019 May 21. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01998971
- Update: Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, Ailawadhi S, Besemer B, de la Rubia Comos J, Encinas C, Mateos MV, Salwender H, Rodriguez-Otero P, Hulin C, Karlin L, Sureda Balari A, Bargay J, Benboubker L, Rosiñol L, Tarantolo S, Terebelo H, Yang S, Wang J, Nnane I, Qi M, Kosh M, Delioukina M, Goldschmidt H. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer J. 2023 Mar 7;13(1):33. link to original article link to PMC article dosing details in supplement have been reviewed by our editors PubMed
- CANDOR: Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 Jul 18;396(10245):186-197. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03158688
- Update: Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 Jan;23(1):65-76. Epub 2021 Dec 3. link to original article PubMed
- REMNANT: NCT04513639
Dara-Kd (SC daratumumab)
Dara-Kd: Daratumumab and hyaluronidase, Kyprolis (Carfilzomib), low-dose dexamethasone
D-Kd: Daratumumab and hyaluronidase, Kyprolis (Carfilzomib), low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Moreau et al. 2023 (PLEIADES) | 2018 to not reported | Phase 2 (RT) |
Note: To our knowledge, Moreau et al. 2023 is the only published manuscript describing PLEIADES.
Targeted therapy
- Daratumumab and hyaluronidase (Darzalex Faspro) as follows:
- Cycles 1 & 2: 1800 mg SC once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 1800 mg SC once per day on days 1 & 15
- Cycle 7 onwards: 1800 mg SC once on day 1
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV once on day 1, then 70 mg/m2 IV once per day on days 8 & 15
- Cycle 2 onwards: 70 mg/m2 IV once per day on days 1, 8, 15
Glucocorticoid therapy
- Dexamethasone (Decadron) by the following age-based criteria:
- 75 years old or younger: 40 mg PO once per day on days 1, 8, 15, 22
- Older than 75 years old: 20 mg PO once per day on days 1, 8, 15, 22
28-day cycles
References
- PLEIADES: Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, Ailawadhi S, Besemer B, de la Rubia Comos J, Encinas C, Mateos MV, Salwender H, Rodriguez-Otero P, Hulin C, Karlin L, Sureda Balari A, Bargay J, Benboubker L, Rosiñol L, Tarantolo S, Terebelo H, Yang S, Wang J, Nnane I, Qi M, Kosh M, Delioukina M, Goldschmidt H. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer J. 2023 Mar 7;13(1):33. link to original article link to PMC article dosing details in supplement have been reviewed by our editors PubMed NCT03412565
Dara-Pd
Dara-Pd: Daratumumab, Pomalidomide, low-dose dexamethasone
DPd: Daratumumab, Pomalidomide, low-dose dexamethasone
Regimen
FDA-recommended dose |
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Chari et al. 2017 (EQUULEUSpom) | 2014 to not reported | Phase 1b (RT) | ORR: 59% (95% CI, 49-69) | |
Dimopoulos et al. 2021 (APOLLO) | 2017-2019 | Phase 3 (E-esc) | Pd | Superior PFS (primary endpoint) Median PFS: 12.4 vs 6.9 mo (HR 0.63, 95% CI 0.47-0.85) Did not meet secondary endpoint of OS1 |
Rodriguez-Otero et al. 2023 (KarMMa-3) | 2019-05 to 2022-04 | Phase 3 (C) | Ide-cel | Inferior PFS |
1Reported efficacy for APOLLO is based on the 2023 update.
Note: EQUULEUS had multiple arms; this one is denoted as pom (pomalidomide).
Prior treatment criteria
- APOLLO: At least 1 prior line of therapy including lenalidomide and a proteasome inhibitor
Targeted therapy
- Daratumumab (Darzalex) as follows:
- Cycles 1 & 2: 16 mg/kg IV once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 16 mg/kg IV once per day on days 1 & 15
- Cycle 7 onwards: 16 mg/kg IV once on day 1
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) by the following criteria:
- Standard patients: 40 mg PO once per day on days 1, 8, 15, 22
- EQUULEUSpom, patients older than 75 years or BMI less than 18.5: 20 mg PO once per day on days 1, 8, 15, 22
- APOLLO & KarMMa-3, patients older than 75 years: 20 mg PO once per day on days 1, 8, 15, 22
Supportive therapy
- Details are per EQUULEUSpom:
- Dexamethasone (Decadron) 20 mg IV or PO once per infusion, prior to daratumumab
- For patients receiving the 40 mg/wk dose, the remainder is given after the infusion on day of infusion
- Acetaminophen (Tylenol) once per infusion, prior to daratumumab
- An antihistamine once per infusion, prior to daratumumab
28-day cycles
References
- EQUULEUSpom: Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017 Aug 24;130(8):974-981. Epub 2017 Jun 21. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01998971
- APOLLO: Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Jun;22(6):801-812. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT03180736
- Update: Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Kampfenkel T, Liu W, Wang J, Kosh M, Tran N, Carson R, Sonneveld P. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. Lancet Haematol. 2023 Oct;10(10):e813-e824. link to original article PubMed
- KarMMa-3: Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. link to original article dosing details in supplement have been reviewed by our editors PubMed NCT03651128
- PRO analysis: Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. link to original article PubMed
- MAGNETISMM-5: NCT05020236
Dara-Pd (SC daratumumab)
Dara-Pd: Daratumumab and hyaluronidase, Pomalidomide, low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Dimopoulos et al. 2021 (APOLLO) | 2017-2019 | Phase 3 (E-RT-esc) | Pd | Superior PFS (primary endpoint) Median PFS: 12.4 vs 6.9 mo (HR 0.63, 95% CI 0.47-0.85) Did not meet secondary endpoint of OS1 |
San-Miguel et al. 2023 (CARTITUDE-4) | 2020-07-10 to 2021-11-17 | Phase 3 (C) | Cilta-cel | Inferior PFS |
1Reported efficacy for APOLLO is based on the 2023 update.
Prior treatment criteria
- APOLLO: At least 1 prior line of therapy including lenalidomide and a proteasome inhibitor
Targeted therapy
- Daratumumab and hyaluronidase (Darzalex Faspro) as follows:
- Cycles 1 & 2: 1800 mg SC once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 1800 mg SC once per day on days 1 & 15
- Cycle 7 onwards: 1800 mg SC once on day 1
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) by the following study-specific criteria:
- APOLLO, standard patients: 40 mg PO once per day on days 1, 8, 15, 22
- APOLLO, patients older than 75 years: 20 mg PO once per day on days 1, 8, 15, 22
- CARTITUDE-4: 40 mg IV or PO once per day on days 1, 8, 15, 22 or 20 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23
28-day cycles
References
- APOLLO: Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Jun;22(6):801-812. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT03180736
- Update: Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Kampfenkel T, Liu W, Wang J, Kosh M, Tran N, Carson R, Sonneveld P. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. Lancet Haematol. 2023 Oct;10(10):e813-e824. link to original article PubMed
- CARTITUDE-4: San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023 Jul 27;389(4):335-347. Epub 2023 Jun 5. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT04181827
- MajesTEC-3: NCT05083169
Dara-Rd
Dara-Rd: Daratumumab, Revlimid (Lenalidomide), low-dose dexamethasone
D-Rd: Daratumumab, Revlimid (Lenalidomide), low-dose dexamethasone
Regimen variant #1, limited duration
Study | Dates of enrollment | Evidence |
---|---|---|
Plesner et al. 2016 (GEN503) | 2012 to not reported | Phase 1/2 |
Targeted therapy
- Daratumumab (Darzalex) as follows:
- Cycles 1 & 2: 16 mg/kg IV once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 16 mg/kg IV once per day on days 1 & 15
- Cycles 7 to 26: 16 mg/kg IV once on day 1
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
28-day cycle for up to 26 cycles (2 years)
Regimen variant #2, indefinite
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Dimopoulos et al. 2016 (POLLUX) | 2014-06-16 to 2015-07-14 | Phase 3 (E-RT-esc) | Rd | Superior PFS1 (primary endpoint) Median PFS: 44.5 vs 17.5 mo (HR 0.44, 95% CI 0.35-0.55) Superior OS2 (secondary endpoint) Median OS: 67.6 vs 51.8 mo (HR 0.73, 95% CI 0.58-0.91) |
1Reported efficacy is based on the 2020 update.
2Reported efficacy is based on the 2023 update.
Prior treatment criteria
- 1 to 3 prior lines of therapy
Targeted therapy
- Daratumumab (Darzalex) as follows:
- Cycles 1 & 2: 16 mg/kg IV once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 16 mg/kg IV once per day on days 1 & 15
- Cycle 7 onwards: 16 mg/kg IV once on day 1
- Lenalidomide (Revlimid) by the following renal function-based criteria:
- CrCl 60 mL/min/1.73m2 or more: 25 mg PO once per day on days 1 to 21
- CrCl 30 to 60 mL/min/1.73m2: 10 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) by the following age- and BMI-based criteria:
- 75 years old or younger AND BMI 18.5 or more: 40 mg PO once per day on days 1, 8, 15, 22
- Older than 75 years old OR BMI less than 18.5: 20 mg PO once per day on days 1, 8, 15, 22
28-day cycles
References
- GEN503: Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016 Oct 6;128(14):1821-8. Epub 2016 Aug 16. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01615029
- POLLUX: Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-1331. link to original article link to original protocol dosing details in manuscript have been reviewed by our editors PubMed NCT02076009
- Update: Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O' Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018 Dec;103(12):2088-96. Epub 2018 Sep 20. link to original article link to PMC article PubMed
- Update: Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Krevvata M, Chiu C, Qin X, Okonkwo L, Trivedi S, Ukropec J, Qi M, San-Miguel J. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020 Jul;34(7):1875-1884. Epub 2020 Jan 30. link to original article link to PMC article PubMed
- Update: Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Moreau P. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 Mar 10;41(8):1590-1599. Epub 2023 Jan 4. link to original article link to PMC article PubMed
- CONFIRMMM: NCT03836014
Dara-Rd (SC daratumumab)
Dara-Rd: Daratumumab and hyaluronidase, Revlimid (Lenalidomide), low-dose dexamethasone
D-Rd: Daratumumab and hyaluronidase, Revlimid (Lenalidomide), low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Chari et al. 2020 (PLEIADES) | 2018 to not reported | Phase 2 (RT) |
Targeted therapy
- Daratumumab and hyaluronidase (Darzalex Faspro) as follows:
- Cycles 1 & 2: 1800 mg SC once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 1800 mg SC once per day on days 1 & 15
- Cycle 7 onwards: 1800 mg SC once on day 1
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
28-day cycles
References
- PLEIADES: Chari A, Rodriguez-Otero P, McCarthy H, Suzuki K, Hungria V, Sureda Balari A, Perrot A, Hulin C, Magen H, Iida S, Maisnar V, Karlin L, Pour L, Parasrampuria DA, Masterson T, Kosh M, Yang S, Delioukina M, Qi M, Carson R, Touzeau C. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. Br J Haematol. 2021 Mar;192(5):869-878. Epub 2020 Jul 30. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03412565
Dara-Vd
Dara-Vd: Daratumumab, Velcade (Bortezomib), low-dose dexamethasone
D-Vd: Daratumumab, Velcade (Bortezomib), low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Palumbo et al. 2016 (CASTOR) | 2014-09-04 to 2015-09-24 | Phase 3 (E-RT-esc) | Vd | Superior PFS1 (primary endpoint) Median PFS: 16.7 vs 7.1 mo (HR 0.31, 95% CI 0.25-0.40) Superior OS2 (secondary endpoint) Median OS: 49.6 vs 38.5 mo (HR 0.74, 95% CI 0.59-0.92) |
Lu et al. 2021 (LEPUS) | 2017-2019 | Phase 3 (E-esc) | Vd | Superior PFS (primary endpoint) Median PFS: NYR vs 6.3 mo (HR 0.28, 95% CI 0.17-0.47) |
Rodriguez-Otero et al. 2023 (KarMMa-3) | 2019-05 to 2022-04 | Phase 3 (C) | Ide-cel | Inferior PFS |
1Reported efficacy for the primary endpoint of CASTOR (PFS) is based on the 2019 update.
2Reported efficacy for the secondary endpoint of CASTOR (OS) is based on the 2022 update.
Note: KarMMa-3 only allowed the oral route for dexamethasone.
Prior treatment criteria
- CASTOR & LEPUS: At least 1 prior line of therapy
Targeted therapy
- Daratumumab (Darzalex) as follows:
- Cycles 1 to 3: 16 mg/kg IV once per day on days 1, 8, 15
- Cycle 4 onwards: 16 mg/kg IV once on day 1
- Bortezomib (Velcade) as follows:
- Cycles 1 to 8: 1.3 mg/m2 SC once per day on days 1, 4, 8, 11
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 8: 20 mg IV or PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
21-day cycle for 8 cycles, then 28-day cycles
Dose and schedule modifications
- Dexamethasone (Decadron) can be dose-reduced to 20 mg IV or PO once per day on days 1, 8, 15 for patients greater than 75 years, with BMI less than 18.5, or with previous side effects
References
- CASTOR: Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. link to original article link to supplementary appendix dosing details in manuscript have been reviewed by our editors PubMed NCT02136134
- Update: Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Dec;103(12):2079-87. Epub 2018 Sep 20. link to original article link to PMC article PubMed
- Update: Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, Corradini P, Min CK, Medvedova E, Weisel K, Chiu C, Schecter JM, Amin H, Qin X, Ukropec J, Kobos R, Spencer A. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):509-518. Epub 2019 Oct 9. link to original article PubMed
- Update: Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Levin MD, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Spencer A. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 Mar 10;41(8):1600-1609. Epub 2022 Nov 22. link to original article link to PMC article PubMed
- LEPUS: Lu J, Fu W, Li W, Hu J, An G, Wang Y, Fu C, Chen L, Jin J, Cen X, Ge Z, Cai Z, Niu T, Qi M, Sun S, Gai X, Liu W, Liu W, Yang X, Huang X. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):e699-e709. Epub 2021 Apr 24. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT03234972
- KarMMa-3: Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. link to original article dosing details in supplement have been reviewed by our editors PubMed NCT03651128
- PRO analysis: Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. link to original article PubMed
- EXCALIBER-RRMM: NCT04975997
Dara-Vd (SC daratumumab)
Dara-Vd: Daratumumab and hyaluronidase, Velcade (Bortezomib), low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Awaiting publication (MajesTEC-3) | 2021-ongoing | Phase 3 (C) | Tec-Dara | TBD if different primary endpoint of PFS |
Targeted therapy
Glucocorticoid therapy
References
- MajesTEC-3: NCT05083169
Elo-Pd
Elo-Pd: Elotuzumab, Pomalidomide, low-dose dexamethasone
EPd: Elotuzumab, Pomalidomide, low-dose dexamethasone
Regimen variant #1, lower-dose dexamethasone
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Dimopoulos et al. 2018 (ELOQUENT-3) | 2016-03 to 2017-04 | Randomized Phase 2 (E-RT-esc) | Pd | Superior OS1 (secondary endpoint) Median OS: 29.8 vs 17.4 mo (HR 0.59, 95% CI 0.37-0.93) Superior PFS (primary endpoint) Median PFS: 10.3 vs 4.7 mo (HR 0.54, 95% CI 0.34-0.86) |
Rodriguez-Otero et al. 2023 (KarMMa-3) | 2019-05 to 2022-04 | Phase 3 (C) | Ide-cel | Inferior PFS |
1Reported efficacy for ELOQUENT-3 is based on the 2022 update.
Note: this variant was intended for patients older than 75 years.
Prior treatment criteria
- 2 or more prior lines of therapy, including lenalidomide and a proteasome inhibitor
Targeted therapy
- Elotuzumab (Empliciti) as follows:
- Cycles 1 & 2: 10 mg/kg IV once per day on days 1, 8, 15, 22
- Cycle 3 onwards: 20 mg/kg IV once on day 1
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Weeks without elotuzumab: 20 mg PO once per week
- Weeks with elotuzumab: 8 mg PO once per infusion, prior to elotuzumab, then 8 mg IV once per infusion, on days when elotuzumab is administered
- According to the elotuzumab package insert, the first dose should be given between 3 and 24 hours before elotuzumab; the second dose should be given 45 to 90 minutes before elotuzumab.
Supportive therapy
- Diphenhydramine (Benadryl) 25 to 50 mg (route not specified) or its equivalent once per infusion, 45 to 90 minutes prior to elotuzumab
- Ranitidine (Zantac) 50 mg (route not specified) or its equivalent once per infusion, 45 to 90 minutes prior to elotuzumab
- Acetaminophen (Tylenol) 650 to 1000 mg (route not specified) once per infusion, 45 to 90 minutes prior to elotuzumab
- "Thromboembolic prophylaxis was required "according to institutional guidelines or at the discretion of the investigator."
28-day cycles
Regimen variant #2, standard-dose dexamethasone
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Dimopoulos et al. 2018 (ELOQUENT-3) | 2016-03 to 2017-04 | Randomized Phase 2 (E-esc) | Pd | Superior OS1 (secondary endpoint) Median OS: 29.8 vs 17.4 mo (HR 0.59, 95% CI 0.37-0.93) Superior PFS (primary endpoint) Median PFS: 10.3 vs 4.7 mo (HR 0.54, 95% CI 0.34-0.86) |
Rodriguez-Otero et al. 2023 (KarMMa-3) | 2019-05 to 2022-04 | Phase 3 (C) | Ide-cel | Inferior PFS |
1Reported efficacy for ELOQUENT-3 is based on the 2022 update.
Note: this variant was intended for patients up to 75 years.
Prior treatment criteria
- 2 or more prior lines of therapy, including lenalidomide and a proteasome inhibitor
Targeted therapy
- Elotuzumab (Empliciti) as follows:
- Cycles 1 & 2: 10 mg/kg IV once per day on days 1, 8, 15, 22
- Cycle 3 onwards: 20 mg/kg IV once on day 1
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Weeks without elotuzumab: 40 mg PO once per week
- Weeks with elotuzumab: 28 mg PO once per infusion, prior to elotuzumab, then 8 mg IV once per infusion, on days when elotuzumab is administered
- According to the elotuzumab package insert, the first dose should be given between 3 and 24 hours before elotuzumab; the second dose should be given 45 to 90 minutes before elotuzumab.
Supportive therapy
- Diphenhydramine (Benadryl) 25 to 50 mg (route not specified) or its equivalent once per infusion, 45 to 90 minutes prior to elotuzumab
- Ranitidine (Zantac) 50 mg (route not specified) or its equivalent once per infusion, 45 to 90 minutes prior to elotuzumab
- Acetaminophen (Tylenol) 650 to 1000 mg (route not specified) once per infusion, 45 to 90 minutes prior to elotuzumab
- "Thromboembolic prophylaxis was required "according to institutional guidelines or at the discretion of the investigator."
28-day cycles
References
- ELOQUENT-3: Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018 Nov 8;379(19):1811-1822. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02654132
- Update: Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol. 2023 Jan 20;41(3):568-578. Epub 2022 Aug 12. link to original article link to PMC article PubMed
- KarMMa-3: Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. link to original article dosing details in supplement have been reviewed by our editors PubMed NCT03651128
- PRO analysis: Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. link to original article PubMed
- EMN29: NCT05028348
Elo-Rd
Elo-Rd: Elotuzumab, Revlimid (Lenalidomide), low-dose dexamethasone
ELd: Elotuzumab, Lenalidomide, low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Lonial et al. 2012 (1703 Study) | 2008 to not reported | Phase 1b/2 | ||
Lonial et al. 2015 (ELOQUENT-2) | 2011-06 to 2012-11 | Phase 3 (E-RT-esc) | Rd | Seems to have superior OS1 (secondary endpoint) Median OS: 48.3 vs 39.6 mo (HR 0.82, 95.4% CI 0.68-1.00) Superior PFS (primary endpoint) Median PFS: 19.4 vs 14.9 mo (HR 0.70, 95% CI 0.57-0.85) |
1Reported OS efficacy for ELOQUENT-2 is based on the 2020 final update.
Prior treatment criteria
- ELOQUENT-2: 1 to 3 prior lines of therapy
Targeted therapy
- Elotuzumab (Empliciti) as follows:
- Cycles 1 & 2: 10 mg/kg IV once per day on days 1, 8, 15, 22
- Cycle 3 onwards: 10 mg/kg IV once per day on days 1 & 15
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Weeks without elotuzumab: 40 mg PO once per week
- Weeks with elotuzumab: 28 mg PO once per infusion, prior to elotuzumab, then 8 mg IV once per infusion, after elotuzumab is administered
- According to the elotuzumab package insert, the 28 mg PO dose should be given between 3 and 24 hours before elotuzumab; the 8 mg IV dose should be given 45 to 90 minutes before elotuzumab.
Supportive therapy
- Diphenhydramine (Benadryl) 25 to 50 mg (route not specified) or its equivalent once per infusion, 30 to 90 minutes prior to elotuzumab
- Ranitidine (Zantac) 50 mg (route not specified) or its equivalent one per infusion, 30 to 90 minutes prior to elotuzumab
- Acetaminophen (Tylenol) 650 to 1000 mg (route not specified) or its equivalent once per infusion, 30 to 90 minutes prior to elotuzumab
- "Thromboembolic prophylaxis (e.g., aspirin, low-molecular-weight heparin, or vitamin K antagonists) was administered according to institutional guidelines or at the discretion of the investigator."
28-day cycles
References
- 1703 Study: Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012 Jun 1;30(16):1953-9. Epub 2012 Apr 30. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00742560
- Update: Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S; 1703 study investigators. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015 Dec;2(12):e516-27. Epub 2015 Nov 16. link to original article dosing details in abstract have been reviewed by our editors link to PMC article PubMed
- ELOQUENT-2: Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. Epub 2015 Jun 2. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01239797
- Update: Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017 Sep;178(6):896-905. Epub 2017 Jul 5. link to original article link to PMC article PubMed
- Update: Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 Oct 15;124(20):4032-4043. Epub 2018 Sep 11. link to original article PubMed
- Update: Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špička I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu KL, Anderson KC, Jou YM, Ganetsky A, Singhal AK, Richardson PG. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020 Sep 4;10(9):91. link to original article link to PMC article PubMed
Elo-Vd
Elo-Vd: Elotuzumab, Velcade (Bortezomib), low-dose dexamethasone
EBd: Elotuzumab, Bortezomib, low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Jakubowiak et al. 2016 (CA204-009) | 2012-2013 | Randomized Phase 2 (E-esc) | Vd | Might have superior PFS (primary endpoint) (HR 0.72, 95% CI 0.49-1.06) |
Prior treatment criteria
- CA204-009: 1 to 3 prior lines of therapy
Targeted therapy
- Elotuzumab (Empliciti) as follows:
- Cycles 1 & 2: 10 mg/kg IV once per day on days 1, 8, 15
- Cycles 3 to 8: 10 mg/kg IV once per day on days 1 & 11
- Cycle 9 onwards: 10 mg/kg IV once per day on days 1 & 15
- Bortezomib (Velcade) as follows:
- Cycles 1 to 8: 1.3 mg/m2 IV or SC once per day on days 1, 4, 8, 11
- Cycle 9 onwards: 1.3 mg/m2 IV or SC once per day on days 1, 8, 15
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 & 2 by the following split schedule:
- 20 mg PO once per day on days 2, 4, 5, 9, 11, 12
- 8 mg PO once per day on days 1, 8, 15, given 3 to 24 hours prior to elotuzumab
- 8 mg IV once per day on days 1, 8, 15, given 45 minutes prior to elotuzumab
- Cycles 3 to 8 by the following split schedule:
- 20 mg PO once per day on days 2, 4, 5, 8, 9, 12
- 8 mg PO once per day on days 1 & 11, given 3 to 24 hours prior to elotuzumab
- 8 mg IV once per day on days 1 & 11, given 45 minutes prior to elotuzumab
- Cycle 9 onwards by the following split schedule:
- 20 mg PO once per day on days 2, 8, 9, 16
- 8 mg PO once per day on days 1 & 15, given 3 to 24 hours prior to elotuzumab
- 8 mg IV once per day on days 1 & 15, given 45 minutes prior to elotuzumab
- Cycles 1 & 2 by the following split schedule:
Supportive therapy
- Diphenhydramine (Benadryl) 25 to 50 mg (route not specified) once per infusion, 30 to 90 minutes prior to elotuzumab
- Ranitidine (Zantac) 50 mg (route not specified) once per infusion, 30 to 90 minutes prior to elotuzumab
- Acetaminophen (Tylenol) 650 to 1000 mg PO once per infusion, 30 to 90 minutes prior to elotuzumab
21-day cycle for 8 cycles, then 28-day cycles
References
- CA204-009: Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 Jun 9;127(23):2833-40. Epub 2016 Apr 18. link to original article dosing details in supplement have been reviewed by our editors link to PMC article PubMed NCT01478048
FRD
FRD: Farydak (Panobinostat), Revlimid (Lenalidomide), Dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Chari et al. 2017 (GCO 12-0469) | 2012 to not reported | Phase 2 |
Targeted therapy
- Panobinostat (Farydak) 20 mg PO once per day on days 1, 3, 5, 15, 17, 19
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15
28-day cycles
References
- GCO 12-0469: Chari A, Cho HJ, Dhadwal A, Morgan G, La L, Zarychta K, Catamero D, Florendo E, Stevens N, Verina D, Chan E, Leshchenko V, Laganà A, Perumal D, Mei AH, Tung K, Fukui J, Jagannath S, Parekh S. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 2017 Aug 21;1(19):1575-1583. eCollection 2017 Aug 22. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01651039
IRd
IRd: Ixazomib, Revlimid (Lenalidomide), low-dose dexamethasone
Regimen variant #1
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Moreau et al. 2016 (TOURMALINE-MM1) | 2012-2014 | Phase 3 (E-RT-esc) | Rd | Superior PFS (primary endpoint) Median PFS: 20.6 vs 14.7 mo (HR 0.74, 95% CI 0.59-0.94) |
Hou et al. 2017 (TOURMALINE-MM1 China Continuation) | 2014-05-08 to 2015-05-08 | Phase 3 (E-esc) | Rd | Superior OS (secondary endpoint) Median OS: 25.8 vs 15.8 mo (HR 0.42, 95% CI 0.24-0.73) Seems to have superior PFS (primary endpoint) Median PFS: 6.7 vs 4 mo (HR 0.60, 95% CI 0.37-0.97) |
Prior treatment criteria
- TOURMALINE-MM1 & TOURMALINE-MM1 China Continuation: 1 to 3 prior lines of therapy
Targeted therapy
- Ixazomib (Ninlaro) 4 mg PO once per day on days 1, 8, 15, taken at least one hour before or at least two hours after food
- Lenalidomide (Revlimid) by the following renal function-based criteria:
- Normal renal function: 25 mg PO once per day on days 1 to 21
- CrCl 60 mL/min/1.73 m2 or less OR 50 mL/min/1.73 m2 or less (depends on local practice): 10 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
Supportive therapy
- Thromboprophylaxis required
28-day cycles
Regimen variant #2
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Rodriguez-Otero et al. 2023 (KarMMa-3) | 2019-05 to 2022-04 | Phase 3 (C) | Ide-cel | Inferior PFS |
Targeted therapy
- Ixazomib (Ninlaro) 4 mg PO once per day on days 1, 8, 15
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 to 40 mg (route not specified) once per day on days 1, 8, 15, 22
28-day cycles
References
- TOURMALINE-MM1: Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Apr 28;374(17):1621-1634. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01564537
- Subgroup analysis: Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017 Dec 14;130(24):2610-2618. Epub 2017 Oct 20. link to original article PubMed
- Update: Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Gimsing P, Garderet L, Touzeau C, Buadi FK, Laubach JP, Cavo M, Darif M, Labotka R, Berg D, Moreau P. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021 Aug 1;39(22):2430-2442. Epub 2021 Jun 11. link to original article PubMed
- TOURMALINE-MM1 China Continuation: Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, Lu J, Du X, Chen X, Li J, Liu J, Gupta N, Hanley MJ, Li H, Hua Z, Wang B, Zhang X, Wang H, van de Velde H, Richardson PG, Moreau P. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J Hematol Oncol. 2017 Jul 6;10(1):137. link to original article link to PMC article dosing details in abstract have been reviewed by our editors PubMed NCT01564537
- KarMMa-3: Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10. link to original article dosing details in supplement have been reviewed by our editors PubMed NCT03651128
- PRO analysis: Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar;11(3):e216-e227. link to original article PubMed
Isa-Kd
Isa-Kd: Isatuximab, Kyprolis (Carfilzomib), low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Moreau et al. 2021 (IKEMA) | 2017-11-15 to 2019-03-21 | Phase 3 (E-RT-esc) | Kd | Superior PFS1 (primary endpoint) Median PFS: 35.7 vs 19.2 mo (HR 0.58, 99% CI 0.42-0.79) |
1Reported efficacy is based on the 2023 update.
Prior treatment criteria
- 1 to 3 prior lines of therapy
Targeted therapy
- Isatuximab (Sarclisa) given second as follows:
- Cycle 1: 10 mg/kg IV once per day on days 1, 8, 15, 22
- Cycle 2 onwards: 10 mg/kg IV once per day on days 1 & 15
- Carfilzomib (Kyprolis) given third as follows:
- Cycle 1: 20 mg/m2 IV once per day on days 1 & 2, then 56 mg/m2 IV once per day on days 8, 9, 15, 16
- Cycle 2 onwards: 56 mg/m2 IV once per day on days 1, 2, 8, 9, 15, 16
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg PO or IV once per day on days 1, 2, 8, 9, 15, 16, 22, 23, given first
28-day cycles
References
- IKEMA: Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 Jun 19;397(10292):2361-2371. Epub 2021 Jun 4. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03275285
- Update: Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023 May 9;13(1):72. Erratum in: Blood Cancer J. 2023 Sep 27;13(1):152. link to original article link to PMC article PubMed
Isa-Pd
Isa-Pd: Isatuximab, Pomalidomide, low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Attal et al. 2019 (ICARIA-MM) | 2017-01-10 to 2018-02-02 | Phase 3 (E-RT-esc) | Pd | Might have superior OS1 (secondary endpoint) Median OS: 24.6 vs 17.7 mo (HR 0.78, 95% CI 0.59-1.02) Superior PFS (primary endpoint) Median PFS: 11.5 vs 6.5 mo (HR 0.60, 95% CI 0.44-0.81) |
1Reported efficacy is based on the 2024 update.
Prior treatment criteria
- ICARIA-MM: At least 2 prior lines of therapy including lenalidomide and a proteasome inhibitor
Targeted therapy
- Isatuximab (Sarclisa) as follows:
- Cycle 1: 10 mg/kg IV once per day on days 1, 8, 15, 22
- Cycle 2 onwards: 10 mg/kg IV once per day on days 1 & 15
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) by the following age-based criteria:
- 75 years old or younger: 40 mg PO once per day on days 1, 8, 15, 22
- Older than 75 years old: 20 mg PO once per day on days 1, 8, 15, 22
Supportive therapy
28-day cycles
References
- ICARIA-MM: Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107. Epub 2019 Nov 14. Erratum in: Lancet. 2019 Dec 7;394(10214):2072. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02990338
- Update: Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 Mar;23(3):416-427. Epub 2022 Feb 10. link to original article PubMed
- Update: Richardson PG, Perrot A, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Macé S, Zhang R, Dubin F, Morisse MC, Anderson KC. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica. 2024 Jul 1;109(7):2239-2249. link to original article link to PMC article PubMed
- EFC15951: NCT05405166
KPD
KPD: Kyprolis (Carfilzomib), Pomalidomide, Dexamethasone
CPD: Carfilzomib, Pomalidomide, Dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Shah et al. 2015 (PO-MM-PI-0034) | 2011 to not reported | Phase 1 |
Note: although this is described as a Phase 1 trial, an additional 20 patients were enrolled at the MTD, which is the dose reported here.
Targeted therapy
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV over 30 minutes once per day on days 1 & 2, then 27 mg/m2 IV over 30 minutes once per day on days 8, 9, 15, 16
- Cycles 2 to 6: 27 mg/m2 IV over 30 minutes once per day on days 1, 2, 8, 9, 15, 16
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 4: 40 mg IV or PO once per day on days 1, 8, 15, 22
- Cycles 5 to 6: 20 mg IV or PO once per day on days 1, 8, 15, 22
Supportive therapy
- "Anti-viral therapy"
- Aspirin 81 mg PO once per day
- Low molecular weight heparin was used in patients intolerant of aspirin
28-day cycle for 6 cycles
Subsequent treatment
- KPD maintenance
References
- PO-MM-PI-0034: Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284-90. Epub 2015 Sep 17. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01464034
KRd
KRd: Kyprolis (Carfilzomib), Revlimid (Lenalidomide), low-dose dexamethasone
CRd: Carfilzomib, Revlimid (Lenalidomide), low-dose dexamethasone
Regimen variant #1, bi-weekly carfilzomib
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Wang et al. 2013 (PX-171-006) | 2008-2010 | Phase 2 | |||
Stewart et al. 2014 (ASPIRE) | 2010-2012 | Phase 3 (E-RT-esc) | Rd | Superior PFS (primary endpoint) Median PFS: 26.3 vs 17.6 mo (HR 0.69, 95% CI 0.57-0.83) Superior OS1 (secondary endpoint) (HR 0.79, 95% CI 0.67-0.95) |
Superior GHS/QoL |
1Reported efficacy for ASPIRE is based on the 2018 update.
Note: In PX-171-006, patients with at least SD after 4 cycles received up to 12 cycles; patients with at least SD after 12 cycles received up to 18 cycles.
Prior treatment criteria
- ASPIRE: 1 to 3 prior lines of therapy
Targeted therapy
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV over 10 minutes once per day on days 1 & 2, then 27 mg/m2 IV over 10 minutes once per day on days 8, 9, 15, 16
- Cycles 2 to 12: 27 mg/m2 IV over 10 minutes once per day on days 1, 2, 8, 9, 15, 16
- Cycles 13 to 18: 27 mg/m2 IV over 10 minutes once per day on days 1, 2, 15, 16
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
Supportive therapy
- Valacyclovir (Valtrex) (dose not specified) or equivalent antiviral while taking Lenalidomide (Revlimid)
- Aspirin (dose not specified) or other anticoagulant or antiplatelet medication such as Clopidogrel (Plavix), low-molecular-weight heparin or Warfarin (Coumadin) while taking Lenalidomide (Revlimid)
- Bisphosphonates while taking Dexamethasone (Decadron)
- Lansoprazole (Prevacid) (dose not specified) or other proton pump inhibitor while taking Dexamethasone (Decadron)
- A prophylactic antibiotic (Ciprofloxacin (Cipro), Amoxicillin, Trimethoprim-Sulfamethoxazole (Bactrim DS) are given as examples)
28-day cycle for 18 cycles
Subsequent treatment
- ASPIRE, no progression: Rd maintenance
Regimen variant #2, weekly carfilzomib
Study | Dates of enrollment | Evidence |
---|---|---|
Biran et al. 2019 (CFZ013) | 2015-2016 | Phase 1b |
Note: this is the dose that is being explored in phase 3 studies.
Targeted therapy
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV once on day 1, then 56 mg/m2 IV once per day on days 8 & 15
- Cycles 2 to 18: 56 mg/m2 IV once per day on days 1, 8, 15
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 8: 40 mg PO once per day on days 1, 8, 15, 22
- Cycles 9 to 18: 40 mg PO once per day on days 1, 8, 15
28-day cycle for up to 18 cycles
References
- PX-171-006: Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31;122(18):3122-8. Epub 2013 Sep 6. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00603447
- ASPIRE: Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. Epub 2014 Dec 6. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01080391
- Subgroup analysis: Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80. Epub 2016 Jul 20. link to original article link to PMC article PubMed
- HRQoL analysis: Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016 Nov 10;34(32):3921-3930. link to original article link to PMC article PubMed
- Update: Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018 Mar 10;36(8):728-734. Epub 2018 Jan 17. link to original article PubMed
- CFZ013: Biran N, Siegel D, Berdeja JG, Raje N, Cornell RF, Alsina M, Kovacsovics T, Fang B, Kimball AS, Landgren O. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a phase 1b study. Am J Hematol. 2019 Jul;94(7):794-802. Epub 2019 May 13. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02335983
PAD
PAD: PS-341 (Bortezomib), Adriamycin (Doxorubicin), Dexamethasone
Note that this regimen is sometimes called VAD but this can create a lot of confusion with the "original" VAD which uses Vincristine.
VAD: Velcade (Bortezomib), Adriamycin (Doxorubicin), Dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Cook et al. 2014 (NCRI Myeloma X Relapse) | 2008-2012 | Non-randomized part of phase 3 RCT |
Note: length of cycle is not reported in the manuscript, but presumably is 28 days, similar to other PAD regimens.
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV once per day on days 1, 4, 8, 11
Chemotherapy
- Doxorubicin (Adriamycin) 9 mg/m2 IV once per day on days 1 to 4
- Could be given as a 4-day continuous infusion or as bolus injections
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycle 1: 40 mg PO once per day on days 1 to 4, 8 to 11, 15 to 18
- Cycles 2 to 4: 40 mg PO once per day on days 1 to 4
28-day cycle for 2 to 4 cycles
Subsequent treatment
- High-dose melphalan & autologous hematopoietic cell transplant consolidation versus weekly oral cyclophosphamide maintenance
References
- NCRI Myeloma X Relapse: Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jul;15(8):874-85. Epub 2014 Jun 16. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Dosage error in article text. link to original article PubMed NCT00747877
- Update: Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016 Jul;3(7):e340-51. link to original article dosing details in abstract have been reviewed by our editors PubMed
- Subgroup analysis: Cook G, Royle KL, O'Connor S, Cairns DA, Ashcroft AJ, Williams CD, Hockaday A, Cavenagh JD, Snowden JA, Ademokun D, Tholouli E, Andrews VE, Jenner M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Drayson MT, Brown JM, Morris TCM; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Br J Haematol. 2019 May;185(3):450-467. Epub 2019 Feb 6. link to original article link to PMC article PubMed
PCD
PCD: Pomalidomide, Cyclophosphamide, Dexamethasone
PomCyDex: Pomalidomide, Cyclophosphamide, Dexamethasone
Regimen variant #1, 4/300/40
Study | Dates of enrollment | Evidence |
---|---|---|
Garderet et al. 2018 (IC 2013-05) | 2014-2017 | Phase 2 |
Targeted therapy
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 21
Chemotherapy
- Cyclophosphamide (Cytoxan) 300 mg PO once per day on days 1, 8, 15, 22
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 4: 40 mg PO once per day on days 1 to 4, 15 to 18
- Cycles 5 to 9: 40 mg PO once per day on days 1, 8, 15, 22
28-day cycle for 4 to 9 cycles, depending on plan for transplant
Subsequent treatment
- Pd maintenance
Regimen variant #2, 4/400/40
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Baz et al. 2016 (PO-MM-PI-0039) | 2011-2014 | Randomized Phase 1/2 (E-esc) | Pd | Seems to have superior ORR (primary endpoint) |
Prior treatment criteria
- PO-MM-PI-0039: At least 2 prior lines of therapy including an immunomodulator; patients were required to be lenalidomide-refractory
Targeted therapy
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 21
Chemotherapy
- Cyclophosphamide (Cytoxan) 400 mg PO once per day on days 1, 8, 15
Glucocorticoid therapy
- Dexamethasone (Decadron) by the following age-based criteria:
- 75 years old or younger: 40 mg PO once per day on days 1, 8, 15, 22
- Older than 75 years old: 20 mg PO once per day on days 1, 8, 15, 22
Supportive therapy
- Aspirin 81 mg PO once per day unless contraindicated
28-day cycles
References
- PO-MM-PI-0039: Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May 26;127(21):2561-8. Epub 2016 Mar 1. Erratum in: Blood. 2016 Jul 21;128(3):461. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01432600
- IC 2013-05: Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, Facon T, Leleu X, Karlin L, Perrot A, Moreau P, Marit G, Stoppa AM, Royer B, Chaleteix C, Tiab M, Araujo C, Lenain P, Macro M, Voog E, Benboubker L, Allangba O, Jourdan E, Orsini-Piocelle F, Brechignac S, Eveillard JR, Belhadj K, Wetterwald M, Pegourie B, Jaccard A, Eisenmann JC, Glaisner S, Mohty M, Hulin C, Loiseau HA, Mathiot C, Attal M. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood. 2018 Dec 13;132(24):2555-2563. Epub 2018 Oct 3. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02244125
PCP
PCP: Pomalidomide, Cyclophosphamide, Prednisone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Larocca et al. 2013 (PO0023) | 2010-2012 | Phase 1/2 |
Note: Details are for the phase 2 portion of the published phase 1/2 trial.
Targeted therapy
- Pomalidomide (Pomalyst) 2.5 mg PO once per day
Chemotherapy
- Cyclophosphamide (Cytoxan) 50 mg PO once every other day
Glucocorticoid therapy
- Prednisone (Sterapred) 50 mg PO once every other day
Supportive therapy
- Aspirin 100 mg PO once per day or low-molecular-weight heparin "according to patient risk"
28-day cycle for 6 cycles
Subsequent treatment
- Pomalidomide & prednisone maintenance
References
- PO0023: Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. Pomalidomide, cyclophosphamide and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open label study. Blood. 2013 Oct 17;122(16):2799-806. Epub 2013 Aug 16. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01166113
PVD
PVD: Pomalidomide, Velcade (Bortezomib), Dexamethasone
Regimen variant #1, 21-day cycles, 75 years old and younger
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Richardson et al. 2019 (OPTIMISMM) | 2013-2017 | Phase 3 (E-esc) | Vd | Superior PFS (primary endpoint) Median PFS: 11.2 vs 7.1 mo (HR 0.61, 95% CI 0.49-0.77) |
San-Miguel et al. 2023 (CARTITUDE-4) | 2020-07-10 to 2021-11-17 | Phase 3 (C) | Cilta-cel | Inferior PFS |
Note: CARTITUDE-4 only used the SC route for bortezomib.
Prior treatment criteria
- OPTIMISMM: 1 to 3 prior lines of therapy including lenalidomide
Targeted therapy
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 14
- Bortezomib (Velcade) as follows:
- Cycles 1 to 8: 1.3 mg/m2 IV or SC once per day on days 1, 4, 8, 11
- Cycle 9 onwards: 1.3 mg/m2 IV or SC once per day on days 1 & 8
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 8: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
- Cycle 9 onwards: 20 mg PO once per day on days 1, 2, 8, 9
21-day cycles
Regimen variant #2, 21-day cycles, older than 75 years old
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Richardson et al. 2019 (OPTIMISMM) | 2013-2017 | Phase 3 (E-esc) | Vd | Superior PFS (primary endpoint) Median PFS: 11.2 vs 7.1 mo (HR 0.61, 95% CI 0.49-0.77) |
Prior treatment criteria
- 1 to 3 prior lines of therapy including lenalidomide
Targeted therapy
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 14
- Bortezomib (Velcade) as follows:
- Cycles 1 to 8: 1.3 mg/m2 IV or SC once per day on days 1, 4, 8, 11
- Cycle 9 onwards: 1.3 mg/m2 IV or SC once per day on days 1 & 8
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 8: 10 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
- Cycle 9 onwards: 10 mg PO once per day on days 1, 2, 8, 9
21-day cycles
Regimen variant #3, 28-day cycles
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Paludo et al. 2017 (MC1082) | 2012-2014 | Phase 1/2 | ORR: 86% |
Note: This is the MTD used in the phase 2 portion of the trial.
Targeted therapy
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 21
- Bortezomib (Velcade) 1.3 mg/m2 IV or SC once per day on days 1, 8, 15, 22
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
Supportive therapy
- Aspirin 325 mg PO once per day
- Full dose anticoagulation with LMWH or Warfarin (Coumadin) could be substituted at physician discretion
- Acyclovir (Zovirax) or equivalent for VZV prophylaxis
28-day cycle for 8 cycles
Subsequent treatment
- Optionally, pomalidomide maintenance
References
- MC1082: Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7;130(10):1198-1204. Epub 2017 Jul 6. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01212952
- OPTIMISMM: Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):781-794. Epub 2019 May 13. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT01734928
- CARTITUDE-4: San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023 Jul 27;389(4):335-347. Epub 2023 Jun 5. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT04181827
RVD
RVD: Revlimid (Lenalidomide), Velcade (Bortezomib), Dexamethasone
VDR: Velcade (Bortezomib), Dexamethasone, Revlimid (Lenalidomide)
VRD: Velcade (Bortezomib), Revlimid (Lenalidomide), Dexamethasone
VRd: Velcade (Bortezomib), Revlimid (Lenalidomide), low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Richardson et al. 2014 (DFCI 06-147) | 2006-2008 | Phase 2 | ORR: 64% |
Targeted therapy
- Lenalidomide (Revlimid) 15 mg PO once per day on days 1 to 14
- Bortezomib (Velcade) 1 mg/m2 IV once per day on days 1, 4, 8, 11
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 4: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
- Cycles 5 to 8: 10 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
Supportive therapy
21-day cycle for 8 cycles
Subsequent treatment
- DFCI 06-147, patients with SD or better: RVD maintenance at previously tolerated dose
References
- DFCI 06-147: Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC. A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 6;123(10):1461-9. Epub 2014 Jan 15. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00378209
SDd
SDd: Selinexor, Daratumumab, low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Gasparetto et al. 2020 (STOMP) | 2017-2019 | Phase 1/2b, >20 pts in this cohort |
Note: this is the dosing used in the expansion cohort.
Targeted therapy
- Selinexor (Xpovio) 100 mg PO once per day on days 1, 8, 15, 22
- Daratumumab (Darzalex) as follows:
- Cycles 1 & 2: 16 mg/kg IV once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 16 mg/kg IV once per day on days 1 & 15
- Cycle 7 onwards: 16 mg/kg IV once on day 1
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg IV or PO once per day on days 1, 8, 15, 22
28-day cycles
References
- STOMP: Gasparetto C, Lentsch S, Schiller G, Callander N, Tuchman S, Chen C, White D, Kotb R, Sutherland H, Sebag M, Baljevic M, Bensinger W, LeBlanc R, Venner C, Bahlis N, Rossi A, Biran N, Sheehan H, Saint Martin JR, Van Domelen D, Kai K, Shah J, Shacham S, Kauffman M, Lipe B. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. eJHaem. 2020 Nov 8;2(1):56-65. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02343042
SKd
SKd: Selinexor, Kyprolis (Carfilzomib), low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Jakubowiak et al. 2019 | 2014-2016 | Phase 1, fewer than 20 pts in this cohort |
Note: this is the RP2D cohort (2b).
Targeted therapy
- Selinexor (Xpovio) 60 mg PO once per day on days 1, 3, 8, 10, 15, 17
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV once per day on days 1 & 2, then 27 mg/m2 IV once per day on days 8, 9, 15, 16
- Cycles 2 to 8: 27 mg/m2 IV once per day on days 1, 2, 8, 9, 15, 16
- Cycle 9 onwards: 27 mg/m2 IV once per day on days 1, 2, 15, 16
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 4: 20 mg PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23
- Cycle 5 onwards: 10 mg PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23
28-day cycles
References
- Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 Aug;186(4):549-560. Epub 2019 May 24. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02199665
SVd
SVd: Selinexor, Velcade (Bortezomib), low-dose dexamethasone
XVd: Xpovio (Selinexor), Velcade (Bortezomib), low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Grosicki et al. 2020 (BOSTON) | 2017-2019 | Phase 3 (E-RT-esc) | Vd | Superior PFS (primary endpoint) Median PFS: 13.9 vs 9.5 mo (HR 0.70, 95% CI 0.53-0.93) |
Prior treatment criteria
- 1 to 3 prior lines of therapy, including proteasome inhibitors
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 SC once per day on days 1, 8, 15, 22
- Selinexor (Xpovio) 100 mg PO once per day on days 1, 8, 15, 22, 29
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23, 29, 30
35-day cycles
References
- BOSTON: Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020 Nov 14;396(10262):1563-1573. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03110562
- BENCH: NCT04939142
VDC
VDC: Velcade (Bortezomib), Dexamethasone, Cyclophosphamide
VCD: Velcade (Bortezomib), Cyclophosphamide, Dexamethasone
CyBorD: Cyclophosphamide, Bortezomib, Dexamethasone
Regimen variant #1
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kropff et al. 2017 (CR015247) | 2008-2010 | Phase 3 (E-esc) | Vd | Did not meet primary endpoint of TTP (HR 1.41, 95% CI 0.84-2.33) |
Note: Treatment details are from the CT.gov record. This is an experimental arm that did not meet its primary endpoint.
Prior treatment criteria
- 1 to 3 prior lines of therapy
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV once per day on days 1, 4, 8, 11
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
Chemotherapy
- Cyclophosphamide (Cytoxan) 50 mg PO once per day
21-day cycle for up to 8 cycles
Regimen variant #2
Study | Dates of enrollment | Evidence |
---|---|---|
de Waal et al. 2015 | 2009-2013 | Phase 2 |
Prior treatment criteria
- Bortezomib-naive
Targeted therapy
- Bortezomib (Velcade) as follows:
- Cycles 1 to 3: 1.3 mg/m2 IV or SC once per day on days 1, 4, 8, 11
- Cycles 4 to 6: 1.6 mg/m2 IV or SC once per day on days 1, 8, 15, 22
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 3: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
- Cycles 4 to 6: 20 mg PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23
Chemotherapy
- Cyclophosphamide (Cytoxan) 50 mg PO once per day
Supportive therapy
- Pneumococccal and anti-fungal prophylaxis "according to local protocols"
- Valacyclovir (Valtrex) (dose not specified) for herpes prophylaxis
21-day cycle for 3 cycles then 35-day cycle for 3 cycles
Subsequent treatment
- de Waal et al. 2015, patients with PR/CR: Bortezomib & cyclophosphamide maintenance
Regimen variant #3
Study | Dates of enrollment | Evidence |
---|---|---|
Kropff et al. 2007 | 2004-2005 | Phase 2 |
Prior treatment criteria
- Bortezomib-naive
Targeted therapy
- Bortezomib (Velcade) as follows:
- Cycles 1 to 3: 1.3 mg/m2 IV once per day on days 1, 4, 8, 11
- Cycles 4 to 6: 1.3 mg/m2 IV once per day on days 1, 8, 15, 22
Chemotherapy
- Cyclophosphamide (Cytoxan) 50 mg PO once per day
Glucocorticoid therapy
- Dexamethasone (Decadron) as follows:
- Cycles 1 to 3: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
- Cycles 4 to 6: 20 mg PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23
21-day cycle for 3 cycles then 35-day cycle for 3 cycles
References
- Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf HH, Einsele H, Volpert S, Heinecke A, Berdel WE, Kienast J; Deutsche Studiengruppe Multiples Myelom,. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007 Aug;138(3):330-7. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- de Waal EG, de Munck L, Hoogendoorn M, Woolthuis G, van der Velden A, Tromp Y, Vellenga E, Hovenga S. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. Br J Haematol. 2015 Dec;171(5):720-5. Epub 2015 Sep 11. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- CR015247: Kropff M, Vogel M, Bisping G, Schlag R, Weide R, Knauf W, Fiechtner H, Kojouharoff G, Kremers S, Berdel WE. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Ann Hematol. 2017 Nov;96(11):1857-1866. Epub 2017 Sep 14. link to original article PubMed NCT00813150
VTD
VTD: Velcade (Bortezomib), Thalidomide, Dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Garderet et al. 2012 (MMVAR/IFM 2005-04) | 2006-2010 | Phase 3 (E-esc) | TD | Superior TTP (primary endpoint) Median TTP: 19.5 vs 13.8 mo (HR 0.59, 95% CI 0.44-0.80) |
Prior treatment criteria
- At least 1 autologous stem-cell transplant
Targeted therapy
- Bortezomib (Velcade) as follows:
- Cycles 1 to 8: 1.3 mg/m2 IV bolus once per day on days 1, 4, 8, 11
- Cycles 9 to 12: 1.3 mg/m2 IV bolus once per day on days 1, 8, 15, 22
- Thalidomide (Thalomid) 200 mg PO once per day
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
Supportive therapy
- Primary prophylaxis: Enoxaparin (Lovenox) 40 mg SC once per day
- Secondary prophylaxis: Warfarin (Coumadin)
- Herpes zoster prophylaxis highly recommended
21-day cycle for 8 cycles, then 42-day cycle for 4 cycles (1 year)
References
- MMVAR/IFM 2005-04: Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012 Jul 10;30(20):2475-82. Epub 2012 May 14. Erratum in: J Clin Oncol. 2012 Sep 20;30(27):3429. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00256776
Ven-Kd
Ven-Kd: Venetoclax, Kyprolis (Carfilzomib), low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Costa et al. 2021 (M15-538) | 2017-02 to 2019-02 | Phase 2 |
Note: this was the dosing used in the dose expansion cohort.
Targeted therapy
- Venetoclax (Venclexta) 800 mg PO once per day on days 1 to 28
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV over 30 minutes once on day 1, then 70 mg/m2 IV over 30 minutes once per day on days 8 & 15
- Cycle 2 onwards: 70 mg/m2 IV over 30 minutes once per day on days 1, 8, 15
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
28-day cycles
References
- M15-538: Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A, Kaufman JL, Hong WJ, Dail M, Salem AH, Yang X, Masud AA, Munasinghe W, Ross JA, Bueno OF, Kumar SK, Stadtmauer EA. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv. 2021 Oct 12;5(19):3748-3759. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02899052
ZRd
ZRd: Zolinza (Vorinostat), Revlimid (Lenalidomide), low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Sanchez et al. 2016 (PRO-2580) | 2012-2014 | Phase 2b |
Targeted therapy
- Vorinostat (Zolinza) 400 mg PO once per day on days 1 to 7, 15 to 21
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
28-day cycles
References
- PRO-2580: Sanchez L, Vesole DH, Richter JR, Biran N, Bilotti E, McBride L, Anand P, Ivanovski K, Siegel DS. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. Br J Haematol. 2017 Feb;176(3):440-447. Epub 2016 Nov 18. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT01502085
Relapsed or refractory, other combinations
Bortezomib, Thalidomide, Dexamethasone, Panobinostat
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Popat et al. 2016 (MUK-six) | 2013-2014 | Phase 1/2 |
Note: this is the dose used in the phase 2 portion of the trial.
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 SC once per day on days 1 & 8
- Thalidomide (Thalomid) 100 mg PO once per day
- Panobinostat (Farydak) 20 mg PO once per day on days 1, 3, 5, 8, 10, 12
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg PO once per day on days 1, 2, 8, 9
21-day cycle for 16 cycles
References
- MUK-six: Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network.. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Lancet Haematol. 2016 Dec;3(12):e572-e580. Epub 2016 Nov 12. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02145715
DCEP
DCEP: Dexamethasone, Cyclophosphamide, Etoposide, Platinol (Cisplatin)
Regimen variant #1
Study | Dates of enrollment | Evidence |
---|---|---|
Lazzarino et al. 2001 | 2000-2001 | Phase 2 |
Note: this protocol is reported as a mobilization regimen prior to high dose autologous transplant; all patients had received prior therapy.
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
Chemotherapy
- Cyclophosphamide (Cytoxan) 400 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose: 1600 mg/m2)
- Etoposide (Vepesid) 40 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose: 160 mg/m2)
- Cisplatin (Platinol) 10 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose: 40 mg/m2)
Supportive therapy
- Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting 48 hours after chemotherapy and continuing through stem cell collection
One course
Regimen variant #2
Study | Dates of enrollment | Evidence |
---|---|---|
Dadacaridou et al. 2007 | Not reported in abstract | Phase 2, fewer than 20 patients reported |
Note: These limited details are based on the abstract's description only. Full article was not available for review.
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg IV bolus once per day on days 1 to 4
Chemotherapy
- Cyclophosphamide (Cytoxan) 400 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1600 mg/m2)
- Etoposide (Vepesid) 40 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 160 mg/m2)
- Cisplatin (Platinol) 15 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 60 mg/m2)
Supportive therapy
- G-CSF SC once per day, starting on day 5, to continue until neutrophil recovery
28-day cycles
References
- Lazzarino M, Corso A, Barbarano L, Alessandrino EP, Cairoli R, Pinotti G, Ucci G, Uziel L, Rodeghiero F, Fava S, Ferrari D, Fiumanò M, Frigerio G, Isa L, Luraschi A, Montanara S, Morandi S, Perego D, Santagostino A, Savarè M, Vismara A, Morra E. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant. 2001 Nov;28(9):835-9. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Mitsouli-Mentzikof C. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON. 2007 Jan-Mar;12(1):41 to 4. PubMed
DTPACE
DTPACE: Dexamethasone, Thalidomide, Platinol (Cisplatin), Adriamycin (Doxorubicin), Cyclophosphamide, Etoposide
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Lee et al. 2003 (UARK-98035) | 1998-2001 | Prospective |
Targeted therapy
- Thalidomide (Thalomid) 400 mg PO once per day, taken at night
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
Chemotherapy
- Cisplatin (Platinol) 10 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m2)
- Doxorubicin (Adriamycin) 10 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m2)
- Cyclophosphamide (Cytoxan) 400 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1600 mg/m2)
- Etoposide (Vepesid) 40 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 160 mg/m2)
Supportive therapy
- Filgrastim (Neupogen) 300 mcg SC once per day from day 5 until ANC greater than 1000/ul for two consecutive days
- Levofloxacin (Levaquin) 250 mg PO once per day from day 1 until ANC greater than 1000/ul for two consecutive days
- Fluconazole (Diflucan) 200 mg PO once per day from day 1 until ANC greater than 1000/ul for two consecutive days
- Acyclovir (Zovirax) 400 mg PO twice per day from day 1 until ANC greater than 1000/ul for two consecutive days
- Trimethoprim-Sulfamethoxazole (Bactrim DS) 800/160 mg PO twice per day twice per week
4- to 6-week cycles
References
- UARK-98035: Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003 Jul 15;21(14):2732-9. Erratum in: J Clin Oncol. 2008 Apr 20;26(12): 2066. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Hyper-CVAD
Hyper-CVAD: Hyperfractionated Cyclophosphamide, Vincristine, Adriamycin (Doxorubicin), Dexamethasone
Regimen variant #1
Study | Dates of enrollment | Evidence |
---|---|---|
Dimopoulos et al. 1996 | Not reported | Phase 2 |
Chemotherapy
- Cyclophosphamide (Cytoxan) 300 mg/m2 IV over 3 hours every 12 hours on days 1 to 3 (total dose per cycle: 1800 mg/m2)
- Vincristine (Oncovin) 1 mg/day IV continuous infusion over 48 hours, started on day 4, 12 hours after last dose of cyclophosphamide, then 2 mg IV once on day 11
- Doxorubicin (Adriamycin) 25 mg/m2/day IV continuous infusion over 48 hours, started on day 4, 12 hours after last dose of cyclophosphamide (total dose per cycle: 50 mg/m2)
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg/m2 PO once per day on days 1 to 5, 11 to 14
Supportive therapy
- Mesna (Mesnex) 600 mg/m2/day IV continuous infusion over 72 hours, started on day 1 (total dose per cycle: 1800 mg/m2)
- Filgrastim (Neupogen) 5 mcg/kg SC once per day from day 6 until WBC count more than 2000/μL for 2 consecutive days
- Ciprofloxacin (Cipro) 500 mg PO twice per day on days 8 to 18
- Fluconazole (Diflucan) 100 mg PO once per day on days 8 to 18
- Acyclovir (Zovirax) 200 mg PO three times per day on days 8 to 18
Up to 2 cycles (length not specified)
Subsequent treatment
- Dimopoulos et al. 1996, responding patients: Cyclophosphamide & Dexamethasone maintenance
Regimen variant #2, modified
Study | Dates of enrollment | Evidence |
---|---|---|
Saraceni et al. 2017 | 2011-11 to 2015-09 | Retrospective |
Note: vincristine is a flat dose.
Chemotherapy
- Cyclophosphamide (Cytoxan) 300 mg/m2 IV every 12 hours on days 1 to 4 (total dose per cycle: 2400 mg/m2)
- Vincristine (Oncovin) 0.4 mg/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1.6 mg)
- Doxorubicin (Adriamycin) 9 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 36 mg/m2)
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
Supportive therapy
- Pegfilgrastim (Neulasta) 6 mg SC once on day 5 or 6
- Mesna (Mesnex) 350 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1400 mg/m2)
- Antiviral prophylaxis with Valacyclovir (Valtrex) daily (dose not specified)
- "Most patients also received antifungal, antibacterial, and Pneumocysitc jiroveci pneumonia prophylaxis"
Duration of each cycle not specified; for most patients, treatment cycles were administered every 4 weeks
References
- Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol. 1996 Jun;52(2):77-81. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Retrospective: Saraceni MM, Scott E, Maziarz RT, Siegel MB, Bassale S, Jiing S, Medvedova E. Modified hyperCVAD versus bortezomib-hyperCAD in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e77-e84. Epub 2017 Nov 2. link to original article dosing details in manuscript have been reviewed by our editors PubMed
KD-PACE
KD-PACE: Kyprolis (Carfilzomib), Dexamethasone, Platinol (Cisplatin), Adriamycin (Doxorubicin), Cyclophosphamide, Etoposide (Toposar)
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Alsouqi et al. 2021 | 2015-09 to 2018-09 | Retrospective |
Targeted therapy
- Carfilzomib (Kyprolis) as follows:
- Cycle 1: 20 mg/m2 IV once per day on days 1 & 2, then 27 mg/m2 once per day on days 8 & 9
- Cycle 2 onwards: 27 mg/m2 once per day on days 1, 2, 8, 9
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
Chemotherapy
- Cisplatin (Platinol) 10 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m2)
- Doxorubicin (Adriamycin) 10 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m2)
- Cyclophosphamide (Cytoxan) 400 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1600 mg/m2)
- Etoposide (Vepesid) 40 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 160 mg/m2)
28- to 42-day cycles
References
- Retrospective: Alsouqi A, Khan M, Dhakal B, Du L, Harrell S, Hari P, Cornell RF. KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):526-535. Epub 2021 Apr 6. link to original article dosing details in manuscript have been reviewed by our editors PubMed
KRD-PACE
KRD-PACE: Kyprolis (Carfilzomib), Revlimid (Lenalidomide), Dexamethasone, Platinol (Cisplatin), Adriamycin (Doxorubicin), Cyclophosphamide, Etoposide
Regimen variant #1
Study | Dates of enrollment | Evidence |
---|---|---|
Cowan et al. 2020 | 2015-09 to 2019-02 | Retrospective |
Note: PACE was administered as a continuous infusion.
Targeted therapy
- Carfilzomib (Kyprolis) 20 mg/m2 IV once per day on days 1, 2, 8, 9
- Lenalidomide (Revlimid) 10 to 25 mg PO once per day on days 1 to 4
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
Chemotherapy
- Cisplatin (Platinol) 10 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m2)
- Doxorubicin (Adriamycin) 10 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m2)
- Cyclophosphamide (Cytoxan) 400 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1600 mg/m2)
- Etoposide (Vepesid) 40 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 160 mg/m2)
Regimen variant #2, modified
Study | Dates of enrollment | Evidence |
---|---|---|
Cowan et al. 2020 | 2015-09 to 2019-02 | Retrospective |
Note: PACE was administered as a continuous infusion.
Targeted therapy
- Carfilzomib (Kyprolis) 20 mg/m2 IV once per day on days 1, 5, 6
- Lenalidomide (Revlimid) 10 to 25 mg PO once per day on days 5 to 8
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 5 to 8
Chemotherapy
- Cisplatin (Platinol) 10 mg/m2/day IV continuous infusion over 96 hours, started on day 5 (total dose per cycle: 40 mg/m2)
- Doxorubicin (Adriamycin) 10 mg/m2/day IV continuous infusion over 96 hours, started on day 5 (total dose per cycle: 40 mg/m2)
- Cyclophosphamide (Cytoxan) 400 mg/m2/day IV continuous infusion over 96 hours, started on day 5 (total dose per cycle: 1600 mg/m2)
- Etoposide (Vepesid) 40 mg/m2/day IV continuous infusion over 96 hours, started on day 5 (total dose per cycle: 160 mg/m2)
Supportive therapy
- Filgrastim (Neupogen) 10 mcg/kg per day S.C. was begun on day 10. Note that this regimen was used to mobilize autologous peripheral blood stem cells in the context of this manuscript.
- Antiviral prophylaxis with Valacyclovir (Valtrex) daily (dose not specified)
- "Most patients also received antifungal, antibacterial, and Pneumocysitc jiroveci pneumonia prophylaxis"
- All patients received anticoagulation therapy; individuals not receiving systemic therapeutic anticoagulation for another reason received enoxaparin 40 mg per day subcutaneously for DVT prophylaxis during chemotherapy
Duration of each cycle not specified; for most patients, treatment cycles were administered every 4 weeks
References
- Retrospective: Cowan AJ, Green DJ, Karami M, Becker PS, Tuazon S, Coffey DG, Hyun TS, Libby EN, Gopal AK, Holmberg LA. KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):602-609. Epub 2020 Apr 14. link to original article dosing details in manuscript have been reviewed by our editors PubMed
V-HyperCAD
V-HyperCAD: Velcade (Bortezomib), Hyperfractionated Cyclophosphamide, Adriamycin (Doxorubicin), Dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Saraceni et al. 2017 | 2011-11 to 2015-09 | Retrospective |
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 SC once per day on days 1 & 4
Chemotherapy
- Cyclophosphamide (Cytoxan) 300 mg/m2 IV every 12 hours on days 1 to 4 (total dose per cycle: 2400 mg/m2)
- Doxorubicin (Adriamycin) 9 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 36 mg/m2)
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
Supportive therapy
- Pegfilgrastim (Neulasta) 6 mg SC once on day 5 or 6
- Mesna (Mesnex) 350 mg/m2/day IV continuous infusion over 96 hours, started on day 1
- Antiviral prophylaxis with Acyclovir (Zovirax) daily (dose not specified)
- "Most patients also received antifungal, antibacterial, and Pneumocysitc jiroveci pneumonia prophylaxis"
Duration of each cycle not specified; for most patients, treatment cycles were administered every 4 weeks
References
- Retrospective: Saraceni MM, Scott E, Maziarz RT, Siegel MB, Bassale S, Jiing S, Medvedova E. Modified hyperCVAD versus bortezomib-hyperCAD in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e77-e84. Epub 2017 Nov 2. link to original article dosing details in manuscript have been reviewed by our editors PubMed
VMPT
VMPT: Velcade (Bortezomib), Melphalan, Prednisone, Thalidomide
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Palumbo et al. 2007 | 2004-2005 | Phase 1/2 |
Note: This is the MTD dosing of this phase 1/2 trial.
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV bolus once per day on days 1, 4, 15, 22
- Thalidomide (Thalomid) 50 mg PO once per day on days 1 to 35
Chemotherapy
- Melphalan (Alkeran) 6 mg/m2 PO once per day on days 1 to 5
Glucocorticoid therapy
- Prednisone (Sterapred) 60 mg/m2 PO once per day on days 1 to 5
35-day cycle for 6 cycles
References
- Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, Cangialosi C, Caravita T, Morabito F, Musto P, Bringhen S, Falco P, Avonto I, Cavallo F, Boccadoro M; Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007 Apr 1;109(7):2767-72. link to original article dosing details in abstract have been reviewed by our editors PubMed
Consolidation after second-line therapy
Bortezomib monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Richardson et al. 2005 (APEX) | 2002-06 to 2003-10 | Phase 3 (E-RT-switch-ooc) | High-dose dexamethasone | Seems to have superior OS1 (secondary endpoint) (HR 0.77) Superior TTP (primary endpoint) Median TTP: 6.22 vs 3.49 mo (HR 0.55) |
1Reported efficacy for APEX is based on the 2007 update.
Preceding treatment
- Bortezomib induction
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV once per day on days 1, 8, 15, 22
Supportive therapy
- Bisphosphonate IV therapy once every 3 to 4 weeks unless contraindicated
35-day cycle for 3 cycles
References
- APEX: Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16;352(24):2487-98. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00048230
- Pooled subgroup analysis: Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007 Jan;21(1):151-7. Epub 2006 Nov 9. link to original article PubMed
- Update: Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov 15;110(10):3557-60. Epub 2007 Aug 9. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Melphalan monotherapy, then auto HSCT
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cook et al. 2014 (NCRI Myeloma X Relapse) | 2008-2012 | Phase 3 (E-esc) | Cyclophosphamide | Seems to have superior OS1 (secondary endpoint) (HR 0.56, 95% CI 0.35-0.90) Superior TTP (primary endpoint) Median TTP: 19 vs 11 mo (HR 0.36, 95% CI 0.25-0.53) |
1Reported efficacy is based on the 2016 update.
Preceding treatment
- Salvage PAD x 4
References
- NCRI Myeloma X Relapse: Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jul;15(8):874-85. Epub 2014 Jun 16. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Dosage error in article text. link to original article PubMed NCT00747877
- Update: Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016 Jul;3(7):e340-51. link to original article dosing details in abstract have been reviewed by our editors PubMed
- Subgroup analysis: Cook G, Royle KL, O'Connor S, Cairns DA, Ashcroft AJ, Williams CD, Hockaday A, Cavenagh JD, Snowden JA, Ademokun D, Tholouli E, Andrews VE, Jenner M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Drayson MT, Brown JM, Morris TCM; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Br J Haematol. 2019 May;185(3):450-467. Epub 2019 Feb 6. link to original article link to PMC article PubMed
Maintenance after second-line therapy
Bortezomib & Cyclophosphamide
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
de Waal et al. 2015 | 2009-2013 | Phase 2 |
Preceding treatment
- Salvage VDC x 6
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV or SC once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 50 mg PO once per day
Supportive therapy
- Pneumococccal and anti-fungal prophylaxis "according to local protocols"
- Valacyclovir (Valtrex) (dose not specified) for herpes prophylaxis
14-day cycle for up to 26 cycles (1 year)
References
- de Waal EG, de Munck L, Hoogendoorn M, Woolthuis G, van der Velden A, Tromp Y, Vellenga E, Hovenga S. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. Br J Haematol. 2015 Dec;171(5):720-5. Epub 2015 Sep 11. link to original article dosing details in manuscript have been reviewed by our editors PubMed
KPD
KPD: Kyprolis (Carfilzomib), Pomalidomide, Dexamethasone
CPD: Carfilzomib, Pomalidomide, Dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Shah et al. 2015 (PO-MM-PI-0034) | 2011 to not reported | Phase 1 |
Note, although this is described as a Phase 1 trial, an additional 20 patients were enrolled at the MTD, which is the dose reported here.
Preceding treatment
- Salvage KPD x 6
Targeted therapy
- Carfilzomib (Kyprolis) 27 mg/m2 IV over 30 minutes once per day on days 1, 2, 15, 16
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg IV or PO once per day on days 1, 8, 15, 22
Supportive therapy
- "Anti-viral therapy"
- Aspirin 81 mg PO once per day
- Low molecular weight heparin was used in patients intolerant of aspirin
28-day cycles
References
- PO-MM-PI-0034: Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284-90. Epub 2015 Sep 17. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01464034
Pomalidomide monotherapy
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Paludo et al. 2017 (MC1082) | 2012-2014 | Phase 1/2 | ORR: 86% |
Preceding treatment
- Salvage PVD x 8
Targeted therapy
- Pomalidomide (Pomalyst) 4 mg PO once per day on days 1 to 21
Supportive therapy
- Aspirin 325 mg PO once per day
- Full dose anticoagulation with LMWH or Warfarin (Coumadin) could be substituted at physician discretion
- Acyclovir (Zovirax) or equivalent for VZV prophylaxis
28-day cycles
References
- MC1082: Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7;130(10):1198-1204. Epub 2017 Jul 6. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01212952
Pomalidomide & Prednisone
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Larocca et al. 2013 (PO0023) | 2010-2012 | Phase 1/2 | ORR: 51% |
Details are for the phase 2 portion of the published phase 1/2 trial.
Preceding treatment
- Salvage PCP x 6
Targeted therapy
- Pomalidomide (Pomalyst) 1 mg PO once per day
Glucocorticoid therapy
- Prednisone (Sterapred) 25 mg PO once every other day
Supportive therapy
- Aspirin 100 mg PO once per day or low-molecular-weight heparin "according to patient risk"
Continued indefinitely
References
- PO0023: Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. Pomalidomide, cyclophosphamide and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open label study. Blood. 2013 Oct 17;122(16):2799-806. Epub 2013 Aug 16. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01166113
RVD
RVD: Revlimid (Lenalidomide), Velcade (Bortezomib), Dexamethasone
VDR: Velcade (Bortezomib), Dexamethasone, Revlimid (Lenalidomide)
VRD: Velcade (Bortezomib), Revlimid (Lenalidomide), Dexamethasone
VRd: Velcade (Bortezomib), Revlimid (Lenalidomide), low-dose dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Richardson et al. 2014 (DFCI 06-147) | 2006-2008 | Phase 2 |
Preceding treatment
- RVD salvage
Targeted therapy
- Lenalidomide (Revlimid) (at previously tolerated dose) PO once per day on days 1 to 14
- Bortezomib (Velcade) (at previously tolerated dose) IV once per day on days 1 & 8
Glucocorticoid therapy
- Dexamethasone (Decadron) 10 mg PO once per day on days 1, 2, 8, 9
Supportive therapy
21-day cycles
References
- DFCI 06-147: Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC. A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 6;123(10):1461-9. Epub 2014 Jan 15. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00378209
Response criteria
- IMWG international uniform response criteria for multiple myeloma. (Durie et al. Leukemia 2006) PubMed
- Make note of these errors which remain in the online version of the IMWG criteria as of 7/7/2013.
- Clarification of the definition of complete response in multiple myeloma (Leukemia 2015) PubMed
- European Blood and Marrow Transplant (EBMT) criteria. (Bladé et al. Br J Hematol 1998) PubMed
Prognosis
Durie-Salmon Staging System - 1975
Composed of four factors with a modifier based on renal function
- Serum levels of monoclonal protein (only defined for IgM, IgA, and Bence-Jones)
- Number of lytic bone lesions
- Hemoglobin
- Serum calcium level
Risk stratification
- Stage I: (must meet ALL criteria)
- Hemoglobin greater than 10 g/dL
- Calcium normal or less than or equal to 12 mg/dL
- Skeletal survey with normal bone structure (scale 0) or solitary bone plasmacytoma only
- Monoclonal protein relatively small (IgG M-spike value less than 5 g/dL OR IgA M-spike value less than 3 g/dL OR urine light chain protein less than 4 g/24 hr)
- Stage II: not stage I or stage III
- Stage III: (if meets ANY of the criteria)
- Hemoglobin less than 8.5 g/dL
- Calcium greater than 12 mg/dL
- Skeletal survey with extensive skeletal destruction and major fractures
- Monoclonal protein relatively large (IgG M-spike value greater than 7 g/dL OR IgA M-spike value greater than 5 g/dL OR urine light chain protein greater than 12 g/24 hr)
Modifier
- A: relatively normal creatinine (less than 2 mg/dL)
- B: creatinine greater than or equal to 2 mg/dL
References
- Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842-54. link to original article PubMed
International Staging System (ISS) - 2005
Composed of two factors
- Serum albumin level
- Serum beta-2 microglobulin level
Risk stratification
- Stage I: Median survival of 62 months
- Beta-2 microglobulin less than 3.5 mg/l
- Albumin greater than or equal to 3.5 g/dl
- Stage II: Median survival of 44 months
- Not meeting stage I or stage III criteria
- Stage III: Median survival of 29 months
- Beta-2 microglobulin greater than or equal to 5.5 mg/l
References
- Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol. 2005 May 20;23(15):3412-20. Epub 2005 Apr 4. link to original article PubMed
- Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009 Jan;23(1):3-9. Epub 2008 Oct 30. link to original article link to PMC article PubMed
IMWG consensus on risk stratification - 2013
Composed of four factors
- Serum albumin level
- Serum beta-2 microglobulin level
- Age
- Chromosomal abnormalities detected by interphase fluorescent in situ hybridization (FISH)
Risk stratification
- Low risk: (must meet all criteria) Median survival of greater than 10 years
- ISS Stage I or II
- Age less than 55 years
- Absence of the following: del(17p13), t(4;14), +1q21
- Standard risk: Median survival of 7 years
- Not meeting low risk or high risk criteria
- High risk: (if meets both criteria) Median survival of 2 years
- ISS Stage II or III
- Either of the following: del(17p13) or t(4;14)
References
- Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, San Miguel J, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014 Feb;28(2):269-77. Epub 2013 Aug 26. link to original article PubMed
Revised International Staging System (R-ISS) - 2015
Composed of four factors
- Serum albumin level
- Serum beta-2 microglobulin level
- Serum LDH
- Chromosomal abnormalities detected by interphase fluorescent in situ hybridization (FISH)
Risk stratification
- Low risk: 5-year overall survival = 82%
- Beta-2 microglobulin less than 3.5 mg/l
- Albumin less than or equal to 3.5 g/dl
- LDH less than the upper limit of normal range
- Absence of the following: del(17p), t(4;14), t(14;16)
- Intermediate risk: 5-year overall survival = 62%
- Not meeting low risk or high risk criteria
- High risk: (if meets ANY of the criteria) 5-year overall survival = 40%
- Beta-2 microglobulin greater than or equal to 5.5 mg/l
- LDH greater than the upper limit of normal range
- Any of the following: del(17p), t(4;14), t(14;16)
References
- Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015 Sep 10;33(26):2863-9. Epub 2015 Aug 3. link to original article link to PMC article PubMed
Miscellaneous
- Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau JL, Facon T, Mathiot C. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007 Apr 15;109(8):3489-95. Epub 2007 Jan 5. link to original article PubMed
- Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M, Royer B, Dib M, Voillat L, Bouscary D, Caillot D, Wetterwald M, Pegourie B, Lepeu G, Corront B, Karlin L, Stoppa AM, Fuzibet JG, Delbrel X, Guilhot F, Kolb B, Decaux O, Lamy T, Garderet L, Allangba O, Lifermann F, Anglaret B, Moreau P, Harousseau JL, Facon T. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the Intergroupe Francophone du Myélome experience. J Clin Oncol. 2013 Aug 1;31(22):2806-9. Epub 2013 Jun 24. link to original article link to PMC article PubMed